Biosynthetic biparatopic or bispecific binding molecules with enhanced effector function - Patents.com
Biparatopic or bispecific antibodies with RE mutations and reduced fucose residues improve ADCC, CDC, and ADCP activities, addressing the limitations of single-function enhancement in therapeutic antibodies for cancer treatment.
Patent Information
- Application Number
- JP2024523708
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-20
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing therapeutic antibodies often struggle to simultaneously enhance multiple effector functions such as ADCC, ADCP, and CDC, as strategies to improve one function can interfere with others, limiting their efficacy in cancer treatment.
Development of biparatopic or bispecific antibodies with K248E and T437R mutations (RE mutations) in the Fc region, combined with reduced core fucose residues, to enhance ADCC, CDC, and ADCP activities by promoting hexamerization and increased C1q engagement.
The proposed antibodies demonstrate enhanced ADCC, CDC, and ADCP activities, potentially leading to more potent cancer therapeutics by overcoming functional dysfunctions in cancer patients.
Smart Images

Figure 2024540951000001_ABST
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of priority to U.S. Patent Application No. 63 / 270,031, filed October 20, 2021, the contents of which are incorporated by reference herein in their entirety.
[0002] (Reference to electronically submitted sequence listing) This application contains a computer readable sequence listing submitted herewith in XML file format, the entire contents of which are incorporated herein by reference in their entirety. The sequence listing XML file submitted herewith is entitled "14620-722-228_SEQ_LISTING.xml", was created on October 3, 2022, and is 431,738 bytes in size.
[0003] FIELD OF THEINVENTION Provided herein are biparatopic or bispecific binding molecules with enhanced antibody-dependent cellular cytotoxicity (ADCC), enhanced complement-dependent cytotoxicity (CDC) and / or enhanced antibody-dependent cellular phagocytosis (ADCP). [Background technology]
[0004] Therapeutic antibodies can bind to Fc receptors expressed on immune effector cells such as natural killer (NK) cells and macrophages, resulting in antitumor activity via ADCC and ADCP. Therapeutic antibodies can also activate CDC to achieve antitumor effects. Summary of the Invention
[0005] In one aspect, a binding molecule is provided comprising an antigen binding domain and an Fc region, wherein (i) the antigen binding domain is biparatopic or bispecific, and (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system, and wherein the binding molecule has an increased ability of hexamerization on a cell surface and / or an increased ability to engage C1q.
[0006] In some embodiments, the antigen binding domain comprises a first domain comprising a first VH region and a first VL region, a first single domain antigen binding fragment, and / or a first engineered binding fragment, and a second domain comprising a second VH region and a second VL region, a second single domain antigen binding fragment, and / or a second engineered binding fragment, wherein the first domain and the second domain bind to two different epitopes of the same antigen or different antigen(s). In some embodiments, (i) each of the first domain and the second domain is a Fab fragment, an scFv, a single domain antigen binding fragment, or an engineered binding fragment; (ii) the first domain is a Fab fragment and the second domain is an scFv; (iii) the first domain is a Fab fragment and the second domain is a single domain antigen binding fragment; (iv) the first domain is a Fab fragment and the second domain is an engineered binding fragment; (v) the first domain is an scFv and the second domain is a single domain antigen binding fragment; (vi) the first domain is an scFv and the second domain is an engineered binding fragment; or (vii) the first domain is a single domain antigen binding fragment and the second domain is an engineered binding fragment.
[0007] In some embodiments, the oligosaccharide covalently attached to the Fc region via residue N297 does not contain a core fucose residue.
[0008] In some embodiments, the binding molecule is a biparatopic or bispecific antibody.
[0009] In some embodiments, the binding molecule has enhanced ADCC, enhanced CDC, and / or enhanced ADCP.
[0010] In another aspect, provided herein is a population of binding molecules comprising the binding molecules disclosed herein. In some embodiments, each binding molecule comprises an antigen-binding domain and an Fc region, (i) the antigen-binding domain is biparatopic or bispecific, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), where the numbering of amino acid residues is according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0011] In another aspect, provided herein is a population of binding molecules, each binding molecule comprising an antigen binding domain and an Fc region, wherein the antigen binding domains of at least 10% of the binding molecules in the population are biparatopic or bispecific, and wherein the Fc region of each binding molecule comprises a K248E and a T437R mutation (RE mutation), and wherein numbering of amino acid residues is according to the EU numbering system, and less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0012] In some embodiments, at least 20% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific. In some embodiments, at least 30% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific. In some embodiments, at least 40% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific. In some embodiments, at least 50% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific. In some embodiments, at least 60% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific. In some embodiments, at least 70% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific. In some embodiments, at least 80% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific. In some embodiments, at least 90% of the antigen binding domains of the binding molecules in the population are biparatopic or bispecific.
[0013] In some embodiments, less than 70% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, less than 60% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, less than 50% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, less than 40% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, less than 30% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, less than 20% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, less than 10% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0014] In some embodiments, the antigen binding domain comprises a first domain comprising a first VH region and a first VL region, a first single domain antigen binding fragment, and / or a first engineered binding fragment, and a second domain comprising a second VH region and a second VL region, a second single domain antigen binding fragment, and / or a second engineered binding fragment, wherein the first domain and the second domain bind to two different epitopes of the same antigen or different antigen(s). In some embodiments, (i) each of the first domain and the second domain is a Fab fragment, an scFv, a single domain antigen binding fragment, or an engineered binding fragment; the first domain is a Fab fragment and the second domain is an scFv; the first domain is a Fab fragment and the second domain is a single domain antigen binding fragment; the first domain is a Fab fragment and the second domain is an engineered binding fragment; the first domain is an scFv and the second domain is a single domain antigen binding fragment; the first domain is an scFv and the second domain is an engineered binding fragment; the first domain is a single domain antigen binding fragment and the second domain is an engineered binding fragment.
[0015] In some embodiments, the binding molecule is a biparatopic or bispecific antibody.
[0016] In some embodiments, the binding molecule is produced by expressing a polynucleotide encoding the binding molecule or a fragment thereof in a host cell that is defective in the addition of fucose to oligosaccharides attached to the Fc region of an antibody. In some embodiments, the host cell has reduced GDP-mannose 4,6-dehydratase (GMD) activity or reduced α-1,6 fucosyltransferase activity. In some embodiments, the gene encoding α-1,6 fucosyltransferase is mutated, expressed at lower than normal levels, or knocked out in the host cell. In some embodiments, the gene encoding GDP-mannose 4,6-dehydratase is mutated, expressed at lower than normal levels, or knocked out in the host cell.
[0017] In some embodiments, the population of binding molecules has enhanced ADCC, enhanced CDC, and / or enhanced ADCP.
[0018] In another aspect, provided herein is a nucleic acid encoding a binding molecule disclosed herein.
[0019] In another aspect, provided herein is a vector comprising the nucleic acid.
[0020] In a further aspect, provided herein is a pharmaceutical composition comprising a binding molecule and a pharma- ceutically acceptable excipient, wherein the binding molecule comprises an antigen-binding domain and an Fc region, (i) the antigen-binding domain is biparatopic or bispecific, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system, and the binding molecule has an increased ability of hexamerization on a cell surface and / or an increased ability to engage C1q.
[0021] In another aspect, provided herein is a pharmaceutical composition comprising a population of binding molecules and a pharma- ceutically acceptable excipient, each binding molecule comprising an antigen-binding domain and an Fc region, (i) the antigen-binding domain is biparatopic or bispecific, (ii) the Fc region comprises a K248E and a T437R mutation (RE mutation), wherein the numbering of the amino acid residues is according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0022] In another aspect, provided herein is a pharmaceutical composition comprising a population of binding molecules and a pharma- ceutically acceptable excipient, wherein each binding molecule comprises an antigen-binding domain and an Fc region, wherein the antigen-binding domains of at least 10% of the binding molecules in the population are biparatopic or bispecific, wherein the Fc region of each binding molecule comprises a K248E and a T437R mutation (RE mutation), and wherein numbering of amino acid residues is according to the EU numbering system, and less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0023] In further one aspect, provided herein is a method of making a population of binding molecules, comprising expressing a polynucleotide encoding the binding molecule or a fragment thereof in a host cell that is deficient in the addition of fucose residues to oligosaccharides attached to the antibody via the N297 residue, wherein the population of binding molecules comprises binding molecules comprising an antigen binding domain and an Fc region, (i) the antigen binding domain is biparatopic or bispecific, and (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system. The binding molecules have an increased ability to hexamerize on a cell surface and / or an increased ability to engage C1q.
[0024] In another aspect, provided herein is a method of making a population of binding molecules, comprising expressing a polynucleotide encoding a binding molecule or a fragment thereof in a host cell that is defective in the addition of fucose residues to oligosaccharides attached to the antibody via the N297 residue, wherein each binding molecule comprises an antigen-binding domain and an Fc region, (i) the antigen-binding domain is biparatopic or bispecific, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0025] In another aspect, provided herein is a method of making a population of binding molecules, comprising expressing a polynucleotide encoding a binding molecule or a fragment thereof in a host cell that is defective in the addition of fucose residues to oligosaccharides attached to the antibody via the N297 residue, wherein each binding molecule comprises an antigen binding domain and an Fc region, wherein the antigen binding domains of at least 10% of the binding molecules in the population are biparatopic or bispecific, wherein the Fc region of each binding molecule comprises a K248E and a T437R mutation (RE mutation), and wherein numbering of the amino acid residues is according to the EU numbering system, and less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0026] In yet one aspect, provided herein is a method for enhancing CDC, ADCP and / or ADCC in a system, or a method of modulating immunity in a host, or a method of treating a disease or disorder in a subject, comprising contacting the system with a binding molecule comprising an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is biparatopic or bispecific, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system, and wherein the binding molecule has an increased ability of hexamerization on a cell surface and / or an increased ability to engage C1q.
[0027] In another aspect, provided herein is a method of enhancing CDC, ADCP and / or ADCC in a system or modulating immunity in a host or treating a disease or disorder in a subject, comprising contacting the system with a population of binding molecules, each binding molecule comprising an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is biparatopic or bispecific, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein numbering of the amino acid residues is according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0028] In another aspect, provided herein is a method of enhancing CDC, ADCP and / or ADCC in a system or modulating immunity in a host or treating a disease or disorder in a subject, comprising contacting the system with a population of binding molecules, each binding molecule comprising an antigen binding domain and an Fc region, wherein the antigen binding domains of at least 10% of the binding molecules in the population are biparatopic or bispecific, wherein the Fc region of each binding molecule comprises a K248E and a T437R mutation (RE mutation), and wherein numbering of amino acid residues is according to the EU numbering system, and less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue in the Fc region comprise a core fucose residue.
[0029] In a further aspect, provided herein is a binding molecule comprising a first means for enhancing CDC and a second means for enhancing CDC. In some embodiments, the binding molecule further comprises a third means for enhancing ADCC. In some embodiments, the binding molecule further comprises a fourth means for enhancing ADCP. In some embodiments, the first means increases hexamerization of the binding molecule on the cell surface and / or increases C1q engagement by the binding molecule. In some embodiments, the first means refers to enhancing CDC, ADCP, and / or ADCC.
[0030] In another aspect, provided herein is a method of making a population of binding molecules, comprising: (i) introducing K248E and T437R mutations (RE mutations) in the Fc region of a binding molecule; and (ii) generating a population of binding molecules having a reduced amount of core fucose in the oligosaccharide attached to the binding molecule via the N297 residue, wherein the binding molecule comprises a biparatopic or bispecific antigen-binding domain. [Brief description of the drawings]
[0031] [Figure 1A] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1B]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1C] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1D]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1E] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1F]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1G] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1H]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutation (Figures 1C and 1D), RE mutation (Figures 1E and 1F), and hypofucosylation and RE mutation (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated for 30 min with titrated concentrations of antibodies as indicated. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 h of incubation, cell viability was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Diagram 2] Figure 1 shows the CDC activity of anti-GPRC5D antibodies with hypofucosylation in wild type and RE mutations on H929 target cells. Target cells were incubated with titrated concentrations of antibodies as indicated for 30 minutes. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After 4 hours of incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 3A]Figure 1 shows in vitro ADCC kinetic killing of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641+10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and cells were allowed to adhere overnight. ADCC assays were performed with freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 for PBMCs as effector cells. KLK2 antibodies were tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging was performed under an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified with Incucyte® software. Data analysis was performed with Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control)×100%. [Figure 3B]Figure 1 shows in vitro ADCC kinetic killing of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641+10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and cells were allowed to adhere overnight. ADCC assays were performed with freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 for PBMCs as effector cells. KLK2 antibodies were tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging was performed under an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified with Incucyte® software. Data analysis was performed with Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control)×100%. [Figure 3C]Figure 1 shows in vitro ADCC kinetic killing of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641+10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and cells were allowed to adhere overnight. ADCC assays were performed with freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 for PBMCs as effector cells. KLK2 antibodies were tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging was performed under an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified with Incucyte® software. Data analysis was performed with Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control)×100%. [Figure 3D]Figure 1 shows in vitro ADCC kinetic killing of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641+10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and cells were allowed to adhere overnight. ADCC assays were performed with freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 for PBMCs as effector cells. KLK2 antibodies were tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging was performed under an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified with Incucyte® software. Data analysis was performed with Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control)×100%. [Figure 3E]Figure 1 shows in vitro ADCC kinetic killing of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641+10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and cells were allowed to adhere overnight. ADCC assays were performed with freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 for PBMCs as effector cells. KLK2 antibodies were tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging was performed under an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified with Incucyte® software. Data analysis was performed with Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control)×100%. [Figure 4] Figure 1 shows in vitro ADCC dose response killing by PBMC to VCaP at 48 hours. Dose response curves were generated 48 hours after addition of effector cells and antibody to target cells. [Figure 5A] 1 shows the ADCC activity of anti-HLA-G antibodies MHGB732 and MHGB738 and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation against JEG-3 and RERF-LC-Ad-1 cells. The percentage of lysis was compared to the maximum lysis of JEG-3 or RERF-LC-Ad-1 cells by Triton-X100 detergent and calculated as (sample value-target only value) / (maximum value-target only value)×100%. [Figure 5B] 1 shows the ADCC activity of anti-HLA-G antibodies MHGB732 and MHGB738 and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation against JEG-3 and RERF-LC-Ad-1 cells. Percentage of lysis was compared to maximum lysis of JEG-3 or RERF-LC-Ad-1 cells by Triton-X100 detergent and calculated as (sample value-target only value) / (maximum value-target only value)×100%. [Figure 5C] Figure 1 shows the CDC activity of anti-HLA-G antibodies MHGB732 and MHGB738 and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation. Target cells were incubated with antibodies as indicated for 30 min at 37°C. Rabbit complement and heat-inactivated complement at 15-20% (stock concentration) were added to the wells to a volume of 25 μL / well, respectively. The mixtures were incubated for 4-12 h at 37°C. Target cell lysis was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 5D] Figure 1 shows the CDC activity of anti-HLA-G antibodies MHGB732 and MHGB738 and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation. Target cells were incubated with antibodies as indicated for 30 min at 37°C. Rabbit complement and heat-inactivated complement at 15-20% (stock concentration) were added to the wells to a volume of 25 μL / well, respectively. The mixtures were incubated for 4-12 h at 37°C. Target cell lysis was measured by addition of CellTiter-Glo reagent (Promega) and measurement of the resulting luminescence, reported in relative luminescence units (RLU). [Figure 6A]Figure 6 shows the in vitro ADCC dose response killing of C42B and LNCaP cells mediated by anti-PSMA antibodies PSMB896 and PSMB898 with hypofucosylation and RE mutations. Specifically, Figure 6A shows the in vitro ADCC dose response killing of C42B cells by PBMC at 6 hours, Figure 6B shows the in vitro ADCC dose response killing of LNCaP cells by PBMC at 6 hours, Figure 6C shows the in vitro ADCC dose response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose response killing of LNCaP cells by NK cells at 24 hours. Dose response curves were generated 6 hours or 24 hours after effector cells and antibodies were added to target cells. [Figure 6B] Figure 6 shows the in vitro ADCC dose response killing of C42B and LNCaP cells mediated by anti-PSMA antibodies PSMB896 and PSMB898 with hypofucosylation and RE mutations. Specifically, Figure 6A shows the in vitro ADCC dose response killing of C42B cells by PBMC at 6 hours, Figure 6B shows the in vitro ADCC dose response killing of LNCaP cells by PBMC at 6 hours, Figure 6C shows the in vitro ADCC dose response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose response killing of LNCaP cells by NK cells at 24 hours. Dose response curves were generated 6 hours or 24 hours after effector cells and antibodies were added to target cells. [Figure 6C]Figure 6 shows the in vitro ADCC dose response killing of C42B and LNCaP cells mediated by anti-PSMA antibodies PSMB896 and PSMB898 with hypofucosylation and RE mutations. Specifically, Figure 6A shows the in vitro ADCC dose response killing of C42B cells by PBMC at 6 hours, Figure 6B shows the in vitro ADCC dose response killing of LNCaP cells by PBMC at 6 hours, Figure 6C shows the in vitro ADCC dose response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose response killing of LNCaP cells by NK cells at 24 hours. Dose response curves were generated 6 hours or 24 hours after effector cells and antibodies were added to target cells. [Figure 6D] Figure 6 shows the in vitro ADCC dose response killing of C42B and LNCaP cells mediated by anti-PSMA antibodies PSMB896 and PSMB898 with hypofucosylation and RE mutations. Specifically, Figure 6A shows the in vitro ADCC dose response killing of C42B cells by PBMC at 6 hours, Figure 6B shows the in vitro ADCC dose response killing of LNCaP cells by PBMC at 6 hours, Figure 6C shows the in vitro ADCC dose response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose response killing of LNCaP cells by NK cells at 24 hours. Dose response curves were generated 6 hours or 24 hours after effector cells and antibodies were added to target cells. [Figure 7] CDC activity of biparatopic anti-PSMA antibodies using IgG1 constant domains with or without RE mutations on LNCaP target cells in the presence of 40% normal human serum. CDC activity of an isotype control antibody on LNCaP target cells was also tested. [Figure 8]8 shows the ADCC activity of the same antibodies tested in FIG. 7 against BATDA-labeled LNCaP target cells in the presence of purified NK cells from normal donors. Detailed Description of the Invention
[0032] Antibodies represent an important and growing class of therapeutic biologics for a variety of diseases or disorders, including oncological indications. Their mechanisms of action include blockade of signals that inhibit antitumor immune responses, agonism of signals that enhance antitumor responses, targeted delivery of antitumor drugs by conjugated antibodies, and target-specific depletion of cells expressing tumor-associated antigens via ADCC, ADCP, and CDC. Among these mechanisms of action, ADCC and ADCP are mediated through the interaction of the fragment crystallizable region (Fc) of the antibody with Fcγ receptors on effector cells (natural killer cells as in ADCC or macrophages as in ADCP). CDC is mediated through the interaction between Fc and the complement component C1q. These mechanisms of target cell killing are collectively referred to as antibody effector functions. Numerous oncological therapeutics exploit these antibody effector functions to specifically deplete or inhibit the proliferation of tumor cells. Thus, strategies that can increase Fc-mediated activation of these pathways may result in more potent cancer therapeutics. Strategies have been described that can enhance ADCC or ADCP effector function. However, they are often incompatible with other functions, such as CDC activity. Here, we describe the combined application of several strategies that can allow simultaneous enhancement of multiple antibody effector functions, such as CDC, ADCC, and / or ADCP. Combining the improvement of effector function can potentially lead to better therapeutic approaches that can overcome the dysfunction in one of these compartments in cancer patients.
[0033] CDC activity requires activation of the complement cascade, which requires activation of complement component C1q by a hexamer of Fc regions flush with the surface of the target cell. This then requires simultaneous binding of five or six antibody molecules in close proximity to the cell surface. Due to the need for Fc-mediated antibody oligomerization, CDC activity requires a relatively high target receptor density. In natural IgG antibodies, the stoichiometry of antibody-receptor binding can vary from 1:2 to 1:1 depending on the antibody concentration, with the former being highly favored for avidity. To maximize the number of antibodies that can bind to a given number of cell surface receptors, the present disclosure incorporates engineered biparatopic or bispecific designs to enforce a 1:1 antibody-receptor binding stoichiometry. This allows for more Fc regions to be brought to the surface of a cell with a given number of receptors compared to natural bivalent IgG. Engineered biparatopic or bispecific antibodies can therefore have stronger CDC activity.
[0034] Another way to increase CDC activity is to enhance the ability of IgG to hexamerize through mutagenesis. One strategy, called RE mutation, involves incorporating two point mutations (K248E and T437R) in the Fc region. As demonstrated, the enhancement of CDC activity by RE mutation is compatible with the enhancement of ADCC and ADCP activity mediated by antibodies produced in low-fucose hosts. Biparatopic or bispecific antibodies featuring RE mutations provided herein are compatible with the enhancement of ADCC / ADCP via low-fucose production, among other advanced properties, as shown in Section 7 below.
[0035] The present disclosure is based in part on the surprising finding that a population of antibodies has both enhanced ADCC activity and enhanced CDC activity when less than 80% of the oligosaccharides covalently attached to the population of antibodies contain fucose residues and the Fc region of the antibodies contains K248E and T437R mutations (RE mutations). In addition, as demonstrated in Section 7 below, hypofucosylation does not interfere with the effect of the RE mutations on enhanced CDC, and the RE mutations do not interfere with the enhanced ADCC activity conferred by hypofucosylation. In one aspect, provided herein is an antibody that comprises a RE mutation in the Fc region and does not contain a core fucose residue in the oligosaccharides covalently attached to the Fc region of the antibody. In another aspect, provided herein is a population of antibodies comprising an antibody that comprises a RE mutation in the Fc region and does not contain a core fucose residue in the oligosaccharides covalently attached to the Fc region of the antibody. In some embodiments, provided herein is a population of antibodies comprising a K248E mutation and a T437R mutation (RE mutation), wherein less than 80% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 70% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 60% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 50% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 40% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 30% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 20% of the oligosaccharides that are covalently attached to a population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 10% of the oligosaccharides that are covalently attached to a population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 5% of the oligosaccharides that are covalently attached to a population of antibodies via their N297 residue comprise a core fucose residue.
[0036] The present disclosure is also based in part on the surprising finding that the combination of a biparatopic or bispecific construct with a RE mutation provides further enhanced CDC activity through increased hexamerization of such binding molecules and thus increased ability to engage C1q on the cell surface, among other advanced properties as demonstrated in Section 7 below. Thus, in another aspect, the present disclosure provides biparatopic or bispecific binding molecules carrying a RE mutation in the Fc region. In some embodiments, such binding molecules do not contain core fucose residues in the oligosaccharides covalently attached to the Fc region of the binding molecule. In some embodiments, provided herein is a population of biparatopic or bispecific antibodies, each bearing a RE mutation, wherein less than 80% of the oligosaccharides covalently attached to the population of biparatopic or bispecific antibodies via their N297 residues contain core fucose residues. In some embodiments, less than 70% of the oligosaccharides covalently attached to the population of biparatopic or bispecific antibodies via their N297 residues contain core fucose residues. In some embodiments, less than 60% of the oligosaccharides that are covalently attached to a population of biparatopic or bispecific antibodies through their N297 residue comprise a core fucose residue. In some embodiments, less than 50% of the oligosaccharides that are covalently attached to a population of biparatopic or bispecific antibodies through their N297 residue comprise a core fucose residue. In some embodiments, less than 40% of the oligosaccharides that are covalently attached to a population of biparatopic or bispecific antibodies through their N297 residue comprise a core fucose residue. In some embodiments, less than 30% of the oligosaccharides that are covalently attached to a population of biparatopic or bispecific antibodies through their N297 residue comprise a core fucose residue. In some embodiments, less than 20% of the oligosaccharides that are covalently attached to a population of biparatopic or bispecific antibodies through their N297 residue comprise a core fucose residue. In some embodiments, less than 10% of the oligosaccharides that are covalently attached to a population of biparatopic or bispecific antibodies through their N297 residue comprise a core fucose residue.In some embodiments, less than 5% of the oligosaccharides covalently attached to a population of biparatopic or bispecific antibodies via their N297 residues contain a core fucose residue.
[0037] In certain embodiments, any antibody having any antigen-binding structure or targeting any antigen is included in the present disclosure, so long as the antibody has an Fc region. Pharmaceutical compositions comprising the antibodies, methods of making, and their uses are also included in the present disclosure.
[0038] definition The techniques and procedures described or referenced herein include those that are generally well understood and / or that are routinely employed by those of skill in the art using conventional techniques, such as the widely used techniques described in Molecular Cloning: A Laboratory Manual (Sambrook, et al., 3d ed. 2001), Current Protocols in Molecular Biology (Ausubel, et al. eds., 2003), Therapeutic Monoclonal Antibodies: From Bench to Clinic (An, ed. 2009), Monoclonal Antibodies: Methods and Protocols (Albitar, ed. 2010), and Antibody Engineering Vols 1 and 2 (Kontermann and Dubel, eds., 2d ed. 2010).
[0039] Unless otherwise defined herein, technical and scientific terms used herein have the meanings that are commonly understood by those skilled in the art. For the purposes of interpreting this specification, the following explanations of terms shall apply, and where necessary, terms used in the singular form shall include the plural form and vice versa. If any explanation of the terms described conflicts with any document incorporated herein by reference, the explanation of the terms described below shall prevail.
[0040] The terms "antibody," "immunoglobulin," or "Ig" are used interchangeably herein and are used in the broadest sense, specifically encompassing monoclonal antibodies (including agonist, antagonist, neutralizing, full-length or intact monoclonal antibodies), antibody compositions with polyepitopic or monoepitopic specificity, polyclonal or monovalent antibodies, multivalent antibodies, and multispecific antibodies formed from at least two intact antibodies (e.g., bispecific antibodies, so long as they exhibit the desired biological activity), e.g., as described below. Antibodies may be human, humanized, chimeric, and / or affinity matured, as well as antibodies from other species, such as mouse and rabbit. The term "antibody" is intended to include a polypeptide product of B cells within the immunoglobulin class of polypeptides capable of binding to a specific molecular antigen and composed of two identical paired polypeptide chains, each pair having one heavy chain (about 50-70 kDa) and one light chain (about 25 kDa), with each amino-terminal portion of each chain containing a variable region of about 100 to about 130 or more amino acids, and each carboxy-terminal portion of each chain containing a constant region. See, e.g., Antibody Engineering (Borrebaeck, ed., 2d ed. 1995), and Kuby, Immunology (3d ed. 1997). In specific embodiments, a specific molecular antigen may be bound by an antibody provided herein that contains a polypeptide or epitope. Antibodies also include, but are not limited to, synthetic antibodies, recombinantly produced antibodies, camelized antibodies or humanized variants thereof, intrabodies, and anti-idiotypic (anti-Id) antibodies. The term "antibody" as used herein also includes any binding molecule having an Fc region and any of the above functional fragments (e.g., antigen-binding fragments), where a functional fragment refers to a portion of an antibody heavy or light chain polypeptide that retains some or all of the binding activity of the antibody from which the fragment is derived. Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single chain Fvs (scFv) (including, e.g., monospecific, bispecific, etc.), Fab fragments, F(ab') fragments, F(ab) 2 Fragment, F(ab') 2Antibody fragments include disulfide-linked Fvs (dsFv), Fd fragments, Fv fragments, diabodies, triabodies, tetrabodies, and minibodies. In particular, the antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, such as antigen-binding domains or molecules that contain an antigen-binding site (e.g., one or more CDRs of an antibody) that binds to an antigen. Such antibody fragments can be found, for example, in Harlow and Lane, Antibodies: A Laboratory Manual (1989), Mol. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, ed., 1995), Huston, et al., 1993, Cell Biophysics 22:189-224, Pluckthun and Skerra, 1989, Meth. Enzymol. 178:497-515, and Day, Advanced Immunochemistry (2d ed. 1990). The antibodies provided herein can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) of immunoglobulin molecule. The antibody can be an agonist antibody or an antagonist antibody.
[0041] The term "biparatopic antibodies" refers to a subset of bispecific antibodies in which each of the two antigen-binding domains recognizes a unique, non-overlapping epitope on the same intended target.
[0042] An "antigen" is a structure to which an antibody can selectively bind. A target antigen can be a polypeptide, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. In some embodiments, the target antigen is a polypeptide. In certain embodiments, the antigen is associated with a cell, e.g., present on or within a cell.
[0043] An "intact" antibody is one that contains an antigen-binding site as well as a constant domain (CL) and at least the heavy chain constant regions CH1, CH2 and CH3. The constant region may include a human constant region or an amino acid sequence variant thereof. In certain embodiments, an intact antibody has one or more effector functions.
[0044] The term "binding" or "binding" refers to interactions between molecules, including, for example, forming a complex. The interactions can be non-covalent interactions, including, for example, hydrogen bonds, ionic bonds, hydrophobic interactions, and / or van der Waals interactions. A complex can also include the binding of two or more molecules held together by covalent or non-covalent bonds, interactions, or forces. The strength of the total non-covalent interactions between a single antigen-binding site of an antibody and a single epitope of a target molecule, such as an antigen, is the affinity of the antibody or functional fragment for that epitope. The dissociation rate (k off ) and association rate (k on ) and the ratio (k off / k on ) is the dissociation constant K D and is inversely related to affinity. D The lower the value, the higher the affinity of the antibody. D The value of k varies for different complexes of antibody and antigen. on and k off The dissociation constant K of the antibodies provided herein depends on both D can be determined using any method provided herein or any other method known to those skilled in the art. The affinity at one binding site does not necessarily reflect the true strength of the interaction between the antibody and the antigen. When a complex antigen containing multiple repeating antigenic determinants, such as a multivalent antigen, contacts an antibody containing multiple binding sites, the interaction of the antibody with the antigen at one site will increase the probability of reaction at a second site. The strength of multiple interactions between such a multivalent antibody and an antigen is called avidity.
[0045] In the context of the antibodies described herein, terms such as "binds to," "specifically binds to," and similar terms are also used interchangeably herein to refer to an antibody of an antigen-binding domain that specifically binds to an antigen, such as a polypeptide. An antibody or antigen-binding domain that binds to an antigen or specifically binds to an antigen may cross-react with related antigens. In certain embodiments, an antibody or antigen-binding domain that binds to an antigen or specifically binds to an antigen does not cross-react with other antigens. An antibody or antigen-binding domain that binds to an antigen or specifically binds to an antigen can be identified, for example, by immunoassay, Octet®, Biacore®, or other techniques known to those of skill in the art. In some embodiments, an antibody or antigen-binding domain binds to an antigen or specifically binds to an antigen if it binds to the antigen with a higher affinity than any cross-reactive antigens as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA). Typically, a specific or selective response is at least twice the background signal or noise, and may be more than 10 times background. For a discussion of binding specificity, see, for example, Fundamental Immunology 332-36 (Paul, ed., 2d ed. 1989). In certain embodiments, the extent of binding of an antibody or antigen-binding domain to a "non-target" protein is less than about 10% of the binding of the antibody or antigen-binding domain to its specific target antigen, as determined, for example, by fluorescence activated cell sorting (FACS) analysis or RIA. With respect to terms such as "specific binding," "specifically binds to," or "specific for," binding refers to binding that is measurably different from non-specific interactions. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which is a molecule of similar structure that generally does not have binding activity. For example, specific binding can be determined by competition with a control molecule similar to the target, for example, an excess of unlabeled target.In this case, specific binding is indicated if binding of the labeled target to the probe is competitively inhibited by excess unlabeled target. Antibodies or antigen-binding domains that bind to an antigen include those that are capable of binding to the antigen with sufficient affinity such that the antibody is useful, for example, as an antigen-targeted diagnostic or therapeutic agent. In certain embodiments, antibodies or antigen-binding domains that bind to an antigen have a dissociation constant (K) of 1000nM, 800nM, 500nM, 250nM, 100nM, 50nM, 10nM, 5nM, 4nM, 3nM, 2nM, 1nM, 0.9nM, 0.8nM, 0.7nM, 0.6nM, 0.5nM, 0.4nM, 0.3nM, 0.2nM, or 0.1nM or less. D In certain embodiments, the antibody or antigen binding domain binds to an epitope of an antigen that is conserved between antigens from different species (e.g., between human and cynomolgus monkey species).
[0046] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a binding protein such as an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a binding molecule X for its binding partner Y is generally determined by the dissociation constant (K D ) Affinity can be measured by common methods known in the art, including those described herein. Low affinity antibodies generally bind antigens slowly and tend to dissociate easily, whereas high affinity antibodies generally bind antigens faster and tend to remain bound longer. Various methods of measuring binding affinity are known in the art, any of which may be used for purposes of the present disclosure. Specific exemplary embodiments include the following. In one embodiment, "K D " or "K D The "K value" can be measured by assays known in the art, for example, by binding assays. Dcan be measured, for example, by RIA performed using the Fab version of the antibody of interest and its antigen (Chen, et al., J. Mol Biol, 1999, 293:865-81). D Or K D Values can be measured by using biolayer interferometry (BLI) or surface plasmon resonance (SPR) assays, for example by Octet® using the Octet® Red 96 system, or by Biacore® using, for example, the Biacore® 2000 or Biacore® 3000. Also referred to as "on rate" or "rate of association" or "association rate" or "k on " can be determined with the same biolayer interferometry (BLI) or surface plasmon resonance (SPR) techniques described above, for example, using an Octet® Red96, Biacore® 2000, or Biacore® 3000 system.
[0047] In certain embodiments, antibodies can contain "chimeric" sequences in which portions of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chains are identical to or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, so long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567, and Morrison, et al., Proc. Natl. Acad. Sci. USA, 1984, 81:6851-55).
[0048] In certain embodiments, an antibody may include portions of "humanized" forms of non-human (e.g., murine) antibodies, which are chimeric antibodies comprising a human immunoglobulin (e.g., recipient antibody) in which native CDR residues are replaced by residues from corresponding CDRs of a non-human species (e.g., donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and capacity. In some cases, one or more FR region residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies can include residues that are not found in the recipient antibody or the donor antibody. These modifications are made to further refine antibody performance. The heavy or light chains of a humanized antibody can include one or more variable regions in which all or substantially all of the CDRs correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of human immunoglobulin sequences. In certain embodiments, a humanized antibody comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones, et al., Nature, 1986, 321:522-25; Riechmann, et al., Nature, 1988, 332:323-29; Presta, Curr. Op. Struct. Biol., 1992, 2:593-96; Carter, et al., Proc. Natl. Acad. Sci. USA, 1992, 89:4285-89; U.S. Patent Nos. 6,800,738, 6,719,971, 6,639,055, 6,407,213, and 6,054,297.
[0049] In certain embodiments, an antibody can include a "fully human antibody" or a portion of a "human antibody," which terms are used interchangeably herein and refer to an antibody that includes a human variable region and, for example, a human constant region. In specific embodiments, these terms refer to an antibody that includes variable and constant regions of human origin. A "fully human" antibody can also encompass, in certain embodiments, an antibody that binds a polypeptide and is encoded by a nucleic acid sequence that is a naturally occurring somatic variant of a human germline immunoglobulin nucleic acid sequence. The term "fully human antibody" includes antibodies that have variable and constant regions that correspond to human germline immunoglobulin sequences as described by Kabat et al. (See Kabat, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242). A "human antibody" is one that has an amino acid sequence that corresponds to that of an antibody produced by a human and / or that has been produced using any of the techniques for producing human antibodies. This definition of a human antibody specifically excludes humanized antibodies that contain non-human antigen-binding residues. Human antibodies can be generated using a variety of techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 1991, 227:381; Marks, et al., 1991, J. Mol. Biol., 1991, 222:581) and yeast display libraries (Chao, et al., Nature Protocols, 2006, 1:755-68).In addition, for preparation of human monoclonal antibodies, the methods described in Cole, et al., Monoclonal Antibodies and Cancer Therapy 77 (1985), Boerner, et al., J. Immunol., 1991, 147(1):86-95, and van Dijk and van de Winkel, Curr. Opin. Pharmacol., 2001, 5:368-74 can also be used. Human antibodies can be prepared by administering antigen to transgenic animals, e.g., mice, that have been engineered to produce such antibodies in response to antigen challenge, but whose endogenous loci have been disabled (see, e.g., Jakobovits, Curr. Opin. Biotechnol., 1995, 6(5):561-66; Bruggemann and Taussing, Curr. Opin. Biotechnol., 1997, 8(4):455-58, and U.S. Pat. Nos. 6,075,181 and 6,150,584 regarding XENO Mouse™ technology). See also, e.g., Li, et al., Proc. Natl. Acad. Sci. USA, 2006, 103:3557-62 (regarding human antibodies generated via human B cell hybridoma technology).
[0050] In certain embodiments, an antibody can comprise a portion of a "recombinant human antibody," which phrase includes human antibodies prepared, expressed, created, or isolated by recombinant means, e.g., antibodies expressed using a recombinant expression vector introduced into a host cell, antibodies isolated from a recombinant combinatorial human antibody library, antibodies isolated from an animal (e.g., a mouse or a cow) that is transgenic and / or transchromosomal for human immunoglobulin genes (e.g., Taylor, LD, et al., Nucl. Acids Res., 1992 20:6287-6295), or antibodies prepared, expressed, created, or isolated by any other means involving splicing human immunoglobulin gene sequences into other DNA sequences. Such recombinant human antibodies can have variable and constant regions derived from human germline immunoglobulin sequences (see Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242). However, in certain embodiments, such recombinant human antibodies have been subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis), and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
[0051] In certain embodiments, an antibody can include a portion of a "monoclonal antibody," a term used herein to refer to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts, and each monoclonal antibody typically recognizes a single epitope on an antigen. In specific embodiments, a "monoclonal antibody," as used herein, is an antibody produced by a single hybridoma or other cell. The term "monoclonal" is not limited to a particular method for making the antibody. For example, monoclonal antibodies useful in the present disclosure can be prepared by the hybridoma method first described by Kohler et al., 1975, Nature 256:495, or can be made using recombinant DNA methods in bacterial or eukaryotic animal or plant cells (see, e.g., U.S. Pat. No. 4,816,567). "Monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described, for example, in Clackson, et al., Nature, 1991, 352:624-28 and Marks, et al., J. Mol. Biol., 1991, 222:581-97. Other methods for preparing clonal cell lines and the monoclonal antibodies expressed thereby are well known in the art. See, for example, Short Protocols in Molecular Biology (Ausubel et al. eds., 5th ed. 2002).
[0052] A typical four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light chains (L) and two identical heavy chains (H). For IgG, the four-chain unit is generally about 150,000 daltons. Each L chain is linked by a H chain with one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at the N-terminus followed by three constant domains (CH) for each of the α and γ chains and four CH domains for the μ and ε isotypes. Each L chain has a variable domain (VL) at the N-terminus followed by a constant domain (CL) at the other end. The VL is aligned with the VH, and the CL is aligned with the first constant domain (CH1) of the heavy chain. Certain amino acid residues are believed to form an interface between the light and heavy chain variable domains. The pairing of VH and VL together forms a single antigen-binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology 71 (Stites, et al. eds., 8th ed. 1994) and Immunobiology (Janeway, et al. eds., 5th ed. 2001).
[0053] As used herein, "core fucose", "core fucose residue", "fucose", or "fucose residue" refers to a fucose residue in the α1,6-linkage to the first GlcNAc of the Asn297-linked N-oligosaccharide. Ferrara et al., Proc Natl Acad Sci USA, 2011, 108:12669-74. "Core fucose", "core fucose residue", "fucose", and "fucose residue" are used interchangeably in this disclosure.
[0054] The term "Fab" or "Fab region" refers to the antibody region that binds to an antigen. A conventional IgG usually contains two Fab regions, each in one of the two arms of the Y-shaped IgG structure. Each Fab region is typically composed of one variable region and one constant region of each of the heavy and light chains. More specifically, the variable and constant regions of the heavy chain in the Fab region are the VH and CH1 regions, and the variable and constant regions of the light chain in the Fab region are the VL and CL regions. The VH, CH1, VL, and CL in the Fab region can be arranged in various ways to confer antigen-binding capability in accordance with the present disclosure. For example, the VH and CH1 regions can be on one polypeptide, while the VL and CL regions can be on separate polypeptides, as in the Fab region of a conventional IgG. Alternatively, the VH, CH1, VL, and CL regions can all be on the same polypeptide and oriented in different orders, as described in more detail in the following sections.
[0055] The terms "variable region," "variable domain," "V region," or "V domain" refer to a portion of an antibody's light or heavy chain that is located generally at the amino terminus of the light or heavy chain, has a length of about 120-130 amino acids for heavy chains and about 100-110 amino acids for light chains, and is used in the binding and specificity of each particular antibody to its particular antigen. The variable region of the heavy chain may be referred to as "VH." The variable region of the light chain may be referred to as "VL." The term "variable" refers to certain segments of the variable region that vary widely in sequence between antibodies. The V region mediates antigen binding and determines the specificity of a particular antibody for a particular antigen. However, that variability is not uniform across the 110 amino acid span of the variable region. Instead, the V region consists of less variable (e.g., relatively invariant) stretches called framework regions (FR) of about 15-30 amino acids separated by shorter regions of greater variability (e.g., extreme variability) called "hypervariable regions," each about 9-12 amino acids in length. The variable regions of the heavy and light chains each contain four FRs, mostly in a β-sheet structure, connected by three hypervariable regions, which form loops connecting the β-sheet structure and sometimes form part of the β-sheet structure. The hypervariable regions in each chain are held in close proximity together by the FRs, and together with the hypervariable regions of the other chain, contribute to the formation of the antigen-binding site of the antibody (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest (5th ed. 1991)). The constant regions are not directly involved in binding the antibody to the antigen, but exhibit various effector functions, such as the participation of the antibody in ADCC and CDC. The variable regions vary widely in sequence between different antibodies. In a specific embodiment, the variable regions are human variable regions.
[0056] The term "variable region residue numbering according to Kabat" or "amino acid position numbering as in Kabat", and variations thereof, refers to the numbering system used in the heavy or light chain variable regions of the compilation of antibodies of Kabat et al. (supra). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to shortening of, or insertion into, the FRs or CDRs of the variable domain. For example, a heavy chain variable domain may contain a single amino acid insertion after residue 52 (residue 52a according to Kabat) and three inserted residues after residue 82 (e.g., residues 82a, 82b, and 82c, etc., according to Kabat). The Kabat numbering of residues can be determined for a given antibody by aligning the sequence of that antibody with the "standard" Kabat numbering sequence at the regions of homology. The Kabat numbering system is generally used when referring to residues of the variable domain (residues 1-107 for the light chain, and residues 1-113 for the heavy chain) (e.g., Kabat et al., supra). The "EU numbering system" or "EU index" is generally used when referring to residues in an immunoglobulin heavy chain constant region (e.g., the EU index reported in Kabat et al., supra). "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody. Other numbering systems have been described, for example, by AbM, Chothia, Contact, IMGT, and AHon.
[0057] The term "heavy chain" when used with respect to an antibody refers to a polypeptide chain of about 50-70 kDa, the amino-terminal portion of which contains a variable region of about 120-130 or more amino acids, and the carboxy-terminal portion of which contains a constant region. The constant region can be one of five distinct types (e.g., isotypes) designated alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), based on the amino acid sequence of the heavy chain constant region. The distinct heavy chains vary in size, with α, δ, and γ containing about 450 amino acids, while μ and ε contain about 550 amino acids. When combined with light chains, these distinct types of heavy chains give rise to five well-known classes (e.g., isotypes) of antibodies, IgA, IgD, IgE, IgG, and IgM (which also includes the four subclasses of IgG, i.e., IgG1, IgG2, IgG3, and IgG4).
[0058] The term "light chain" when used in reference to an antibody refers to a polypeptide chain of about 25 kDa, the amino-terminal portion of which contains a variable region of about 100 to about 110 or more amino acids, and the carboxy-terminal portion of which contains a constant region. The approximate length of a light chain is 211 to 217 amino acids. There are two different types, called kappa (κ) or lambda (λ), based on the amino acid sequence of the constant domain.
[0059] As used herein, the terms "hypervariable region", "hypervariable region, HVR", "complementarity determining region" and "Complementarity Determining Region, CDR" are used interchangeably. "CDR" refers to one of the three hypervariable regions (H1, H2, or H3) in the non-framework region of an immunoglobulin (Ig or antibody) VH β-sheet framework or one of the three hypervariable regions (L1, L2, or L3) in the non-framework region of an antibody VL β-sheet framework. Thus, CDRs are variable region sequences interspersed within framework region sequences.
[0060] CDR regions are well known to those skilled in the art and are defined by well-known numbering systems. For example, Kabat complementarity determining regions (CDRs) are based on sequence variability and are the most commonly used (see, e.g., Kabat et al., supra). Chothia instead refers to the position of the structural loop (see, e.g., Chothia and Lesk, J. Mol. Biol., 1987, 196:901-17). The end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies from H32 to H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertion at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32, if only 35A is present, the loop ends at 33, and if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and the Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software (see, for example, Antibody Engineering Vol. 2 (Kontermann and Dubel, eds., 2d ed. 2010)). The "contact" hypervariable regions are based on the analysis of available complex crystal structures. Another universal numbering system that has been developed and widely adopted is the ImMunoGeneTics (IMGT) Information System® (Lafranc, et al., Dev. Comp. Immunol., 2003, 27(1):55-77). IMGT is an integrated information system dedicated to immunoglobulins (IG), T cell receptors (TCR), and major histocompatibility complexes (MHC) of humans and other vertebrates. CDRs are referred to herein in terms of both amino acid sequence and location within a light or heavy chain.The "locations" of the CDRs within the structure of immunoglobulin variable domains are conserved among species and reside in structures called loops, so that the CDR and framework residues are easily identified by using a numbering system that aligns the variable domain sequences according to structural features. This information can be used to graft and replace CDR residues from one species of immunoglobulin into an acceptor framework, typically from a human antibody. An additional numbering system (AHon) has been developed by Honegger and Pluckthun, J. Mol. Biol., 2001, 309:657-70. The correspondence between numbering systems, including, for example, Kaba numbering and the IMGT specific numbering system, is well known to those skilled in the art (see, for example, Kabat, supra; Chothia and Lesk, supra; Martin, supra; Lefranc et al., supra). The residues of each of these hypervariable regions or CDRs are shown below:
[0061] [Table 1]
[0062] The boundaries of a given CDR may vary depending on the scheme used for identification. Thus, unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof, such as a variable region, and the individual CDRs of an antibody or region thereof (e.g., "CDR-H1, CDR-H2"), should be understood to encompass the complementarity determining regions defined by any of the known schemes described herein above. In some cases, a scheme for the identification of a particular CDR or CDRs is specified, such as the CDRs defined by Kabat, Chothia, or Contact methods. In other cases, a particular amino acid sequence of the CDR is included.
[0063] The hypervariable regions may include "extended hypervariable regions" such as: 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3) in VL, and 26-35 or 26-35A (H1), 50-65 or 49-65 (H2), and 93-102, 94-102, or 95-102 (H3) in VH.
[0064] The term "constant region" or "constant domain" refers to the carboxy-terminal portions of the light and heavy chains that are not directly involved in binding the antibody to an antigen, but exhibit various effector functions, such as interaction with Fc receptors. The term refers to the portion of the immunoglobulin molecule that has a more conserved amino acid sequence compared to the other portion of the immunoglobulin, the variable region, which contains the antigen-binding site. The constant region may include the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain.
[0065] The term "framework" or "FR" refers to the variable region residues adjacent to the CDRs. FR residues are present, for example, in chimeric, humanized, human, domain, diabodies, linear, and bispecific antibodies. FR residues are variable domain residues other than hypervariable region or CDR residues. Typically, there are four FR regions in each of the VH and VL regions. The FR regions in VH are VH FR1, VH FR2, VH FR3, and VH FR4 (or FR H1, FR H2, FR H3, and FR H4). The FR regions in VL are VL FR1, VL FR2, VL FR3, and VL FR4 (or FR L1, FR L2, FR L3, and FR L4).
[0066] As used herein, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain, including, for example, native sequence Fc regions, recombinant Fc regions, and variant Fc regions. Although the boundaries of an immunoglobulin heavy chain Fc region can vary, the Fc region of a human IgG heavy chain is often defined as extending from the amino acid residue at position Cys226, or from the amino acid residue at position Pro230, to the carboxyl terminus. The C-terminal lysine of the Fc region (residue 447 according to the EU numbering system) can be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding the antibody heavy chain. Thus, a composition of intact antibodies can include an antibody population in which all K447 residues have been removed, an antibody population in which the K447 residue has not been removed, and an antibody population having a mixture of antibodies with and without the K447 residue. A "functional Fc region" has the "effector functions" of a native sequence Fc region. Exemplary "effector functions" include C1q binding, CDC, Fc receptor binding, ADCC, phagocytosis, downregulation of cell surface receptors (e.g., B cell receptors), and the like. Such effector functions generally require that the Fc region be combined with a binding region or domain (e.g., an antibody variable region or domain) and can be assessed using a variety of assays known to those of skill in the art. A "variant Fc region" comprises an amino acid sequence that differs from that of a native sequence Fc region by at least one amino acid modification (e.g., substitution, addition, or deletion). In certain embodiments, a variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or the Fc region of a parent polypeptide, e.g., about 1 to about 10 amino acid substitutions, or about 1 to about 5 amino acid substitutions in the native sequence Fc region or the Fc region of a parent polypeptide. The variant Fc region herein may have at least about 80% homology to a native sequence Fc region and / or the Fc region of a parent polypeptide, or at least about 90% homology thereto, for example at least about 95% homology thereto.
[0067] The term "variant" when used with respect to an antigen or antibody can refer to a peptide or polypeptide that contains one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) amino acid sequence substitutions, deletions, and / or additions compared to the native or unmodified sequence. For example, a CD37 variant can result from one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) modifications to the amino acid sequence of native CD37. Also, by way of example, a variant of an anti-CD37 antibody can result from one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) modifications to the amino acid sequence of a native or previously unmodified anti-CD37 antibody. The variants may be naturally occurring, such as allelic variants or splice variants, or may be artificially constructed. Polypeptide variants may be prepared from the corresponding nucleic acid molecules encoding the variants. In specific embodiments, the CD37 variants or anti-CD37 antibody variants retain at least the functional activity of CD37 or anti-CD37 antibodies, respectively. In specific embodiments, the anti-CD37 antibody variants bind to CD37 and / or are antagonistic to CD37 activity. In certain embodiments, the variants are encoded by single nucleotide polymorphism (SNP) variants of a nucleic acid molecule encoding a CD37 or anti-CD37 antibody VH or VL region or subregion, e.g., one or more CDRs.
[0068] The term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. "Percent (%) amino acid sequence identity" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, without considering any conservative substitutions as part of the sequence identity to achieve the maximum sequence identity percentage. Alignment for purposes of determining percent amino acid sequence identity can be achieved using a variety of methods within the skill of the art, for example, publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNAStar, Inc.) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared.
[0069] An "alteration" of an amino acid residue / position refers to a change in the primary amino acid sequence compared to the starting amino acid sequence, where the alteration results from a sequence change involving that amino acid residue / position. For example, typical alterations include substitution of a residue with another amino acid (e.g., a conservative or non-conservative substitution), insertion of one or more (e.g., generally less than 5, 4, or 3) amino acids adjacent to that residue / position, and / or deletion of that residue / position.
[0070] As used herein, "epitope" is a term of the art and refers to a localized region of an antigen to which an antibody can specifically bind. An epitope can be a linear or conformational epitope, a non-linear epitope, or a discontinuous epitope. In the case of a polypeptide antigen, for example, an epitope can be consecutive amino acids of a polypeptide (a "linear" epitope), or an epitope can include amino acids from two or more non-contiguous regions of a polypeptide (a "conformational", "non-linear", or "discontinuous" epitope). In general, it will be understood by those skilled in the art that a linear epitope may or may not depend on secondary, tertiary, or quaternary structure. For example, in some embodiments, an antibody binds to a group of amino acids, regardless of whether the amino acids are folded into the native three-dimensional protein structure. In other embodiments, antibodies require that the amino acid residues that make up the epitope exhibit a particular conformation (eg, a bend, twist, turn, or fold) in order to recognize and bind to the epitope.
[0071] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term also refers to amino acid polymers that are naturally modified or modified by intervention, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification. Also included in the definition are polypeptides that contain one or more analogs of an amino acid, including, but not limited to, unnatural amino acids, as well as other modifications known in the art. Because the polypeptides of the present disclosure may be based on antibodies or other members of the immunoglobulin superfamily, it is understood that in certain embodiments, a "polypeptide" can occur as a single chain or as two or more related chains.
[0072] The term "vector" refers to a material used to carry or contain a nucleic acid sequence, such as, for example, a nucleic acid sequence encoding an antibody described herein, to introduce a nucleic acid sequence into a host cell. Vectors applicable for use include, for example, expression vectors, plasmids, phage vectors, viral vectors, episomes, and artificial chromosomes, which may contain an operable selection sequence or marker that can be stably integrated into a host cell chromosome. In addition, the vector may contain one or more selectable marker genes and appropriate expression control sequences. Selectable marker genes that may be included are, for example, those that provide resistance to antibiotics or toxins, complement deficiencies in auxiliary auxotrophies, or supply critical nutrients that are absent in the culture medium. Expression control sequences may include constitutive and inducible promoters, transcription enhancers, transcription terminators, and the like, which are well known in the art. When two or more nucleic acid molecules are to be co-expressed (e.g., both heavy and light chains of an antibody, or antibody VH and VL), both nucleic acid molecules may, for example, be inserted into a single expression vector or into separate expression vectors. In the case of expression in a single vector, the encoding nucleic acids may be operably linked to one common expression control sequence or to different expression control sequences, such as one inducible promoter and one constitutive promoter. Introduction of the nucleic acid molecule into the host cell can be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis such as Northern blot or amplification of mRNA by polymerase chain reaction (PCR), immunoblotting for expression of gene products, or other suitable analytical methods to test the expression of the introduced nucleic acid sequence or its corresponding gene product. Those skilled in the art will understand that the nucleic acid molecule will be expressed in sufficient amounts to produce the desired product, and will further understand that expression levels can be optimized to obtain sufficient expression using methods well known to those skilled in the art.
[0073] As used herein, the term "host" refers to an animal, such as a mammal (eg, a human).
[0074] The term "host cell," as used herein, refers to a particular subject cell into which a nucleic acid molecule can be transfected, and the progeny or potential progeny of such a cell. The progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur during the subsequent generation or integration of the nucleic acid molecule into the host cell genome.
[0075] An "isolated nucleic acid" is a nucleic acid, e.g., RNA, DNA, or mixed nucleic acid, that is substantially separated from other genomic DNA sequences, and from proteins or complexes, such as ribosomes and polymerases, that are naturally associated with the natural sequence. An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid molecule. Additionally, an "isolated" nucleic acid molecule, such as a cDNA molecule, may be substantially free of other cellular material or culture medium if produced by recombinant techniques, or substantially free of chemical precursors or other chemicals if chemically synthesized. In certain embodiments, one or more nucleic acid molecules encoding an antibody described herein are isolated or purified. This term encompasses a nucleic acid sequence that has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates, and chemically synthesized analogs, or biologically synthesized analogs from heterologous systems. A substantially pure molecule may include isolated forms of the molecule.
[0076] "Polynucleotide", "nucleotide" or "nucleic acid", as used interchangeably herein, refers to a polymer of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction. Polynucleotides can include modified nucleotides, such as methylated nucleotides and their analogs. "Oligonucleotides", as used herein, refer to short, generally single-stranded, synthetic polynucleotides, generally, but not necessarily, less than about 200 nucleotides in length. The terms "oligonucleotide" and "polynucleotide" are not mutually exclusive. The above description of polynucleotides is fully applicable to oligonucleotides as well. Cells that produce the antibodies of the present disclosure can include parent hybridoma cells, as well as bacterial and eukaryotic host cells into which nucleic acid encoding the antibody has been introduced. Unless otherwise specified, the left-hand end of any single-stranded polynucleotide sequence disclosed herein is the 5' end. The left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The direction of 5' to 3' addition of the nascent RNA transcript is referred to as the transcription direction. The region of the DNA strand with the same sequence as the RNA transcript at the 5' to 5' end of the RNA transcript is referred to as the "upstream sequence," and the region of the DNA strand with the same sequence as the RNA transcript at the 3' to 3' end of the RNA transcript is referred to as the "downstream sequence."
[0077] As used herein, the term "pharmaceutical acceptable" means approved by a federal or state regulatory agency for use in animals, and more particularly for use in humans, or listed in the United States Pharmacopoeia, the European Pharmacopoeia, or other generally recognized pharmacopoeias.
[0078] "Excipient" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, encapsulating material, etc. Excipients include, for example, encapsulating materials or additives such as absorption enhancers, antioxidants, binders, buffers, carriers, coating agents, colorants, diluents, disintegrants, emulsifiers, expanders, fillers, flavorings, wetting agents, lubricants, flavorings, preservatives, propellants, release agents, bactericides, sweeteners, solubilizers, wetting agents, and mixtures thereof. The term "excipient" can also refer to a diluent, adjuvant (e.g., Freund's adjuvant (complete or incomplete)), or vehicle.
[0079] In some embodiments, the excipient is a pharma- ceutically acceptable excipient. Examples of pharma-ceutically acceptable excipients include buffers such as phosphate, citrate, and other organic acids, antioxidants including ascorbic acid, proteins such as low molecular weight (e.g., less than about 10 amino acid residues) polypeptides, serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine, or lysine, monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, salt-forming counterions such as sodium, and / or non-ionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™. Other examples of pharma-ceutically acceptable excipients are described in Remington and Gennaro, Remington's Pharmaceutical Sciences (18th ed. 1990).
[0080] In one embodiment, each component is "pharmaceutical acceptable" in the sense of being compatible with the other components of the pharmaceutical formulation and suitable for use in contact with human and animal tissues or organs without undue toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio. See, e.g., Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed., Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed., Ash and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed., Gibson Ed., CRC Press LLC: Boca Raton, FL, 2009. In some embodiments, a pharmaceutical acceptable excipient is non-toxic to cells or mammals exposed thereto at the dosages and concentrations employed. In some embodiments, the pharma- ceutically acceptable excipient is an aqueous pH buffered solution.
[0081] In some embodiments, the excipient may be a sterile liquid, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is an exemplary excipient when the composition (e.g., pharmaceutical composition) is administered intravenously. Saline and aqueous dextrose and glycerol solutions may also be employed as liquid excipients, particularly for injectable solutions. Excipients may also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, dried skim milk, glycerin, propylene, glycol, water, ethanol, and the like. If necessary, the composition may further contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition may take the form of a solution, suspension, emulsion, tablet, pill, capsule, powder, sustained-release formulation, and the like. Oral composition containing formulations can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
[0082] The composition containing the pharmaceutical compound can include, for example, the antibody in isolated or purified form, together with a suitable amount of excipients.
[0083] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of an antibody or pharmaceutical composition provided herein that is sufficient to effect a desired result.
[0084] The terms "subject" and "patient" may be used interchangeably herein. As used herein, in certain embodiments, a subject is a mammal, such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) or a primate (e.g., monkeys and humans). In specific embodiments, a subject is a human. In one embodiment, a subject is a mammal, e.g., a human, diagnosed with a condition or disorder. In another embodiment, a subject is a mammal, e.g., a human, at risk of developing a condition or disorder.
[0085] "Administering" or "administration" refers to the act of injecting or otherwise physically delivering a substance present outside the body to a patient, such as by mucosal, intradermal, intravenous, intramuscular, subcutaneous delivery, and / or any other physical delivery method described herein or known in the art.
[0086] As used herein, the terms "treatment" and "treatment / treating" refer to the reduction or amelioration of the progression, severity, and / or duration of a disease or condition resulting from the administration of one or more therapeutics. Treatment may be determined by assessing whether there has been a reduction, alleviation, and / or remission of one or more symptoms associated with the underlying disease, such that an improvement is observed in the patient, even though the patient may still be suffering from the underlying disease. The term "treating" includes both management and amelioration of disease. The terms "manage", "managing", and "management" refer to the beneficial effects that a subject derives from a treatment, and do not necessarily result in a cure of the disease.
[0087] The terms "prevent," "preventing," and "prevention" refer to reducing the likelihood of the onset (or recurrence) of a disease, disorder, condition, or associated symptom.
[0088] The terms "about" and "approximately" refer to within 20%, within 15%, within 10%, within 9%, within 8%, within 7%, within 6%, within 5%, within 4%, within 3%, within 2%, within 1%, or less of a given value or range.
[0089] As used in this disclosure and claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise.
[0090] Whenever an embodiment is described herein with the term "comprising," it is understood that other similar embodiments that would otherwise be described in terms of "consisting of" and / or "consisting essentially of" are also provided. Whenever an embodiment is described herein with the phrase "consisting essentially of," it is also understood that similar embodiments that would otherwise be described in terms of "consisting of" are also provided.
[0091] The term "between" when used in phrases such as "between A and B" or "between A and B" refers to a range that includes both A and B.
[0092] The term "and / or" as used herein in phrases such as "A and / or B" is intended to include both A and B, A or B, A (alone), and B (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C, A, B, or C, A or C, A or B, B or C, A and C, A and B, B and C, A (alone), B (alone), and C (alone).
[0093] Fc variants with enhanced effector function The antibodies provided herein have mutations at lysine at position 248 (K248) (EU numbering) and threonine at position 437 (T437) (EU numbering) in the Fc region.
[0094] Lysine at position 248 (K248) (EU numbering) and threonine at position 437 (T437) (EU numbering) are both conserved residues in the Fc region among different IgG subtypes (Zhang, D., et al., supra). Fc mutations T437R and K248E (EU numbering) have been shown to promote oligomerization of the Fc domain upon antigen binding at the cell surface and to have enhanced effector function (Zhang, D., et al., supra). The T437R and K248E double mutation ("RE mutation") has been shown to confer CDC activity to wild-type IgG1 antibodies that did not possess CDC activity in a dose-dependent manner (Zhang, D., et al., supra).
[0095] "EU numbering" or "EU index" is generally used when referring to residues in immunoglobulin heavy chain constant regions. It refers to the residue numbering of the human IgG1 EU antibody. It is calculated by aligning the antibody sequence with the sequence of the Eu antibody (Edelman, GM, et al., Proc Natl Acad Sci USA, 1969, 63(1):78-85; Kabat, et al., supra), such that each residue that is homologous to a residue in the Eu antibody will have the same residue number as the Eu residue.
[0096] It has also been shown that antibodies containing other Fc region mutations, such as S239D / I332E and S239D / I332E / A330L (EU numbering), exhibit greatly enhanced ADCC via enhanced binding to FcγR (Lazar, GA et al., Proc Natl Acad Sci USA, 2006, 103(11):4005-10).
[0097] Biparatopic or bispecific antibodies In one aspect, provided herein are biparatopic or bispecific binding molecules (such as biparatopic or bispecific antibodies) with RE mutations in the Fc region of the biparatopic or bispecific binding molecule. As demonstrated below, the combination of the biparatopic or bispecific format with the RE mutations further enhances CDC activity compared to the RE mutations alone, among other advantages.
[0098] CDC activity requires activation of the complement cascade, which requires activation of the complement component C1q by a hexamer of the Fc region that is flush with the surface of the target cell. This then requires the simultaneous binding of five or six antibody molecules in close proximity to the cell surface. Due to the need for Fc-mediated antibody oligomerization, CDC activity requires a relatively high target receptor density. In natural IgG antibodies, the stoichiometry of antibody-receptor binding can vary from 1:2 to 1:1 depending on the antibody concentration, with the former being highly favored due to avidity.
[0099] To maximize the number of antibodies that can bind to a given number of cell surface receptors, the antibodies provided herein are formatted as biparatopic or bispecific antibodies that enforce a 1:1 antibody-receptor binding stoichiometry. This allows more Fc regions to be presented on the surface of a cell with a given number of receptors compared to natural bivalent IgG. The biparatopic or bispecific antibodies provided herein have stronger CDC activity than their natural bivalent counterparts.
[0100] For example, antibodies can be formatted as biparatopic or bispecific antibodies using standard techniques known to those of skill in the art, including in vitro expression of recombinant proteins.
[0101] Any biparatopic or bispecific antibody format can be applied to the present constructs, as long as it confers further enhanced CDC activity via increased oligomerization (e.g., hexamerization) of the binding molecule at the cell surface and / or increased C1q engagement.
[0102] In some embodiments, a biparatopic or bispecific antibody comprises a first antigen binding domain comprising a first VH region and a first VL region, a first single domain antigen binding fragment, and / or a first engineered binding fragment, and a second antigen binding domain comprising a second VH region and a second VL region, a second single domain antigen binding fragment, and / or a second engineered binding fragment, wherein the first antigen binding domain and the second antigen binding domain bind to two different epitopes of the same antigen or different antigen(s).
[0103] In some embodiments, each of the first antigen binding domain and the second antigen binding domain is a Fab fragment, an scFv, a single domain antigen binding fragment, or an engineered binding fragment. In some embodiments, the first antigen binding domain is a Fab fragment and the second antigen binding domain is an scFv. In some embodiments, the first antigen binding domain is a Fab fragment and the second antigen binding domain is a single domain antigen binding fragment. In some embodiments, the first antigen binding domain is a Fab fragment and the second antigen binding domain is an engineered binding fragment. In some embodiments, the first antigen binding domain is an scFv and the second antigen binding domain is a single domain antigen binding fragment. In some embodiments, the first antigen binding domain is an scFv and the second antigen binding domain is an engineered binding fragment. In some embodiments, the first antigen binding domain is a single domain antigen binding fragment and the second antigen binding domain is an engineered binding fragment.
[0104] In some embodiments, a biparatopic or bispecific antibody comprises two Fab and Fc domains, A first Fab binds to a first epitope on the antigen and a second Fab binds to a second epitope on the antigen; a biparatopic or bispecific antibody comprises two heavy chains and two light chains, where the first heavy chain and the first light chain form a first Fab, the second heavy chain and the second light chain form a second Fab, and the C-terminus of the two heavy chains form an Fc domain.
[0105] In some embodiments, a biparatopic or bispecific antibody comprises two single chain variable fragments (scFvs) and an Fc domain, where a first scFv binds to a first epitope of an antigen and a second scFv binds to a second epitope of an antigen; a biparatopic or bispecific antibody comprises two polypeptides, where the first polypeptide comprises the first scFv at its N-terminus and the second polypeptide comprises the second scFv at its N-terminus, and the C-terminus of the two polypeptides form the Fc domain.
[0106] In some embodiments, a biparatopic or bispecific antibody comprises two single domain antigen-binding fragments and an Fc domain, a first single domain antigen-binding fragment binds a first epitope of an antigen and a second single domain antigen-binding fragment binds a second epitope of an antigen, the biparatopic or bispecific antibody comprises two polypeptides, the first polypeptide comprises the first single domain antigen-binding fragment at its N-terminus and the second polypeptide comprises the second single domain antigen-binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0107] In some embodiments, a biparatopic or bispecific antibody comprises two engineered binding fragments and an Fc domain, where a first engineered binding fragment binds to a first epitope of an antigen and a second engineered binding fragment binds to a second epitope of the antigen; a biparatopic or bispecific antibody comprises two polypeptides, where the first polypeptide comprises a first engineered binding fragment at its N-terminus and the second polypeptide comprises a second engineered binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0108] In some embodiments, the biparatopic or bispecific antibody comprises a Fab, a single chain variable fragment (scFv) and an Fc domain, wherein the Fab binds to a first epitope of an antigen and the scFv binds to a second epitope of the antigen, the biparatopic or bispecific antibody comprises a heavy chain, a light chain and a polypeptide, wherein the heavy chain and the light chain form a Fab, and the polypeptide comprises an scFv at its N-terminus and a domain at its C-terminus that forms the Fc domain together with the heavy chain.
[0109] In some embodiments, the biparatopic or bispecific antibody comprises a Fab, a single domain antigen-binding fragment and an Fc domain, wherein the Fab binds to a first epitope of the antigen and the single domain antigen-binding fragment binds to a second epitope of the antigen; the biparatopic or bispecific antibody comprises a heavy chain, a light chain and a polypeptide, wherein the heavy chain and the light chain form a Fab, and the polypeptide comprises at its N-terminus the single domain antigen-binding fragment and at its C-terminus a domain which, together with the heavy chain, forms the Fc domain.
[0110] In some embodiments, the biparatopic or bispecific antibody comprises a Fab, an engineered binding fragment, and an Fc domain, where the Fab binds to a first epitope of an antigen and the engineered binding fragment binds to a second epitope of the antigen, the biparatopic or bispecific antibody comprises a heavy chain, a light chain, and a polypeptide, where the heavy chain and the light chain form a Fab, and the polypeptide comprises the engineered binding fragment at its N-terminus and a domain at its C-terminus that forms the Fc domain with the heavy chain.
[0111] In some embodiments, a biparatopic or bispecific antibody comprises a single chain variable fragment (scFv), a single domain antigen-binding fragment and an Fc domain, wherein the scFv binds to a first epitope of an antigen and the single domain antigen-binding fragment binds to a second epitope of an antigen; a biparatopic or bispecific antibody comprises two polypeptides, a first polypeptide comprising an scFv at its N-terminus and a second polypeptide comprising a single domain antigen-binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0112] In some embodiments, a biparatopic or bispecific antibody comprises a single chain variable fragment (scFv), an engineered binding fragment and an Fc domain, where the scFv binds to a first epitope of an antigen and the engineered binding fragment binds to a second epitope of the antigen, and the biparatopic or bispecific antibody comprises two polypeptides, where a first polypeptide comprises an scFv at its N-terminus and a second polypeptide comprises the engineered binding fragment at its N-terminus, and the C-terminus of the two polypeptides form the Fc domain.
[0113] In some embodiments, a biparatopic or bispecific antibody comprises a single domain antigen-binding fragment, an engineered binding fragment and an Fc domain, wherein the single domain antigen-binding fragment binds to a first epitope of an antigen and the engineered binding fragment binds to a second epitope of the antigen, a biparatopic or bispecific antibody comprises two polypeptides, a first polypeptide comprises a single domain antigen-binding fragment at its N-terminus and a second polypeptide comprises an engineered binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0114] Hypofucosylation In another aspect, the biparatopic or bispecific binding molecules provided herein do not contain fucose in the oligosaccharides covalently attached to the Fc region of the binding molecule. In another aspect, a population of biparatopic or bispecific binding molecules is provided herein, wherein less than 80% of the oligosaccharides covalently attached to the Fc region of the binding molecule contain fucose.
[0115] Antibody glycosylation is a type of post-translational modification that can occur through the addition of oligosaccharides to antibodies via two types of covalent bonds: attachment to asparagine residues (N-oligosaccharides) or attachment to serine / threonine residues (O-oligosaccharides) (Alter, G., et al., Semin Immunol., 2018, 39:102-10), and has a profound impact on the therapeutic function of antibodies (Walsh, G. and Jefferis, R., Nat. Biotechnol., 2006, 24:1241-52; Jefferis, R., Nat. Rev. Drug Discov., 2009, 8(3):226-34; Dalziel, M., et al., Science, 2014, 343(6166):1235681). In particular, all IgG antibodies are glycosylated at the conserved Asn-297 residue in their Fc region (Alter G., et al., supra).
[0116] The Asn-297-linked N-oligosaccharides consist of a conserved biantennary core structure (Liu, L., J Pharm Sci., 2015, 104(6):1866-84), which consists of two covalently linked N-acetylglucosamine (GlcNAc) residues, further linked to a mannose, which is linked to two other mannose residues in a 1,3- and 1,6-branched manner (Alter, G., et al., supra). Additional monosaccharides including two galactoses, a fucose, a bisecting GlcNAc, and two sialic acids (Alter, G., et al., supra) may extend the core structure, resulting in considerable structural and functional heterogeneity (Jefferis, R., Biochem J., 1990, 268(3):529-37; Rudd, P. M., Science, 2001, 291(5512):2370-6; Liu, L., supra). At least 30 structures (glycoforms) of the Asn-297-linked N-oligosaccharide of IgG have been reported (Alter, G., et al., supra).
[0117] Antibodies expressed in mammalian cells are typically greater than 80% fucosylated (Kamoda, S., et al., J Chromatogr A., 2004, 1050(2):211-6; Shinkawa, T., et al., J Biol Chem., 2003, 278(5):3466-73). For example, normal Chinese Hamster Ovary (CHO) cells and HEK293 cells add fucose to 80-98% of the Asn-297-linked N-oligosaccharides to IgG antibodies (Shields, RL et al., J Biol Chem., 2002, 277(30):26733-40).
[0118] In one aspect, provided herein is an antibody that does not have fucose in the oligosaccharides attached to its Fc region and has a RE mutation in the Fc region. In another aspect, provided herein is a population of antibodies comprising antibodies that do not have fucose in the oligosaccharides attached to their Fc region and have a RE mutation in the Fc region. In yet another aspect, provided herein is a population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue, and the Fc regions of these antibodies comprise a K248E mutation and a T437R mutation (RE mutation).
[0119] In some embodiments, less than 70% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In some embodiments, less than 60% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In some embodiments, less than 50% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In some embodiments, less than 40% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In still other embodiments, less than 30% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In still other embodiments, less than 20% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In still other embodiments, less than 10% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue.
[0120] Standard techniques known to those skilled in the art, such as mass spectrometry, can be used to characterize the Asn297-linked N-oligosaccharides on the antibodies (Pereira, NA, et al., supra; Shields, RL et al., supra). For example, for matrix-assisted laser desorption / ionization time-of-flight mass spectral (MALDI-TOF-MS) analysis, 50 mg of IgG antibodies were immobilized on a polyvinylidene difluoride membrane in a MultiScreen 96-well IP plate (Millipore). The proteins were then reduced using 50 mL of a 0.1 M solution of DTT in RCM buffer (pH 8.6, 3.2 mM EDTA, 360 mM Tris, and 8 M urea). They were then incubated in the dark at 25° C. for 30 min in RCM buffer containing 0.1 M iodoacetic acid to carboxymethylate the free sulfhydryl groups resulting from the reduction step. The membrane-bound proteins were then incubated in a 1% aqueous solution of polyvinylpyrrolidone 360 (Sigma) for 1 h at 25° C., and their oligosaccharides were cleaved from the proteins by a three-step process: incubation in pH 8.4 Tris acetate buffer (25 mL) containing 32 units of peptide:N-glycosidase F (New England Biolabs, Beverly, Mass.) for 3 h at 37° C., addition of 1.5 M acetic acid (2.5 mL) to lower the pH, and incubation at 25° C. for 3 h (Shields, RR et al., J Biol Chem., 2001, 276(9):6591-604).
[0121] In some embodiments, the antibodies provided herein are produced by expressing a polynucleotide encoding the antibody or fragment thereof in a host cell that is defective in adding fucose to the oligosaccharides attached to the antibody.
[0122] In mammalian cells, FUT8 encodes the sole enzyme, α-1,6 fucosyltransferase, that catalyzes core fucosylation (the transfer of a GDP-fucose residue to the innermost GlcNAc via an α-1,6-linkage) (Imai-Nishiya, H., et al., BMC Biotechnol., 2007, 7:84). Oligosaccharide fucosylation requires intracellular GDP-fucose as a substrate, which is synthesized in the cytoplasm via de novo or salvage pathways. In the de novo pathway, GDP-mannose 4,6-dehydratase (GMD) mediates the synthesis of GDP-4-keto-6-deoxy-mannose (GKDM) from GDP-mannose, followed by GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase (FX) to synthesize GDP-fucose (Imai-Nishiya, H., et al., supra). Thus, cell lines deficient in the GMD enzyme, such as CHO Lec13 cells, or reduced α-1,6 fucosyltransferase activity due to mutations in the FUT8 gene, have been shown to produce afucosylated antibodies (Pereira, NA, et al., Mabs, 2018, 10(5):693-711). For example, antibodies with about 10% fucosylation (Shields, RL et al., supra) or less can be consistently produced in Lec13 cells (Shields, RL et al., supra; Kanda Y., Biotechnol Bioeng., 2006, 94(4):680-8), whereas increased fucosylation can occur when cells are cultured to confluence in static flasks (Pereira, NA, et al., supra).
[0123] Addition of a bisecting GlcNAc to the oligosaccharide core structure sterically hampers fucosylation (Alter, G., et al., supra). Accordingly, overexpression of β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (GnT-III), which catalyzes the addition of a bisecting GlcNAc to the innermost mannose, was shown to significantly reduce Fc fucosylation (Pereira, N. A., et al., supra).
[0124] Furthermore, an inactivated Golgi GDP-fucose transporter (GFT) gene (Slc35c1) has been shown to produce afucosylated antibodies, for example, in CHO-gmt3 cells (Pereira, NA, et al., supra). Afucosylated antibodies can also be generated by using biochemical inhibitors of fucosylation, such as fucose analogs, such as 2-fluorofucose and 5-alkynylfucose (Pereira, NA, et al., supra). The intermediate GKDM in the fucose de novo synthesis pathway in mammalian cells can be reduced to GDP-rhamnose by bacterial GDP-4-keto-6-deoxy mannose reductase (RMD), thus bypassing the fucose biosynthetic pathway. Afucosylated antibodies can also be generated in cells in which bacterial RMD is heterologously expressed in the cytosol (Pereira, NA, et al., supra).
[0125] In some embodiments, the antibody provided herein is produced by expressing the antibody in a host cell that has a deficiency in any of the above enzymes.In some embodiments, the host cell has reduced GDP-mannose 4,6-dehydratase (GMD) activity.In some embodiments, the host cell has reduced α-1,6 fucosyltransferase activity.
[0126] ADCC, CDC, and ADCP effector functions The antibodies or populations of antibodies provided herein have enhanced ADCC activity, enhanced CDC activity, and / or enhanced ADCP activity.
[0127] Therapeutic antibodies bind to Fc receptors on the cell surface of effector cells such as NK cells, macrophages, monocytes, neutrophils and eosinophils (Saunder, KO, Front Immunol., 2019, 10:1296), resulting in important antibody-dependent effector functions such as ADCC and ADCP. The family of receptors for the Fc region of IgG is called Fcγ receptors (FcγR) (Cohen-Solal, JF, Immunol Lett., 2004, 92(3):199-205), and consists of FcγRI; FcγRII, which includes isoforms FcγRIIa, FcγRIIb, and FcγRIIc; and FcγRIII, which includes isoforms FcγRIIIa and FcγRIIIb (Jefferis, R. and Lund, J., Immunol Lett., 2002, 82(1-2):57-65).
[0128] Among various effector functions, ADCC and ADCP have been shown to have clinically significant antitumor effects. For example, ADCC has been shown to be a key mechanism of antitumor efficacy of trastuzumab in vitro, as evidenced by the ability of NK cells to kill trastuzumab-coated tumor cells via an FcγRIII receptor (CD16)-mediated ADCC mechanism (Cooley, S., et al., Exp Hematol., 1999;27(10):1533-41; Carson, WE, et al., Eur J Immunol., 2001,31(10):3016-3025; Kubo, M., et al., Anticancer Res., 2003,23(6a):4443-9), and in vivo, as evidenced by increased numbers of NK cells in tumor infiltrates following trastuzumab treatment (Clynes, RA, et al., Nat Med., 2000,6(4):443-6; Arnould, L., et al., Br J Immunol., 2003,23(6a):4443-9). Cancer, 2006, 94(2):259-67). In addition, macrophage-mediated ADCP has been shown to be important in the antitumor effect of trastuzumab (Shi, Y., et al., J Immunol., 2015, 194(9):4379-86).
[0129] Non- or hypofucosylated antibodies showed dramatically enhanced ADCC activity due to their enhanced binding ability to FcγRIIIa binding without detectable changes in CDC or antigen binding ability (Okazaki, A., et al., J Mol Biol., 2004, 336(5):1239-49; Kanda, Y., et al., Glycobiology, 2007, 17(1):104-18). N-oligosaccharides of antibody Fc regions are essential for binding to FcγR, which is involved in the effector functions of antibodies (Yamane-Ohnuki, N. and Satoh, M., Mabs, 2009, 1(3):230-6).
[0130] It has been shown that the absence of fucose on the N-oligosaccharides of the antibody Fc region dramatically enhances the binding ability of the antibody to the FcγRIIIa receptor present on immune effector cells such as NK cells and macrophages, resulting in antitumor therapeutic effects (Pereira, NA, et al., supra). The FcγRIIIa receptor binds to the Fc region through interactions with the hinge region and CH2 domain of Fc (Radaev, S., et al., J Biol Chem., 2001, 276:16469-77; Sondermann, P., et al., Nature, 2000, 406:267-73). Thus, the absence of fucose eliminates steric hindrance and enhances Fc-FcγRIIIa interaction, resulting in enhanced effector function (Pereira, NA, et al., supra).
[0131] CDC is another important antibody effector function. In the antibody-dependent classical complement activation pathway, binding between the complement C1q heterohexameric headpiece and oligomeric antibody complexes initiates the protein complement cascade reaction (Wang, G. et al., Mol Cell, 2016, 63: 135-45; Diebolder, CA et al., Science, 2014, 343: 1260-3), which leads to opsonization of target cells with C3-derived opsonins (e.g., C3b) and the generation of potent inflammatory mediators (C3a and C5a), ultimately resulting in the formation of the membrane attack complex (MAC) (C5b-C9) on the target cell membrane (Reis, ES, et al., Nat Rev Immunol., 2018, 18: 5-18). CDC has also been shown to have clinically significant antitumor effects with the anti-CD20 mAb rituximab and the anti-CD38 mAb daratumumab (de Weers, M., et al., J Immunol., 2011, 186:1840-8; Lokhorst, HM, et al., N Engl J Med., 2015, 373:1207-19; Taylor, RP and Lindorfer, MA, Semin Immunol., 2016, 28:309-16).
[0132] Mutations in the Fc region that promote antibody oligomerization, such as the RE mutation and E345R (EU numbering), have been demonstrated to significantly enhance the CDC activity of antibodies (Diebolder, CA et al., supra; Zhang, D., et al., supra).
[0133] The biparatopic or bispecific antibodies disclosed herein allow for more Fc regions to be presented on the surface of a cell with a given number of receptors compared to natural bivalent IgG, and therefore the engineered biparatopic or bispecific antibodies have stronger CDC activity.
[0134] In some embodiments, the ADCC activity of the antibody is 10% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 20% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 30% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 40% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 50% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 60% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 70% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 80% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 90% higher than the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than twice as high as the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than three times that of the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than four times that of the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than five times that of the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than six times that of the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than seven times that of the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than eight times that of the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than nine times that of the antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than ten times that of the antibody with normal fucosylation.
[0135] In some embodiments, the antibody also has a higher CDC activity. In some embodiments, the CDC activity of the antibody is 10% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 20% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 30% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 40% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 50% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 60% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 70% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 80% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is 90% higher than the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than twice as high as the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than three times that of the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than four times that of the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than five times that of the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than six times that of the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than seven times that of the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than eight times that of the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than nine times that of the antibody without the RE mutation. In some embodiments, the CDC activity of the antibody is more than ten times that of the antibody without the RE mutation.
[0136] In some embodiments, the antibodies also have higher CDC activity. In some embodiments, the CDC activity of the antibody is 10% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 20% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 30% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 40% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 50% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 60% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 70% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 80% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is 90% higher than the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than two times higher than the CDC activity of the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than three times higher than the CDC activity of the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than four times higher than the CDC activity of the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than five times higher than the CDC activity of the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than six times higher than the CDC activity of the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than seven times higher than the CDC activity of the antibody without a biparatopic or bispecific format.In some embodiments, the CDC activity of the antibody is more than 8-fold higher than the CDC activity of the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than 9-fold higher than the CDC activity of the antibody without a biparatopic or bispecific format. In some embodiments, the CDC activity of the antibody is more than 10-fold higher than the CDC activity of the antibody without a biparatopic or bispecific format.
[0137] Exemplary Biparatopic or Bispecific Antibodies In one embodiment, provided herein are biparatopic or bispecific antibodies derived from one or more conventional bivalent antibodies.
[0138] In yet another aspect, biparatopic or bispecific antibodies are provided herein that compete with one of the known biparatopic or bispecific antibodies. Such biparatopic or bispecific antibodies may bind to the same epitope as one of the known biparatopic or bispecific antibodies, or to an overlapping epitope. Antibodies that compete with or bind to the same epitope are expected to exhibit similar functional properties.
[0139] In certain embodiments, the biparatopic or bispecific antibodies described herein comprise an amino acid sequence that has a certain percent identity compared to one of the known biparatopic or bispecific antibodies or exemplary biparatopic or bispecific antibodies described in Section 7 below.
[0140] The determination of percent identity between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be achieved using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm used to compare two sequences is the algorithm of Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 1990, 87:2264-8, modified as in Karlin and Altschul, Proc. Natl. Acad. Sci. USA 1993, 90:5873-7. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al., J. Mol. Biol., 1990, 215:403. BLAST nucleotide searches can be performed with the parameters of the NBLAST nucleotide program set to, for example, score=100 and word length=12 to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed with XBLAST program parameters set, for example, to score 50 and word length = 3 to obtain amino acid sequences homologous to the protein molecules described herein. To obtain gapped alignments for comparison purposes, GappedBLAST can be used as described in Altschul et al., Nucleic Acids Res., 1997, 25:3389-402. Alternatively, PSI BLAST can be used to perform an iterated search that detects distant relationships between molecules (ibid.). When using BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used (see, for example, the National Center for Biotechnology Information (NCBI) on the World Wide Web, ncbi.nlm.nih.gov). Another preferred, non-limiting example of a mathematical algorithm used for sequence comparison is the algorithm of Myers and Miller, 1988, CABIOS 4:11 17.Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
[0141] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating the percent identity, typically only exact matches are counted.
[0142] In certain embodiments, provided herein are biparatopic or bispecific antibodies comprising an Fc region having RE mutations but no fucose residues.
[0143] Standard techniques known to those of skill in the art can be used to introduce mutations into the nucleotide sequences encoding the biparatopic or dual specificity provided herein, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis resulting in amino acid substitutions.
[0144] In some embodiments, the Fc region of the biparatopic or bispecific antibody provided herein is substituted with lysine for glutamic acid at position 248 (K248E) (EU numbering). In some embodiments, the Fc region of the biparatopic or bispecific antibody provided herein is substituted with alanine for glutamic acid at position 338 (K338A) (EU numbering). In some embodiments, the Fc region of the biparatopic or bispecific antibody provided herein is substituted with threonine at position 437 (T437R) (EU numbering). In some embodiments, the Fc region of the biparatopic or bispecific antibody provided herein is substituted with lysine for glutamic acid at position 248 and threonine for arginine at position 437 (K248E / T437R) (EU numbering). In some embodiments, the Fc region of a biparatopic or bispecific antibody provided herein has a substitution of alanine for glutamic acid at position 338 and threonine for arginine at position 437 (K248E / T437R) (EU numbering).
[0145] In some embodiments, the biparatopic or bispecific antibodies provided herein comprise a heavy chain that comprises a T437R mutation. In some embodiments, the biparatopic or bispecific antibodies provided herein comprise a heavy chain that comprises a K248E mutation. In some embodiments, the biparatopic or bispecific antibodies provided herein comprise a heavy chain that comprises a K338A mutation. In some embodiments, the biparatopic or bispecific antibodies provided herein comprise a heavy chain that comprises a K248E / T437R mutation. In some embodiments, the biparatopic or bispecific antibodies provided herein comprise a heavy chain that comprises a K338A / T437R mutation.
[0146] Standard techniques known to those of skill in the art can be used to produce biparatopic or bispecific antibodies provided herein having heavy chains that do not contain a fucose residue in their Asn-297 linked N-oligosaccharide. For example, mammalian cell lines that are deficient in GMD enzymes (e.g., CHO Lec13 cells), have reduced α-1,6 fucosyltransferase activity due to a mutated FUT8 gene, overexpress β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (GnT-III), have an inactivated Golgi GDP-fucose transporter (GFT) gene Slc35c1 (e.g., CHO-gmt3 cells), heterologously express bacterial RMD, or with the use of biochemical inhibitors of fucosylation (e.g., fucose analogs such as 2-fluorofucose and 5-alkynylfucose) have been shown to produce antibodies that do not have a fucose residue in the Asn-297 linked N-oligosaccharide on the heavy chain (Pereira, NA, et al., supra; Shields, RL et al., supra; Kanda Y., supra).
[0147] In some embodiments, a biparatopic or bispecific antibody comprises a heavy chain that does not contain a fucose residue on its Asn-297 linked N-oligosaccharide.
[0148] For example, antibodies can be formatted as biparatopic or bispecific antibodies using standard techniques known to those of skill in the art, including in vitro expression of recombinant proteins.
[0149] In some embodiments, a biparatopic or bispecific antibody comprises a first antigen binding domain comprising a first VH region and a first VL region, a first single domain antigen binding fragment, and / or a first engineered binding fragment, and a second antigen binding domain comprising a second VH region and a second VL region, a second single domain antigen binding fragment, and / or a second engineered binding fragment, wherein the first antigen binding domain and the second antigen binding domain bind to two different epitopes of the same antigen or different antigen(s).
[0150] In some embodiments, each of the first antigen binding domain and the second antigen binding domain is a Fab fragment, an scFv, a single domain antigen binding fragment, or an engineered binding fragment. In some embodiments, the first antigen binding domain is a Fab fragment and the second antigen binding domain is an scFv. In some embodiments, the first antigen binding domain is a Fab fragment and the second antigen binding domain is a single domain antigen binding fragment. In some embodiments, the first antigen binding domain is a Fab fragment and the second antigen binding domain is an engineered binding fragment. In some embodiments, the first antigen binding domain is an scFv and the second antigen binding domain is a single domain antigen binding fragment. In some embodiments, the first antigen binding domain is an scFv and the second antigen binding domain is an engineered binding fragment. In some embodiments, the first antigen binding domain is a single domain antigen binding fragment and the second antigen binding domain is an engineered binding fragment.
[0151] In some embodiments, a biparatopic or bispecific antibody comprises two Fab and Fc domains, A first Fab binds to a first epitope on the antigen and a second Fab binds to a second epitope on the antigen; a biparatopic or bispecific antibody comprises two heavy chains and two light chains, where the first heavy chain and the first light chain form a first Fab, the second heavy chain and the second light chain form a second Fab, and the C-terminus of the two heavy chains form an Fc domain.
[0152] In some embodiments, a biparatopic or bispecific antibody comprises two single chain variable fragments (scFvs) and an Fc domain, where a first scFv binds to a first epitope of an antigen and a second scFv binds to a second epitope of an antigen; a biparatopic or bispecific antibody comprises two polypeptides, where the first polypeptide comprises the first scFv at its N-terminus and the second polypeptide comprises the second scFv at its N-terminus, and the C-terminus of the two polypeptides form the Fc domain.
[0153] In some embodiments, a biparatopic or bispecific antibody comprises two single domain antigen-binding fragments and an Fc domain, a first single domain antigen-binding fragment binds a first epitope of an antigen and a second single domain antigen-binding fragment binds a second epitope of an antigen, the biparatopic or bispecific antibody comprises two polypeptides, the first polypeptide comprises the first single domain antigen-binding fragment at its N-terminus and the second polypeptide comprises the second single domain antigen-binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0154] In some embodiments, a biparatopic or bispecific antibody comprises two engineered binding fragments and an Fc domain, where a first engineered binding fragment binds to a first epitope of an antigen and a second engineered binding fragment binds to a second epitope of the antigen; a biparatopic or bispecific antibody comprises two polypeptides, where the first polypeptide comprises a first engineered binding fragment at its N-terminus and the second polypeptide comprises a second engineered binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0155] In some embodiments, the biparatopic or bispecific antibody comprises a Fab, a single chain variable fragment (scFv) and an Fc domain, wherein the Fab binds to a first epitope of an antigen and the scFv binds to a second epitope of the antigen, the biparatopic or bispecific antibody comprises a heavy chain, a light chain and a polypeptide, wherein the heavy chain and the light chain form a Fab, and the polypeptide comprises an scFv at its N-terminus and a domain at its C-terminus that forms the Fc domain together with the heavy chain.
[0156] In some embodiments, the biparatopic or bispecific antibody comprises a Fab, a single domain antigen-binding fragment and an Fc domain, wherein the Fab binds to a first epitope of the antigen and the single domain antigen-binding fragment binds to a second epitope of the antigen; the biparatopic or bispecific antibody comprises a heavy chain, a light chain and a polypeptide, wherein the heavy chain and the light chain form a Fab, and the polypeptide comprises at its N-terminus the single domain antigen-binding fragment and at its C-terminus a domain which, together with the heavy chain, forms the Fc domain.
[0157] In some embodiments, the biparatopic or bispecific antibody comprises a Fab, an engineered binding fragment, and an Fc domain, where the Fab binds to a first epitope of an antigen and the engineered binding fragment binds to a second epitope of the antigen, the biparatopic or bispecific antibody comprises a heavy chain, a light chain, and a polypeptide, where the heavy chain and the light chain form a Fab, and the polypeptide comprises the engineered binding fragment at its N-terminus and a domain at its C-terminus that forms the Fc domain with the heavy chain.
[0158] In some embodiments, a biparatopic or bispecific antibody comprises a single chain variable fragment (scFv), a single domain antigen-binding fragment and an Fc domain, wherein the scFv binds to a first epitope of an antigen and the single domain antigen-binding fragment binds to a second epitope of an antigen; a biparatopic or bispecific antibody comprises two polypeptides, a first polypeptide comprising an scFv at its N-terminus and a second polypeptide comprising a single domain antigen-binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0159] In some embodiments, a biparatopic or bispecific antibody comprises a single chain variable fragment (scFv), an engineered binding fragment and an Fc domain, where the scFv binds to a first epitope of an antigen and the engineered binding fragment binds to a second epitope of the antigen, and the biparatopic or bispecific antibody comprises two polypeptides, where a first polypeptide comprises an scFv at its N-terminus and a second polypeptide comprises the engineered binding fragment at its N-terminus, and the C-terminus of the two polypeptides form the Fc domain.
[0160] In some embodiments, a biparatopic or bispecific antibody comprises a single domain antigen-binding fragment, an engineered binding fragment and an Fc domain, wherein the single domain antigen-binding fragment binds to a first epitope of an antigen and the engineered binding fragment binds to a second epitope of the antigen, a biparatopic or bispecific antibody comprises two polypeptides, a first polypeptide comprises a single domain antigen-binding fragment at its N-terminus and a second polypeptide comprises an engineered binding fragment at its N-terminus, and the C-terminus of the two polypeptides form an Fc domain.
[0161] In some embodiments, the cancer cell is a cell of adrenal gland cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic, head and neck cancer, Hodgkin's lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, soft tissue sarcoma spinal cancer, gastric cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer. In some embodiments, the cancer is adrenal gland cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic, head and neck cancer, Hodgkin's lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, soft tissue sarcoma spinal cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer. In some embodiments, the cancer is adrenal gland cancer. In some embodiments, the cancer is anal cancer. In some embodiments, the cancer is appendix cancer. In some embodiments, the cancer is bile duct cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is bone cancer. In some embodiments, the cancer is brain cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is cervical cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is gallbladder cancer. In some embodiments, the cancer is gestational trophoblastic. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is Hodgkin's lymphoma. In some embodiments, the cancer is intestinal cancer. In some embodiments, the cancer is renal cancer. In some embodiments, the cancer is leukemia. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is mesothelioma. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is a neuroendocrine tumor. In some embodiments, the cancer is a non-Hodgkin's lymphoma.In some embodiments, the cancer is oral cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is sinus cancer. In some embodiments, the cancer is skin cancer. In some embodiments, the cancer is soft tissue sarcoma spinal cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is testicular cancer. In some embodiments, the cancer is pharyngeal cancer. In some embodiments, the cancer is thyroid cancer. In some embodiments, the cancer is uterine cancer endometrial cancer. In some embodiments, the cancer is vaginal cancer. In some embodiments, the cancer is vulvar cancer.
[0162] In some embodiments, the adrenal cancer is an adrenal cortical carcinoma (ACC), adrenocortical carcinoma, pheochromocytoma, or neuroblastoma. In some embodiments, the anal cancer is a squamous cell carcinoma, a cloacal carcinoma, an adenocarcinoma, a basal cell carcinoma, or a melanoma. In some embodiments, the appendix cancer is a neuroendocrine tumor (NET), a mucinous adenocarcinoma, a goblet cell carcinoid, an intestinal type adenocarcinoma, or a signet ring cell adenocarcinoma. In some embodiments, the cholangiocarcinoma is an extrahepatic cholangiocarcinoma, an adenocarcinoma, a perihilar cholangiocarcinoma, a perihilar cholangiocarcinoma, a distal cholangiocarcinoma, or an intrahepatic cholangiocarcinoma. In some embodiments, the bladder cancer is a transitional cell carcinoma (TCC), a papillary carcinoma, a squamous carcinoma, a squamous cell carcinoma, an adenocarcinoma, a small cell carcinoma, or a sarcoma. In some embodiments, the bone cancer is primary bone cancer, sarcoma, osteosarcoma, chondrosarcoma, sarcoma, fibrosarcoma, malignant fibrous histiocytoma, giant cell tumor of bone, chordoma, or metastatic bone cancer. In some embodiments, the brain cancer is astrocytoma, brain stem glioma, glioblastoma, meningioma, ependymoma, oligodendroglioma, mixed glioma, pituitary carcinoma, pituitary adenoma, craniopharyngioma, germ cell tumor, pineal tumor, medulloblastoma, or primary CNS lymphoma. In some embodiments, the breast cancer is breast adenocarcinoma, invasive breast cancer, non-invasive breast cancer, breast sarcoma, metaplastic carcinoma, adenocystic carcinoma, phyllodes tumor, angiosarcoma, HER2 positive breast cancer, triple negative breast cancer, or inflammatory breast cancer. In some embodiments, the cervical cancer is squamous cell carcinoma or adenocarcinoma. In some embodiments, the colorectal cancer is colorectal adenocarcinoma, primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, carcinoid tumor, mucinous adenocarcinoma, signet ring cell adenocarcinoma, gastrointestinal carcinoid tumor, or melanoma. In some embodiments, the esophageal cancer is an adenocarcinoma or squamous cell carcinoma. In some embodiments, the gallbladder cancer is an adenocarcinoma, papillary adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, small cell carcinoma, or sarcoma. In some embodiments, the gestational trophoblastic disease (GTD) is a hydatidiform mole, a gestational trophoblastic neoplasm (GTN), choriocarcinoma, placental site trophoblastic tumor (PSTT), or an epithelioid trophoblastic tumor (ETT). In some embodiments, the head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity cancer, paranasal sinus cancer, salivary gland cancer, oral cavity cancer, oropharyngeal cancer, or tonsil cancer.In some embodiments, the Hodgkin's lymphoma is classical Hodgkin's lymphoma, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocytopenic, or nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). In some embodiments, the intestinal cancer is small intestine cancer, small bowel cancer, adenocarcinoma, sarcoma, gastrointestinal stromal tumor, carcinoid tumor, or lymphoma. In some embodiments, the kidney cancer is renal cell carcinoma (RCC), clear cell RCC, papillary RCC, chromophobe RCC, collecting duct RCC, unclassified RCC, transitional cell carcinoma, urothelial carcinoma, renal pelvic carcinoma, or renal sarcoma. In some embodiments, the leukemia is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), hairy cell leukemia (HCL), or myelodysplastic syndrome (MDS). In certain embodiments, the leukemia is AML. In some embodiments, the liver cancer is hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, or liver metastasis. In some embodiments, the lung cancer is small cell lung cancer, small cell carcinoma, hybrid small cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, squamous cell lung carcinoma, large cell undifferentiated carcinoma, lung nodule, metastatic lung cancer, adenosquamous carcinoma, large cell neuroendocrine carcinoma, salivary gland type lung carcinoma, lung carcinoid, mesothelioma, sarcomatoid carcinoma of the lung, or malignant granular cell lung tumor. In some embodiments, the melanoma is superficial spreading melanoma, nodular melanoma, acral lentigo melanoma, lentigo maligna melanoma, amelanotic melanoma, desmoplastic melanoma, ocular melanoma, or metastatic melanoma. In some embodiments, the mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or testicular mesothelioma. In some embodiments, the multiple myeloma is active or smoldering multiple myeloma. In some embodiments, the neuroendocrine tumor is a gastrointestinal neuroendocrine tumor, a pancreatic neuroendocrine tumor, or a pulmonary neuroendocrine tumor.In some embodiments, the non-Hodgkin's lymphoma is selected from the group consisting of anaplastic large cell lymphoma, lymphoblastic lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma, Burkitt's lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), precursor T-lymphoblastic leukemia / lymphoma, acute lymphocytic leukemia (ALL), adult T-cell lymphoma / leukemia (ATLL), hairy cell leukemia, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, primary central nervous system (CNS) lymphoma, and / or primary idiopathic leukemia. The primary cutaneous anaplastic large cell lymphoma is a peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), systemic ALCL, enteropathy-type T-cell lymphoma (EATL), or hepatosplenic gamma / delta T-cell lymphoma. In some embodiments, the oral cancer is squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, lymphoma, benign oral tumor, eosinophilic granuloma, fibroma, granular cell tumor, keratoacanthoma, leiomyoma, osteochondroma, lipoma, schwannoma, neurofibroma, papilloma, condyloma acuminata, verrucous xanthomas, pyogenic granuloma, rhabdomyoma, odontogenic tumor, leukoplakia, erythroplakia, squamous cell lip cancer, basal cell lip cancer, oral cancer, gingival cancer, or tongue cancer. In some embodiments, the ovarian cancer is ovarian epithelial cancer, mucinous epithelial ovarian cancer, endometrioid epithelial ovarian cancer, clear cell epithelial ovarian cancer, undifferentiated epithelial ovarian cancer, ovarian low malignant potential tumor, primary peritoneal carcinoma, fallopian tube carcinoma, germ cell tumor, teratoma, undifferentiated ovarian germ cell carcinoma, endodermal sinus tumor, sex cord stromal tumor, sex cord gonadal stromal tumor, ovarian stromal tumor, granulosa cell tumor, granulosa theca tumor, Sertoli-Leydig tumor, ovarian sarcoma, ovarian carcinosarcoma, ovarian adenosarcoma, ovarian leiomyosarcoma, ovarian fibrosarcoma, Krukenberg tumor, or ovarian cyst.In some embodiments, the pancreatic cancer is a pancreatic exocrine adenocarcinoma, a pancreatic endocrine adenocarcinoma, or a pancreatic adenocarcinoma, a pancreatic islet cell tumor, or a neuroendocrine tumor. In some embodiments, the prostate cancer is a prostate adenocarcinoma, a prostatic sarcoma, a transitional cell carcinoma, a small cell carcinoma, or a neuroendocrine tumor. In some embodiments, the sinus cancer is a squamous cell carcinoma, a mucosal cell carcinoma, an adenoid cystic cell carcinoma, an acinar cell carcinoma, a paranasal sinus undifferentiated carcinoma, a nasal cavity carcinoma, a paranasal sinus carcinoma, a maxillary sinus carcinoma, an ethmoid sinus carcinoma, or a nasopharyngeal carcinoma. In some embodiments, the skin cancer is a basal cell carcinoma, a squamous cell carcinoma, a melanoma, a Merkel cell carcinoma, a Kaposi's sarcoma (KS), an actinic keratosis, a cutaneous lymphoma, or a keratoacanthoma. In some embodiments, the soft tissue cancer is angiosarcoma, dermatofibrosarcoma, epithelioid sarcoma, Ewing's sarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, dedifferentiated liposarcoma (DL), myxoid / round cell liposarcoma (MRCL), well-differentiated liposarcoma (WDL), malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma. In some embodiments, the spinal cancer is a spinal metastatic tumor. In some embodiments, the gastric cancer is a gastric adenocarcinoma, gastric lymphoma, gastrointestinal stromal tumor, carcinoid tumor, gastric carcinoid tumor, type I ECL cell carcinoid, type II ECL cell carcinoid, or type III ECL cell carcinoid. In some embodiments, the testicular cancer is a seminoma, a non-seminoma, an embryonal carcinoma, a yolk sac carcinoma, a choriocarcinoma, a teratoma, a gonadal stromal tumor, a Leydig cell tumor, or a Sertoli cell tumor. In some embodiments, the pharyngeal cancer is a squamous cell carcinoma, an adenocarcinoma, a sarcoma, a laryngeal carcinoma, a pharyngeal carcinoma, a nasopharyngeal carcinoma, an oropharyngeal carcinoma, a hypopharyngeal carcinoma, a laryngeal carcinoma, a laryngeal squamous cell carcinoma, a laryngeal adenocarcinoma, a lymphoepithelioma, a spindle cell carcinoma, a verrucous carcinoma, an undifferentiated carcinoma, or a lymph node carcinoma. In some embodiments, the thyroid cancer is a papillary carcinoma, a follicular carcinoma, a Hurthle cell carcinoma, a medullary thyroid carcinoma, or an undifferentiated carcinoma. In some embodiments, the uterine cancer is endometrial carcinoma, endometrial adenocarcinoma, endometrioid carcinoma, serous adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leiomyosarcoma, endometrial stromal sarcoma, or undifferentiated sarcoma. In some embodiments, the vaginal cancer is squamous cell carcinoma, adenocarcinoma, melanoma, or sarcoma. In some embodiments, the vulvar cancer is squamous cell carcinoma or adenocarcinoma.
[0163] In some embodiments, one antigen bound by the biparatopic or bispecific antibody is a cancer antigen. In some embodiments, the cancer antigen is angiopoietin, BCMA, CD19, CD20, CD22, CD25 (IL2-R), CD30, CD33, CD37, CD38, CD52, CD56, CD123 (IL-3R), cMET, DLL / Notch, EGFR, EpCAM, FGF, FGF-R, GD2, HER2, mesothelin, nectin-4, PDGFRα, RANKL, SLAMF7, TROP2, VEGF, or VEGF-R. In some embodiments, the cancer antigen is angiopoietin. In some embodiments, the cancer antigen is BCMA. In some embodiments, the cancer antigen is CD19. In some embodiments, the cancer antigen is CD20. In some embodiments, the cancer antigen is CD22. In some embodiments, the cancer antigen is CD25 (IL2-R). In some embodiments, the cancer antigen is CD30. In some embodiments, the cancer antigen is CD33. In some embodiments, the cancer antigen is CD37. In some embodiments, the cancer antigen is CD38. In some embodiments, the cancer antigen is CD52. In some embodiments, the cancer antigen is CD56. In some embodiments, the cancer antigen is CD123 (IL-3R). In some embodiments, the cancer antigen is cMET. In some embodiments, the cancer antigen is DLL / Notch. In some embodiments, the cancer antigen is EGFR. In some embodiments, the cancer antigen is EpCAM. In some embodiments, the cancer antigen is FGF. In some embodiments, the cancer antigen is FGF-R. In some embodiments, the cancer antigen is GD2. In some embodiments, the cancer antigen is HER2. In some embodiments, the cancer antigen is mesothelin. In some embodiments, the cancer antigen is nectin-4. In some embodiments, the cancer antigen is PDGFRα. In some embodiments, the cancer antigen is RANKL. In some embodiments, the cancer antigen is SLAMF7. In some embodiments, the cancer antigen is TROP2. In some embodiments, the cancer antigen is VEGF.In some embodiments, the cancer antigen is VEGF-R.
[0164] In some embodiments, the cancer antigen is CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, calcium activated chloride channel 2, cyclin-B1, 9D7, EpCAM, EphA3, Her2 / neu, telomerase, mesothelin, SAP-1, survivin, BAGE family antigens, CAGE family antigens, GAGE family antigens, MAGE family antigens, SAGE family antigens, XAGE family antigens, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2, P. polypeptide, MC1R, prostate specific antigen, β-catenin, BRCA1, BRCA2, CDK4, CML66, fibronectin, MART-2, p53, Ras, TGF-βRII, or MUC1. In some embodiments, the cancer antigen is CEA. In some embodiments, the cancer antigen is immature laminin receptor. In some embodiments, the cancer antigen is TAG-72. In some embodiments, the cancer antigen is HPV E6. In some embodiments, the cancer antigen is HPV E7. In some embodiments, the cancer antigen is BING-4. In some embodiments, the cancer antigen is calcium activated chloride channel 2. In some embodiments, the cancer antigen is cyclin-B1. In some embodiments, the cancer antigen is 9D7. In some embodiments, the cancer antigen is EpCAM. In some embodiments, the cancer antigen is EphA3. In some embodiments, the cancer antigen is Her2 / neu. In some embodiments, the cancer antigen is telomerase. In some embodiments, the cancer antigen is mesothelin. In some embodiments, the cancer antigen is SAP-1. In some embodiments, the cancer antigen is survivin. In some embodiments, the cancer antigen is a BAGE family antigen. In some embodiments, the cancer antigen is a CAGE family antigen. In some embodiments, the cancer antigen is a GAGE family antigen. In some embodiments, the cancer antigen is a MAGE family antigen. In some embodiments, the cancer antigen is a SAGE family antigen.In some embodiments, the cancer antigen is a XAGE family antigen. In some embodiments, the cancer antigen is NY-ESO-1 / LAGE-1. In some embodiments, the cancer antigen is PRAME. In some embodiments, the cancer antigen is SSX-2. In some embodiments, the cancer antigen is Melan-A. In some embodiments, the cancer antigen is MART-1. In some embodiments, the cancer antigen is Gp100. In some embodiments, the cancer antigen is pmel17. In some embodiments, the cancer antigen is tyrosinase. In some embodiments, the cancer antigen is TRP-1. In some embodiments, the cancer antigen is TRP-2. In some embodiments, the cancer antigen is P. polypeptide. In some embodiments, the cancer antigen is MC1R. In some embodiments, the cancer antigen is prostate specific antigen. In some embodiments, the cancer antigen is β-catenin. In some embodiments, the cancer antigen is BRCA1. In some embodiments, the cancer antigen is BRCA2. In some embodiments, the cancer antigen is CDK4. In some embodiments, the cancer antigen is CML66. In some embodiments, the cancer antigen is fibronectin. In some embodiments, the cancer antigen is MART-2. In some embodiments, the cancer antigen is p53. In some embodiments, the cancer antigen is Ras. In some embodiments, the cancer antigen is TGF-βRII. In some embodiments, the cancer antigen is MUC1.
[0165] In some embodiments, the biparatopic or bispecific antibody binds to a B cell antigen. In some embodiments, the B cell antigen is CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD6, CD9, CD11a, CD11b, CD11c, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45R, CD45S, CD45T ... D45RC, CD45RO, CD46, CD47, CD48, CD49b, CD49c, CD49d, CD50, CD52, CD53, CD54, CD55, CD58, CD60a, CD62L, CD63, CD68, CD 69, CD70, CD72, CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85E, CD85I, CD85J, CD86, CD 92, CD95, CD97, CD98, CD99, CD100, CD102, CD108, CD119, CD120a, CD120b, CD121b, CD122, CD124, CD125, CD126, CD130, CD 132, CD137, CD138, CD139, CD147, CD148, CD150, CD152, CD162, CD164, CD166, CD167a, CD170, CD171, CD175, CD175s, CD180 , CD184, CD185, CD192, CD196, CD197, CD200, CD205, CD201a, CDw210b, CD212, CD213a1, CD213a2, CD215, CD217, CD218a, C D218b, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD267, CD268, CD269, CD270, CD272, CD2 74, CD275, CD277, CD279, CD283, CD289, CD290, CD295, CD298, CD300, CD300c, CD305, CD306,In some embodiments, the B cell antigen is a CD307a, CD307b, CD307c, CD307d, CD307e, CD314, CD215, CD316, CD317, CD319, CD321, CD327, CD328, CD329, CD338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD360, CD361, CD362, or CD363 antigen. In some embodiments, the B cell antigen is a CD1a antigen. In some embodiments, the B cell antigen is a CD1b antigen. In some embodiments, the B cell antigen is a CD1c antigen. In some embodiments, the B cell antigen is a CD1d antigen. In some embodiments, the B cell antigen is a CD2 antigen. In some embodiments, the B cell antigen is a CD5 antigen. In some embodiments, the B cell antigen is a CD6 antigen. In some embodiments, the B cell antigen is a CD9 antigen. In some embodiments, the B cell antigen is a CD11a antigen. In some embodiments, the B cell antigen is a CD11b antigen. In some embodiments, the B cell antigen is a CD11c antigen. In some embodiments, the B cell antigen is a CD17 antigen. In some embodiments, the B cell antigen is a CD18 antigen. In some embodiments, the B cell antigen is a CD19 antigen. In some embodiments, the B cell antigen is a CD20 antigen. In some embodiments, the B cell antigen is a CD21 antigen. In some embodiments, the B cell antigen is a CD22 antigen. In some embodiments, the B cell antigen is a CD23 antigen. In some embodiments, the B cell antigen is a CD24 antigen. In some embodiments, the B cell antigen is a CD25 antigen. In some embodiments, the B cell antigen is a CD26 antigen. In some embodiments, the B cell antigen is a CD27 antigen. In some embodiments, the B cell antigen is a CD29 antigen. In some embodiments, the B cell antigen is a CD30 antigen. In some embodiments, the B cell antigen is a CD31 antigen. In some embodiments, the B cell antigen is a CD32a antigen. In some embodiments, the B cell antigen is a CD32b antigen. In some embodiments, the B cell antigen is a CD35 antigen. In some embodiments,The B cell antigen is a CD37 antigen. In some embodiments, the B cell antigen is a CD38 antigen. In some embodiments, the B cell antigen is a CD39 antigen. In some embodiments, the B cell antigen is a CD40 antigen. In some embodiments, the B cell antigen is a CD45 antigen. In some embodiments, the B cell antigen is a CD45RA antigen. In some embodiments, the B cell antigen is a CD45RB antigen. In some embodiments, the B cell antigen is a CD45RC antigen. In some embodiments, the B cell antigen is a CD45RO antigen. In some embodiments, the B cell antigen is a CD46 antigen. In some embodiments, the B cell antigen is a CD47 antigen. In some embodiments, the B cell antigen is a CD48 antigen. In some embodiments, the B cell antigen is a CD49b antigen. In some embodiments, the B cell antigen is a CD49c antigen. In some embodiments, the B cell antigen is a CD49d antigen. In some embodiments, the B cell antigen is a CD50 antigen. In some embodiments, the B cell antigen is a CD52 antigen. In some embodiments, the B cell antigen is a CD53 antigen. In some embodiments, the B cell antigen is a CD54 antigen. In some embodiments, the B cell antigen is a CD55 antigen. In some embodiments, the B cell antigen is a CD58 antigen. In some embodiments, the B cell antigen is a CD60a antigen. In some embodiments, the B cell antigen is a CD62L antigen. In some embodiments, the B cell antigen is a CD63 antigen. In some embodiments, the B cell antigen is a CD68 antigen. In some embodiments, the B cell antigen is a CD69 antigen. In some embodiments, the B cell antigen is a CD70 antigen. In some embodiments, the B cell antigen is a CD72 antigen. In some embodiments, the B cell antigen is a CD73 antigen. In some embodiments, the B cell antigen is a CD74 antigen. In some embodiments, the B cell antigen is a CD75 antigen. In some embodiments, the B cell antigen is a CD75S antigen. In some embodiments, the B cell antigen is a CD77 antigen. In some embodiments, the B cell antigen is a CD79a antigen. In some embodiments,The B cell antigen is a CD79b antigen. In some embodiments, the B cell antigen is a CD80 antigen. In some embodiments, the B cell antigen is a CD81 antigen. In some embodiments, the B cell antigen is a CD82 antigen. In some embodiments, the B cell antigen is a CD83 antigen. In some embodiments, the B cell antigen is a CD84 antigen. In some embodiments, the B cell antigen is a CD85E antigen. In some embodiments, the B cell antigen is a CD85I antigen. In some embodiments, the B cell antigen is a CD85J antigen. In some embodiments, the B cell antigen is a CD86 antigen. In some embodiments, the B cell antigen is a CD92 antigen. In some embodiments, the B cell antigen is a CD95 antigen. In some embodiments, the B cell antigen is a CD97 antigen. In some embodiments, the B cell antigen is a CD98 antigen. In some embodiments, the B cell antigen is a CD99 antigen. In some embodiments, the B cell antigen is a CD100 antigen. In some embodiments, the B cell antigen is a CD102 antigen. In some embodiments, the B cell antigen is a CD108 antigen. In some embodiments, the B cell antigen is a CD119 antigen. In some embodiments, the B cell antigen is a CD120a antigen. In some embodiments, the B cell antigen is a CD120b antigen. In some embodiments, the B cell antigen is a CD121b antigen. In some embodiments, the B cell antigen is a CD122 antigen. In some embodiments, the B cell antigen is a CD124 antigen. In some embodiments, the B cell antigen is a CD125 antigen. In some embodiments, the B cell antigen is a CD126 antigen. In some embodiments, the B cell antigen is a CD130 antigen. In some embodiments, the B cell antigen is a CD132 antigen. In some embodiments, the B cell antigen is a CD137 antigen. In some embodiments, the B cell antigen is a CD138 antigen. In some embodiments, the B cell antigen is a CD139 antigen. In some embodiments, the B cell antigen is a CD147 antigen. In some embodiments, the B cell antigen is a CD148 antigen. In some embodiments, the B cell antigen isThe B cell antigen is a CD150 antigen. In some embodiments, the B cell antigen is a CD152 antigen. In some embodiments, the B cell antigen is a CD162 antigen. In some embodiments, the B cell antigen is a CD164 antigen. In some embodiments, the B cell antigen is a CD166 antigen. In some embodiments, the B cell antigen is a CD167a antigen. In some embodiments, the B cell antigen is a CD170 antigen. In some embodiments, the B cell antigen is a CD171 antigen. In some embodiments, the B cell antigen is a CD175 antigen. In some embodiments, the B cell antigen is a CD175s antigen. In some embodiments, the B cell antigen is a CD180 antigen. In some embodiments, the B cell antigen is a CD184 antigen. In some embodiments, the B cell antigen is a CD185 antigen. In some embodiments, the B cell antigen is a CD192 antigen. In some embodiments, the B cell antigen is a CD196 antigen. In some embodiments, the B cell antigen is a CD197 antigen. In some embodiments, the B cell antigen is a CD200 antigen. In some embodiments, the B cell antigen is a CD205 antigen. In some embodiments, the B cell antigen is a CD201a antigen. In some embodiments, the B cell antigen is a CDw210b antigen. In some embodiments, the B cell antigen is a CD212 antigen. In some embodiments, the B cell antigen is a CD213a1 antigen. In some embodiments, the B cell antigen is a CD213a2 antigen. In some embodiments, the B cell antigen is a CD215 antigen. In some embodiments, the B cell antigen is a CD217 antigen. In some embodiments, the B cell antigen is a CD218a antigen. In some embodiments, the B cell antigen is a CD218b antigen. In some embodiments, the B cell antigen is a CD220 antigen. In some embodiments, the B cell antigen is a CD221 antigen. In some embodiments, the B cell antigen is a CD222 antigen. In some embodiments, the B cell antigen is a CD224 antigen. In some embodiments, the B cell antigen is the CD225 antigen. In some embodiments, the B cell antigen is the CD226 antigen. In some embodiments, the B cell antigen isIn some embodiments, the B cell antigen is a CD227 antigen. In some embodiments, the B cell antigen is a CD229 antigen. In some embodiments, the B cell antigen is a CD230 antigen. In some embodiments, the B cell antigen is a CD232 antigen. In some embodiments, the B cell antigen is a CD252 antigen. In some embodiments, the B cell antigen is a CD252 antigen. In some embodiments, the B cell antigen is a CD254 antigen. In some embodiments, the B cell antigen is a CD255 antigen. In some embodiments, the B cell antigen is a CD256 antigen. In some embodiments, the B cell antigen is a CD257 CD258 antigen. In some embodiments, the B cell antigen is a CD259 antigen. In some embodiments, the B cell antigen is a CD260 antigen. In some embodiments, the B cell antigen is a CD261 antigen. In some embodiments, the B cell antigen is a CD262 antigen. In some embodiments, the B cell antigen is a CD263 antigen. In some embodiments, the B cell antigen is a CD264 antigen. In some embodiments, the B cell antigen is a CD267 antigen. In some embodiments, the B cell antigen is a CD268 antigen. In some embodiments, the B cell antigen is a CD269 antigen. In some embodiments, the B cell antigen is a CD270 antigen. In some embodiments, the B cell antigen is a CD272 antigen. In some embodiments, the B cell antigen is a CD274 antigen. In some embodiments, the B cell antigen is a CD275 antigen. In some embodiments, the B cell antigen is a CD277 antigen. In some embodiments, the B cell antigen is a CD279 antigen. In some embodiments, the B cell antigen is a CD283 antigen. In some embodiments, the B cell antigen is a CD289 antigen. In some embodiments, the B cell antigen is a CD290 antigen. In some embodiments, the B cell antigen is a CD295 antigen. In some embodiments, the B cell antigen is a CD298 antigen. In some embodiments, the B cell antigen is a CD300 antigen. In some embodiments, the B cell antigen is a CD300c antigen. In some embodiments, the B cell antigen is a CD305 antigen. In some embodiments, the B cell antigen is a CD306 antigen. In some embodiments, the B cell antigen is a CD307a antigen. In some embodiments, the B cell antigen is a CD307b antigen. In some embodiments, the B cell antigen is a CD307c antigen. In some embodiments, the B cell antigen is a CD307d antigen.In some embodiments, the B cell antigen is a CD307e antigen. In some embodiments, the B cell antigen is a CD314 antigen. In some embodiments, the B cell antigen is a CD215 antigen. In some embodiments, the B cell antigen is a CD316 antigen. In some embodiments, the B cell antigen is a CD317 antigen. In some embodiments, the B cell antigen is a CD319 antigen. In some embodiments, the B cell antigen is a CD321 antigen. In some embodiments, the B cell antigen is a CD327 antigen. In some embodiments, the B cell antigen is a CD328 antigen. In some embodiments, the B cell antigen is a CD329 antigen. In some embodiments, the B cell antigen is a CD338 antigen. In some embodiments, the B cell antigen is a CD351 antigen. In some embodiments, the B cell antigen is a CD352 antigen. In some embodiments, the B cell antigen is a CD353 antigen. In some embodiments, the B cell antigen is a CD354 antigen. In some embodiments, the B cell antigen is a CD355 antigen. In some embodiments, the B cell antigen is a CD356 antigen. In some embodiments, the B cell antigen is a CD357 antigen. In some embodiments, the B cell antigen is a CD358 antigen. In some embodiments, the B cell antigen is a CD360 antigen. In some embodiments, the B cell antigen is a CD361 antigen. In some embodiments, the B cell antigen is a CD362 antigen. In some embodiments, the B cell antigen is a CD363 antigen.
[0166] In one embodiment, the biparatopic or bispecific antibody binds to a pathogen. In some embodiments, the pathogen is acute flaccid myelitis (AFM), anaplasmosis, anthrax, babesiosis, botulism, brucellosis, campylobacteriosis, carbapenem-resistant infections, chancroid, chikungunya virus infection, chlamydia, ciguatera, difficile infection, perfringens, coccidioidomycosis fungal infection, coronavirus infection, Covid-19 (SARS-CoV-2), Creutzfeldt-Jakob disease / transmissible spongiform encephalopathy, cryptosporidiosis (Cr ypto), Cyclosporiasis, Dengue 1, 2, 3, or 4, Diphtheria, Escherichia coli infection / Shiga toxin producing (STEC), Eastern equine encephalitis, Hemorrhagic fever (Ebola), Ehrlichiosis, Encephalitis, Arbovirus or parainfectious encephalitis, Non-polio enterovirus, Enterovirus D68 (EV-D68), Giardiasis, Glanders, Gonococcal infection, Inguinal granuloma, Haemophilus influenzae infection type B (Hib or H-flu), Hantavirus pulmonary syndrome (HPS), Hemolytic uremic syndrome (HUS), Hepatitis A (Hep A), Hepatitis B (Hep B), Hepatitis C (Hep C), Hepatitis D (Hep D), Hepatitis E (Hep E), Herpes, Herpes Zoster (Shingles), Histoplasmosis, Human Immunodeficiency Virus / AIDS (HIV / AIDS), Human Papillomavirus (HPV), Influenza (Flu), Legionnaires' Disease (Legionnaires' Disease), Leprosy (Hansen's Disease), Leptospirosis, Listeriosis (Listeria), Lyme Disease, Lymphogranuloma Venaeum Infection (LGV), Malaria, Measles, Melanocoronavirus, Meningitis (Viral), Meningococcal Disease (Meningitis (Bacterial)), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Mumps, Norovirus Illness, Pediculosis, Pelvic Infection (PID), Pertussis, Plague (Bug, Septicemic, Pneumonic), Pneumococcal Disease (Pneumonia), Poliovirus Infection (Polio), Powassan, Psittacosis, Pediculosis, Pubic Disease (Smallpox, Monkeypox, Cowpox), Q Fever, Rabies, Rickettsiosis (Rocky Mountain Spotted Fever), Rubella (German Measles), Salmonellosis (Salmonella), Scabies, Scombroids, Septicemia, Severe Acute Respiratory Syndrome (SARS), Shigella (Shigella), Smallpox,Methicillin-resistant Staphylococcal infections (MRSA), Staphylococcal food poisoning Enterotoxin B poisoning (Staphylococcal food poisoning), Vancomycin-intermediate saphylococcal infections (VISA), Vancomycin-resistant Staphylococcal infections (VRSA), Group A Streptococcal infections (invasive) (Strep A (invasive), Group B Streptococcal infections (Strep-B), Streptococcal toxic shock syndrome (STSS) toxic shock, Syphilis (primary, secondary, early latent, latent, congenital), Tetanus infection, Trichomoniasis, Trichonoccus infection, Tuberculosis (TB), Latent Tuberculosis (LTBI), Tularemia, Typhoid fever group D, Vaginosis, Chickenpox (varicella), Vibrio cholerae (cholera), Vibrio (vibrio), Ebola virus hemorrhagic fever, Lassa virus hemorrhagic fever, Marburg virus hemorrhagic fever, West Nile virus, Yellow fever In some embodiments, the infection causes an infection selected from the group consisting of fever, yersenia, and Zika virus infection. In some embodiments, the infection is acute flaccid myelitis (AFM). In some embodiments, the infection is anaplasmosis. In some embodiments, the infection is anthrax. In some embodiments, the infection is babesiosis. In some embodiments, the infection is botulism. In some embodiments, the infection is brucellosis. In some embodiments, the infection is erythrocyte sedimentation ... In some embodiments, the infection is campylobacteriosis. In some embodiments, the infection is a carbapenem-resistant infection. In some embodiments, the infection is chancroid. In some embodiments, the infection is a chikungunya virus infection. In some embodiments, the infection is chlamydia. In some embodiments, the infection is ciguatera poisoning. In some embodiments, the infection is a B. difficile infection. In some embodiments, the infection is B. perfringens. In some embodiments, the infection is a coccidioidomycosis fungal infection. In some embodiments, the infection is a coronavirus. In some embodiments, the infection is Covid-19 (SARS-CoV-2). In some embodiments, the infection is Creutzfeldt-Jakob disease / transmissible spongiform encephalopathy. In some embodiments, the infection is cryptosporidiosis (Crypto). In some embodiments, the infection isIn some embodiments, the infection is cyclosporia. In some embodiments, the infection is dengue 1, 2, 3, or 4. In some embodiments, the infection is diphtheria. In some embodiments, the infection is Escherichia coli infection / Shiga toxin producing (STEC). In some embodiments, the infection is Eastern equine encephalitis. In some embodiments, the infection is hemorrhagic fever (Ebola). In some embodiments, the infection is ehrlichiosis. In some embodiments, the infection is encephalitis. In some embodiments, the infection is an arbovirus or parainfectious. In some embodiments, the infection is a non-polioenterovirus. In some embodiments, the infection is D68 enterovirus (EV-D68). In some embodiments, the infection is giardiasis. In some embodiments, the infection is glanders. In some embodiments, the infection is a gonococcal infection. In some embodiments, the infection is granuloma venereum. In some embodiments, the infection is Haemophilus influenzae infection type B (Hib or H-flu). In some embodiments, the infection is Hantavirus Pulmonary Syndrome (HPS). In some embodiments, the infection is Hemolytic Uremic Syndrome (HUS). In some embodiments, the infection is Hepatitis A (Hep A). In some embodiments, the infection is Hepatitis B (Hep B). In some embodiments, the infection is Hepatitis C (Hep C). In some embodiments, the infection is Hepatitis D (Hep D). In some embodiments, the infection is Hepatitis E (Hep E). In some embodiments, the infection is Herpes. In some embodiments, the infection is Herpes Zoster (Shingles). In some embodiments, the infection is Histoplasmosis. In some embodiments, the infection is Human Immunodeficiency Virus / AIDS (HIV / AIDS). In some embodiments, the infection is Human Papilloma Virus (HPV). In some embodiments, the infection is Influenza (Flu). In some embodiments, the infection is Legionnaires' Disease (Legionnaires' Disease). In some embodiments, the infectious disease is leprosy. In some embodiments, the infectious disease isIn some embodiments, the infection is leptospirosis. In some embodiments, the infection is listeriosis (Listeria). In some embodiments, the infection is Lyme disease. In some embodiments, the infection is lymphogranuloma venereum infection (LGV). In some embodiments, the infection is malaria. In some embodiments, the infection is measles. In some embodiments, the infection is melioidosis. In some embodiments, the infection is meningitis (viral). In some embodiments, the infection is meningococcal disease (meningitis (bacterial)). In some embodiments, the infection is Middle East Respiratory Syndrome Coronavirus (MERS-CoV). In some embodiments, the infection is mumps. In some embodiments, the infection is Norovirus. In some embodiments, the infection is pediculosis. In some embodiments, the infection is pelvic infection (PID). In some embodiments, the infection is pertussis (whooping cough). In some embodiments, the infection is plague (bubonic. In some embodiments, the infection is septicemic. In some embodiments, the infection is pneumonic). In some embodiments, the infection is pneumococcal disease (pneumonia). In some embodiments, the infection is poliovirus infection (polio). In some embodiments, the infection is Powassan. In some embodiments, the infection is psittacosis. In some embodiments, the infection is pediculosis (pubic lice). In some embodiments, the infection is pustular disease (smallpox. In some embodiments, the infection is monkeypox. In some embodiments, the infection is cowpox). In some embodiments, the infection is Q fever. In some embodiments, the infection is rabies. In some embodiments, the infection is rickettsiosis (Rocky Mountain spotted fever). In some embodiments, the infection is rubella (German measles). In some embodiments, the infection is salmonellosis gastroenteritis (Salmonella). In some embodiments, the infection is scabies. In some embodiments, the infection is scombroid. In some embodiments, the infection is septicemia. In some embodiments,The infection is Severe Acute Respiratory Syndrome (SARS). In some embodiments, the infection is Shigella gastroenteritis (Shigella). In some embodiments, the infection is smallpox. In some embodiments, the infection is Methicillin-Resistant Staphylococcal Infections (MRSA). In some embodiments, the infection is Staphylococcal Foodborne Enterotoxin B Poisoning (Staphylococcal Food Poisoning). In some embodiments, the infection is Vancomycin-Intermediate Saphylococcal Infections (VISA). In some embodiments, the infection is Vancomycin-Resistant Staphylococcal Infections (VRSA). In some embodiments, the infection is Group A Streptococcal Infections (Invasive) (Strep In some embodiments, the infection is Group A (invasive). In some embodiments, the infection is a Streptococcus infection. In some embodiments, the infection is Group B (Strep-B). In some embodiments, the infection is Streptococcus toxic shock syndrome (STSS). In some embodiments, the infection is syphilis (primary stage. In some embodiments, the infection is secondary stage. In some embodiments, the infection is early latent. In some embodiments, the infection is late latent. In some embodiments, the infection is congenital). In some embodiments, the infection is a tetanus infection. In some embodiments, the infection is trichomoniasis. In some embodiments, the infection is a trichomoniasis infection. In some embodiments, In some embodiments, the infection is tuberculosis (TB). In some embodiments, the infection is latent tuberculosis (LTBI). In some embodiments, the infection is tularemia. In some embodiments, the infection is typhoid group D. In some embodiments, the infection is chickenpox (varicella), Vibrio cholerae (cholera). In some embodiments, the infection is vibriosis (vibrio). In some embodiments, the infection is Ebola virus hemorrhagic fever. In some embodiments, the infection is Lassa virus hemorrhagic fever. In some embodiments, the infection is Marburg virus hemorrhagic fever. In some embodiments, the infection is West Nile virus. In some embodiments, the infection is yellow fever. In some embodiments, the infection isIn some embodiments, the infection is a Yersinia infection.
[0167] In some embodiments, the pathogen is a virus. In some embodiments, the virus is an Adenoviridae, Arenaviridae, Astroviridae, Bunyaviridae, Caliciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Hepeviridae, Orthomyxoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Polyomaviridae, Poxviridae, Reoviridae, Retroviridae, Rhabdoviridae, or Togaviridae virus. In some embodiments, the virus is an Adenoviridae virus. In some embodiments, the virus is an Arenaviridae virus. In some embodiments, the virus is an Astroviridae virus. In some embodiments, the virus is a Bunyaviridae virus. In some embodiments, the virus is a Caliciviridae virus. In some embodiments, the virus is a Coronaviridae virus. In some embodiments, the virus is a Filoviridae virus. In some embodiments, the virus is a Flaviviridae virus. In some embodiments, the virus is a Hepadnaviridae virus. In some embodiments, the virus is a Hepeviridae virus. In some embodiments, the virus is an Orthomyxoviridae virus. In some embodiments, the virus is a Papillomaviridae virus. In some embodiments, the virus is a Paramyxoviridae virus. In some embodiments, the virus is a Parvoviridae virus. In some embodiments, the virus is a Picornaviridae virus. In some embodiments, the virus is a Polyomaviridae virus. In some embodiments, the virus is a Poxviridae virus. In some embodiments, the virus is a Reoviridae virus. In some embodiments, the virus is a Retroviridae virus. In some embodiments, the virus is a Rhabdoviridae virus. In some embodiments, the virus is a Togaviridae virus.
[0168] In some embodiments, the virus is an adenovirus, a coronavirus, a coxsackie virus, an Epstein-Barr virus, a hepatitis A virus, a hepatitis B virus, a hepatitis C virus, a herpes simplex virus type 2, a cytomegalovirus, a human herpes virus type 8, a human immunodeficiency virus, an influenza virus, a measles virus, a mumps virus, a human papilloma virus, a parainfluenza virus, a poliovirus, a rabies virus, a respiratory syncytial virus, a rubella virus, or a varicella zoster virus. In some embodiments, the virus is an adenovirus. In some embodiments, the virus is a coronavirus. In some embodiments, the coronavirus virus is Covid-19 (SARS-CoV-2). In some embodiments, the virus is a coxsackie virus. In some embodiments, the virus is an Epstein-Barr virus. In some embodiments, the virus is a hepatitis A virus. In some embodiments, the virus is a hepatitis B virus. In some embodiments, the virus is a hepatitis C virus. In some embodiments, the virus is herpes simplex virus type 2. In some embodiments, the virus is cytomegalovirus. In some embodiments, the virus is human herpes virus type 8. In some embodiments, the virus is human immunodeficiency virus. In some embodiments, the virus is influenza virus. In some embodiments, the virus is measles virus. In some embodiments, the virus is mumps virus. In some embodiments, the virus is human papillomavirus. In some embodiments, the virus is parainfluenza virus. In some embodiments, the virus is poliovirus. In some embodiments, the virus is rabies virus. In some embodiments, the virus is respiratory syncytial virus. In some embodiments, the virus is rubella virus. In some embodiments, the virus is varicella zoster virus.
[0169] In some embodiments, the pathogen is a bacterium. In some embodiments, the bacterium is a bacterium of the genus Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacteria, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, or Yersinia. In some embodiments, the bacterium is a bacterium of the genus Bacillus. In some embodiments, the bacterium is a bacterium of the genus Bartonella. In some embodiments, the bacterium is a bacterium of the genus Bordetella. In some embodiments, the bacterium is a bacterium of the genus Borrelia. In some embodiments, the bacterium is a bacterium of the genus Brucella. In some embodiments, the bacterium is a bacterium of the genus Campylobacter. In some embodiments, the bacterium is a bacterium of the genus Chlamydia. In some embodiments, the bacterium is a bacterium of the genus Chlamydophila. In some embodiments, the bacterium is a bacterium of the genus Clostridium. In some embodiments, the bacterium is a bacterium of the genus Corynebacterium. In some embodiments, the bacterium is a bacterium of the genus Enterococcus. In some embodiments, the bacterium is a bacterium of the genus Escherichia. In some embodiments, the bacterium is a bacterium of the genus Francisella. In some embodiments, the bacterium is a bacterium of the genus Haemophilus. In some embodiments, the bacterium is a bacterium of the genus Helicobacter. In some embodiments, the bacterium is a bacterium of the genus Legionella. In some embodiments, the bacterium is a bacterium of the genus Leptospira. In some embodiments, the bacterium is a bacterium of the genus Listeria. In some embodiments, the bacterium is a bacterium of the genus Mycobacteria. In some embodiments, the bacterium is a bacterium of the genus Mycoplasma. In some embodiments, the bacterium is a bacterium of the genus Neisseria. In some embodiments, the bacterium is a bacterium of the genus Pseudomonas. In some embodiments, the bacterium is a bacterium of the genus Rickettsia. In some embodiments, the bacterium is a bacterium of the genus Salmonella.In some embodiments, the bacterium is a bacterium of the Shigella genus. In some embodiments, the bacterium is a bacterium of the Staphylococcus genus. In some embodiments, the bacterium is a bacterium of the Streptococcus genus. In some embodiments, the bacterium is a bacterium of the Treponema genus. In some embodiments, the bacterium is a bacterium of the Ureaplasma genus. In some embodiments, the bacterium is a bacterium of the Vibrio genus. In some embodiments, the bacterium is a bacterium of the Yersinia genus.
[0170] In some embodiments, the pathogen is a parasite. In some embodiments, the parasite is a protozoan, a helminth, or an ectoparasite. In some embodiments, the protozoan is an Entamoeba, Giardia, Leishmania, Balantidium, Plasmodium, or Cryptosporidium. In some embodiments, the helminth is a trematode, a tapeworm, an anchocephalic worm, or a roundworm. In some embodiments, the ectoparasite is an arthropod.
[0171] In some specific embodiments, the biparatopic or bispecific antibodies provided herein bind to CD22. In some specific embodiments, the biparatopic or bispecific antibodies provided herein bind to CD37. In some specific embodiments, the biparatopic or bispecific antibodies provided herein bind to GPRC5D. In some specific embodiments, the biparatopic or bispecific antibodies provided herein bind to KLK2. In some specific embodiments, the biparatopic or bispecific antibodies provided herein bind to HLA-G. In some specific embodiments, the biparatopic or bispecific antibodies provided herein bind to PSMA. In some specific embodiments, the biparatopic or bispecific antibodies provided herein bind to BCMA.
[0172] Other Exemplary Binding Molecules In some embodiments, the biparatopic or bispecific antibodies provided herein are derived from certain known antibodies that contain Fc regions with RE mutations and, optionally, without fucosylation. Exemplary known antibodies include, but are not limited to, ReoPro (abciximab), Humira (adalimumab), Hyrimoz (adalimumab-adaz), Cyltezo (adalimumab-adbm), Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Hadlima (adalimumab-bwwd), Campath, Lemtrada (alemtuzumab), Praluent (alirocumab), Tecentri (alirocumab), and others. q (atezolizumab), Bavencio (avelumab), Simulect (basiliximab), Benlysta (belimumab), Fasenra (benralizumab), Avastin (bevacizumab), Mvasi (bevacizumab-awwb), Zirabev (bevacizumab-bvzr), Zinplava (bezlotoxumab), Blincyto (blinatumomab), Siliq (brodalumab), Beovu (brolucizumab-dbll), Crysvita (burosumab-twza), Ilaris (canakinumab), Cablivi (caplacizumab-yhdp), Libtayo (cemiplimab-rwlc), Erbitux (cetuximab), Adakveo (crizanlizumab-tmca), Zenapax (daclizumab), Zinbryta (daclizumab), Darzalex (daratumumab), Prolia, Xgeva (denosumab), Unituxin (dinutuximab), Dupixent (dupilumab) ), Imfinzi (durvalumab), Soliris (eculizumab), Empliciti (elotuzumab), Gamifant (emapalumab-lzsg), Hemlibra (emicizumab-kxwh), Vyepti (eptinezumab-jjmr), Aimovig (erenumab-aooe), Repatha (evolocumab), Ajovy (freema-vfrm), Emgality (galcanezumab-gnlm), Simponi (golimumab), Simponi Aria (golimumab), Tremfya (guselkumab),Trogarzo (ibalizumab-uiyk), Praxbind (idarucizumab), Remicade (infliximab), Renflexis (infliximab-abda), Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), Ixifi (infliximab-qbtx), Yervoy (ipilimumab), Sarclisa (isatuximab-irfc), Taltz (ixekizumab), Takhzyro (lanadelumab-flyo), Nucala (mepolizumab), Nuc ala (mepolizumab), Poteligeo (mogamulizumab-kpkc), Tysabri (natalizumab), Portrazza (necitumumab), Opdivo (nivolumab), Anthimu (obiltoxaximab), Gazyva (obinutuzumab), Ocrevus (ocrelizumab), Arzerra (ofatumumab), Lartruvo (olaratumab), Xolair (omalizumab), Synagis (palivizumab), Vectibix (panitumumab), Keytruda (pembrolizumab), Perjeta ( Pertuzumab), Cyramza (ramucirumab), Lucentis (ranibizumab), Ultomiris (ravulizumab-cwvz), raxibacumab (raxibacumab), Cinqair (reslizumab), Skyrizi (risankizumab-rzaa), Rituxan (rituximab), Truxima (rituximab-abbs), Ruxience (rituximab-pvvr), Evenity (romosozumab-aqqg), Kevzara (sarilumab), Cosentyx (secukinumab), Sylvant (siltuximab (trastuzumab-trbw), Tepezza (teprotumumab-trbw), Ilumya (tildrakizumab-asmn), Actemra (tocilizumab), Actemra (tocilizumab), Herceptin (trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Herzuma (trastuzumab-pkrb), Trazimera (trastuzumab-qyyp), Stelara (ustekinumab), Stelara (ustekinumab),and Entyvio (vedolizumab). Methods for introducing RE mutations and reducing fucosylation are described in more detail in other sections provided herein and are well known in the art.
[0173] In some embodiments, each of the antigen binding domains of a biparatopic or bispecific binding molecule is a single domain antigen binding fragment, hi some embodiments, each of the antigen binding domains of a biparatopic or bispecific binding molecule is an engineered binding fragment.
[0174] Polynucleotides In certain embodiments, the present disclosure encompasses polynucleotides encoding the antibodies described herein. The term "polynucleotide encoding a polypeptide" encompasses polynucleotides that contain only the coding sequence of a polypeptide, as well as polynucleotides that contain additional coding and / or non-coding sequences. The polynucleotides of the present disclosure may be in the form of RNA or in the form of DNA. DNA includes cDNA, genomic DNA, and synthetic DNA, which may be double-stranded or single-stranded, and if single-stranded, may be the coding strand or the non-coding (antisense) strand.
[0175] In certain embodiments, a polynucleotide comprises a coding sequence for a polypeptide, e.g., fused in frame with a polynucleotide that aids in the expression and secretion of the polypeptide from a host cell (e.g., a leader sequence that functions as a secretory sequence to control transport of the polypeptide). The polypeptide can have a leader sequence that is cleaved by the host cell to form a "mature" form of the polypeptide.
[0176] In certain embodiments, the polynucleotide comprises a coding sequence for a polypeptide fused in frame to a marker or tag sequence. For example, in some embodiments, in the case of a bacterial host, the marker sequence is a hexahistidine tag provided by the vector that allows for efficient purification of the polypeptide fused to the marker. In some embodiments, the marker is used in conjunction with other affinity tags.
[0177] The disclosure further relates to variants of the polynucleotides described herein, where the variants encode, for example, fragments, analogs, and / or derivatives of the polynucleotides. In certain embodiments, the disclosure provides polynucleotides, including polynucleotides having a nucleotide sequence at least about 80% identical, at least about 85% identical, at least about 90% identical, at least about 95% identical, and in some embodiments at least about 96%, 97%, 98% or 99% identical to a polynucleotide encoding a polypeptide comprising an antibody described herein.
[0178] As used herein, the phrase "a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence" is intended to mean that the nucleotide sequence of the polynucleotide is identical to the reference sequence, except that the polynucleotide sequence may contain up to 5 point mutations for every 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides of the reference sequence may be deleted or replaced with another nucleotide, or up to 5% of the total number of nucleotides of the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal position of the reference nucleotide sequence, or anywhere between these terminal positions, and may be interspersed between the nucleotides of the reference sequence individually or in one or more contiguous groups within the reference sequence.
[0179] Polynucleotide variants may contain changes in coding regions, non-coding regions, or both. In some embodiments, polynucleotide variants contain changes that result in silent substitutions, additions, or deletions, but do not change the properties or activities of the encoded polypeptide. In some embodiments, polynucleotide variants contain silent substitutions that do not result in changes to the amino acid sequence of a polypeptide (due to the degeneracy of the genetic code). Polynucleotide variants can be generated for a variety of reasons, for example, to optimize codon expression for a particular host (i.e., changing the codons of human mRNA to those preferred by a bacterial host, such as E. coli). In some embodiments, polynucleotide variants contain at least one silent mutation in a non-coding or coding region of the sequence.
[0180] In some embodiments, polynucleotide variants are produced to modulate or alter expression (or expression levels) of an encoded polypeptide. In some embodiments, polynucleotide variants are produced to increase expression of an encoded polypeptide. In some embodiments, polynucleotide variants are produced to decrease expression of an encoded polypeptide. In some embodiments, polynucleotide variants increase expression of an encoded polypeptide compared to the parent polynucleotide sequence. In some embodiments, polynucleotide variants decrease expression of an encoded polypeptide compared to the parent polynucleotide sequence.
[0181] In certain embodiments, the polynucleotide is isolated. In certain embodiments, the polynucleotide is substantially pure.
[0182] Also provided are vectors and cells comprising the polynucleotides described herein. In some embodiments, an expression vector comprises the polynucleotide molecule. In some embodiments, a host cell comprises the polynucleotide molecule. In some embodiments, a host cell comprises one or more expression vectors comprising the polynucleotide molecule. In some embodiments, a host cell comprises the polynucleotide molecule. In some embodiments, a host cell comprises one or more polynucleotide molecules. Construction of vectors provided herein is exemplified in Section 7 below.
[0183] Polyclonal and monoclonal antibodies In some embodiments, the population of antibodies provided herein comprises polyclonal antibodies. Methods for preparing polyclonal antibodies are known to those skilled in the art. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, optionally, an adjuvant. Typically, the immunizing agent and / or adjuvant are injected into the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent can comprise a polypeptide (such as HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA or fragments thereof) or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal to be immunized and immunize the mammal with the protein and one or more adjuvants. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants that may be employed include Ribi, CpG, Poly(I:C), Freund's complete adjuvant, and MPL-TDM adjuvant (monophosphoryl lipid, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one of skill in the art without undue experimentation. The mammal may then be bled and the serum may be assayed for, for example, anti-HLA-G, anti-CD37, anti-GPRC5D, anti-KLK2 antibody, anti-PSMA, or anti-BCMA titer. If desired, the mammal may be boosted until antibody titer increases or reaches a plateau. Additionally or alternatively, lymphocytes may be obtained from the immunized animal for fusion and preparation of monoclonal antibodies from hybridomas.
[0184] In some embodiments, the antibodies provided herein include monoclonal antibodies, which may be made using the hybridoma method first described by Kohler, et al., Nature, 1975, 256:495-7, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
[0185] In the hybridoma method, a mouse, or other suitable host animal, such as a hamster, is immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the protein used for immunization. Alternatively, lymphocytes can be immunized in vitro. After immunization, lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice 59-103 (1986)).
[0186] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that, in certain embodiments, contains one or more substances that inhibit the growth or survival of the unfused parental myeloma cells (also referred to as the fusion partner). For example, if the parental myeloma cells lack the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT or HPRT), then the selective culture medium for the hybridomas typically contains hypoxanthine, aminopterin, and thymidine (HAT medium), which prevents the growth of HGPRT-deficient cells.
[0187] Exemplary fusion partner myeloma cells are myeloma cells that fuse efficiently, support stable high-level antibody production by selected antibody-producing cells, and are sensitive to selective media that select against unfused parent cells. Exemplary myeloma cell lines are mouse myeloma lines such as SP-2 cells and derived cells, e.g., X63-Ag8-653 cells, available from the American Type Culture Collection (Manassas, VA), and mouse myeloma lines derived from MOPC-21 and MPC-11 mouse tumors, available from the Salk Institute Cell Distribution Center (San Diego, CA). Human myeloma cell lines and mouse-human heteromyeloma cell lines for producing human monoclonal antibodies have also been described (Kozbor, Immunol., 1984, 133:3001-05; and Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, 1987, 51-63).
[0188] The culture medium in which the hybridoma cells grow is assayed for the production of monoclonal antibodies against the antigen. The binding specificity of the monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or an in vitro binding assay such as RIA or ELISA. The binding affinity of the monoclonal antibody can be determined, for example, by Scatchard analysis as described in Munson et al., Anal. Biochem., 1980, 107:220-39.
[0189] Once hybridoma cells that produce antibodies with the desired specificity, affinity, and / or activity are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, DMEM medium or RPMI-1640 medium. In addition, hybridoma cells can be grown in vivo as ascites tumors in animals, for example, by ip injection of the cells into mice.
[0190] The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (using, for example, protein A-Sepharose or protein G-Sepharose) or ion exchange chromatography, hydroxylapatite chromatography, gel electrophoresis, dialysis, or the like.
[0191] DNA encoding monoclonal antibodies is easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of mouse antibodies). Hybridoma cells can be used as a source of such DNA. Once isolated, the DNA can be placed into an expression vector, which can then be transfected into host cells that do not normally produce antibody proteins, such as E. coli cells, monkey COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression of antibody-encoding DNA in bacteria include Skerra, et al., Curr. Opinion in Immunol., 1993, 5:256-62 and Pluckthun, Immunol. Revs., 1992, 130:151-88.
[0192] In some embodiments, antibodies that bind to an epitope (e.g., of HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA) are (1) hybridized under stringent conditions (e.g., hybridization in which the bound DNA is filtered in 6x sodium chloride / sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2x SSC / 0.1% SDS at about 50-65° C.), or (2) under highly stringent conditions (e.g., hybridization in which the bound nucleic acid is filtered in 6x SSC at about 45° C., followed by one or more washes in 0.2x SSC / 0.1% SDS at about 50-65° C.). The VH domain and / or VL domain may be encoded by a nucleotide sequence that hybridizes to the complement of a nucleotide sequence encoding any one of the VH domains and / or VL domains described herein under hybridization with a nucleotide sequence of 0.1×SSC / 0.2% SDS at about 68° C., followed by one or more washes in 0.1×SSC / 0.2% SDS, or other stringent hybridization conditions known to those of skill in the art (see, for example, Current Protocols in Molecular Biology Vol. I, 6.3.1-6.3.6 and 2.10.3 (Ausubel et al. eds., 1989)).
[0193] In further embodiments, monoclonal antibodies can be isolated from antibody phage libraries generated using, for example, the techniques described in Antibody Phage Display: Methods and Protocols (O'Brien and Aitken, eds., 2002), in which functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. Examples of phage display methods that can be used to generate the antibodies described herein include those described in Brinkman, et al., J. Immunol. Methods, 1995, 182:41-50; Ames, et al., J. Immunol. Methods, 1995, 184:177-86; Kettleborough, et al., Eur. J. Immunol., 1994, 24:952-8; Persic, et al., Gene, 1997, 187:9-18; Burton et al., Advances in Immunology, 1994, 57:191-280; PCT Application No. GB91 / 01134, WO 90 / 02809, WO 91 / 10737, WO 92 / 01047, WO 92 / 18619, WO 93 / 11236, WO 95 / 15982, WO 95 / 20401, and WO 97 / 13844, and U.S. Pat. Nos. 5,698,426, 5,223,409, Nos. 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727, 5,733,743 and 5,969,108.
[0194] In principle, synthetic antibody clones are selected by screening a phage library containing phages displaying various fragments of the antibody variable region (Fv) fused to a phage coat protein. Such a phage library is screened against the desired antigen. Clones expressing Fv fragments capable of binding to the desired antigen are adsorbed to the antigen and thus separated from non-binding clones in the library. Binding clones are then eluted from the antigen and can be further enriched by additional cycles of antigen adsorption / elution.
[0195] The variable domains are fused to, and non-covalently interact with, their respective constant domains, as described, for example, in Winter et al., 1994, Ann. Rev. Immunol. 12:433-55.
[0196] Repertoires of VH and VL genes can be individually cloned and randomly recombined in phage libraries by PCR as described in Winter et al., supra, and then screened for antigen-binding clones. Libraries from immunized sources provide high affinity antibodies to immunogens without the need to construct hybridomas. Alternatively, naive repertoires can be cloned to provide a single source of human antibodies to a broad range of non-self, and also to self-antigens without immunization, as described by Griffiths et al., EMBO J, 1993, 12:725-34. Finally, naive libraries can also be generated synthetically by cloning unrearranged V gene segments derived from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and achieve rearrangement in vitro, e.g., as described by Hoogenboom and Winter, J. Mol. Biol., 1992, 227:381-88.
[0197] Screening of the library can be accomplished by a variety of techniques known in the art. For example, HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA (e.g., an HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA polypeptide, fragment, or epitope) can be used to coat the wells of an adsorption plate, can be expressed on host cells immobilized to an adsorption plate, can be used in cell sorting, can be conjugated to biotin for capture by streptavidin-coated beads, or can be used in any other method for panning display libraries. Selection of antibodies with slow dissociation kinetics (e.g., good binding affinity) can be facilitated by the use of extensive washes and monovalent phage display as described in Bass, et al., Proteins, 1990, 8:309-14 and WO 92 / 09690, and by the use of low coating densities of antigen as described in Marks et al., Biotechnol., 1992, 10:779-83.
[0198] Antibodies can be obtained by designing construction of full-length antibody clones using VH and / or VL sequences (e.g., Fv sequences) derived from the phage clone of interest and suitable constant region (e.g., Fc) sequences, or diverse CDR sequences derived from the VH and VL sequences, including the K248E, T437R, or K248E / T437R mutations, as described in Kabat, et al. (supra).
[0199] The antibodies described herein may also include, for example, chimeric antibodies. Chimeric antibodies are molecules in which different portions of the antibody are derived from different immunoglobulin molecules. For example, chimeric antibodies may contain the variable region of a mouse or rat monoclonal antibody fused to the constant region of a human antibody. Methods for producing chimeric antibodies are known in the art. See, for example, Morrison, Science, 1985, 229:1202; Oi et al., 1986, BioTechniques 4:214; Gillies et al., 1989, J. Immunol. Methods 125:191-202, and U.S. Patent Nos. 5,807,715, 4,816,567, 4,816,397, and 6,331,415.
[0200] Antibodies produced using techniques such as those described herein can be isolated using well-known standard techniques. For example, the antibodies can be suitably separated from, for example, culture medium, ascites fluid, serum, cell lysates, synthetic reaction materials, and the like, by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. As used herein, an "isolated" or "purified" antibody is substantially free of cellular material or other proteins from the cell or tissue source from which the antibody is derived, or, if chemically synthesized, substantially free of chemical precursors or other chemicals.
[0201] In certain specific embodiments, monoclonal antibodies are generated using the methods exemplified in Section 7.
[0202] Humanized antibodies In some embodiments, the antibody provided herein may be a humanized antibody. A humanized antibody may comprise a human framework region and a human constant region sequence. For example, a humanized antibody may comprise a human constant region sequence. In certain embodiments, a humanized antibody may be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE, and any isotype, including IgG1, IgG2, IgG3, and IgG4 (e.g., IgG4 mutants and IgG4 null bodies). In certain embodiments, a humanized antibody may comprise a kappa or lambda light chain constant sequence. Humanized antibodies can be produced by a variety of techniques, including CDR grafting (EP 239,400; WO 91 / 09967; U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (EP 592,106; U.S. Pat. Nos. 519,596; Padlan, Molecular Immunology, 1991, 28(4 / 5):489-498; Studnicka, et al., Protein Engineering, 1994, 7(6):805-814; and Roguska, et al., Protein Engineering, 1994, 7(6):805-814; and al., Proc. Natl. Acad. Sci. USA, 1994, 91:969-73), chain shuffling (US Pat. No. 5,565,332), and, for example, US Pat. No. 6,407,213, US Pat. al.,J.Immunol.,2002,169:1119-25;Caldas,et al.,Protein Eng.,2000,13(5):353-60;Morea et al.,Methods,2000,20(3):267-79,Baca,et al., J. Biol. Chem., 1997, 272(16):10678-84; Roguska, et al., Protein Eng., 1996, 9(10):895 904; Couto, et al., Cancer Res., 1995, 55(23 Supp):5973s-5977s; Couto, et al., Cancer Res., 1995, 55(8):1717-22; Sandhu, JS, Gene, 1994, 150(2):409-10 and Pedersen, et al., J. Mol. Biol., 1994, 235(3):959-73. See also U.S. Patent Application Publication No. 2005 / 0042664(A1) (February 24, 2005), each of which is incorporated herein by reference in its entirety.
[0203] Various methods for humanizing non-human antibodies are known in the art. For example, a humanized antibody may have one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, and are typically taken from an "import" variable domain. Humanization can be carried out by substituting the sequences of hypervariable regions for the corresponding sequences of a human antibody, for example, according to the methods of Jones, et al., 1986, Nature 321:522-5; Riechmann, et al., Nature, 1988, 332:323-7; and Verhoeyen, et al., Science, 1988, 239:1534-6.
[0204] In some cases, humanized antibodies are constructed by CDR grafting, which involves grafting the amino acid sequences of the six CDRs of a parent non-human antibody (e.g., rodent) onto a human antibody framework. For example, Padlan et al. determined that only about one-third of the residues in the CDRs actually contact the antigen, and named these "specificity determining residues" or SDRs (Padlan, et al., FASEB J., 1995, 9:133-9). In the SDR grafting technique, only the SDR residues are grafted onto a human antibody framework (see, for example, Kashmiri, et al., Methods, 2005, 36:25-34).
[0205] The choice of human variable domains, both light and heavy, used to make a humanized antibody can be important to reduce antigenicity. For example, according to the so-called "best-fit" method, the sequence of the variable domain of a non-human (e.g., rodent) antibody is screened against the entire library of known human variable domain sequences. The human sequence that is closest to the rodent sequence can be selected as the human framework for the humanized antibody (Sims et al., J. Immunol., 1993, 151:2296-308; and Chothia et al., J. Mol. Biol., 1987, 196:901-17). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 1992, 89:4285-89; and Presta et al., J. Immunol., 1993, 151:2623-32). In some cases, the framework is derived from the consensus sequence of the most abundant human subclasses, VL6 subgroup I (VL6I) and VH subgroup III (VHIII). In other methods, human germline genes are used as the source of the framework regions.
[0206] In an alternative paradigm based on CDR comparison, called superhumanization, the homology of FR is irrelevant. This method consists of comparing non-human sequences and functional human germline gene repertoires. Then, genes that code for the same or closely related canonical structures as mouse sequences are selected. Next, among the genes that share canonical structures with non-human antibodies, the genes with the highest homology within CDRs are selected as FR donors. Finally, non-human CDRs are grafted into these FRs (see, for example, Tan et al., J.Immunol., 2002,169:1119-25).
[0207] Furthermore, it is generally desirable for antibodies to be humanized while retaining their affinity for the antigen and other favorable biological properties. To achieve this goal, according to one method, humanized antibodies are prepared by a process of analyzing the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available that illustrate and display probable three-dimensional conformations of selected candidate immunoglobulin sequences. These include, for example, WAM (Whitelegg and Rees, Protein Eng., 2000, 13:819-24), Modeller (Sali and Blundell, J. Mol. Biol., 1993, 234:779-815), and Swiss PDB Viewer (Guex and Peitsch, Electrophoresis, 1997, 18:2714-23). Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, for example, for residues that affect the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen, is achieved. In general, the hypervariable region residues are directly and most substantially involved in antigen binding.
[0208] Another method of antibody humanization is based on a metric of antibody humanness called Human String Content (HSC). This method compares the mouse sequence with a repertoire of human germline genes and scores the differences as HSC. The target sequence is then humanized by maximizing its HSC, rather than using an overall identity measure to generate diverse humanized variants (Lazar et al., Mol. Immunol., 2007, 44:1986-98).
[0209] In addition to the above methods, empirical methods can be used to generate and select humanized antibodies. These methods include methods based on generating large libraries of humanized variants and selecting the best clones using enrichment or high-throughput screening techniques. Antibody variants can also be isolated from phage, ribosomal, and yeast display libraries, as well as by screening bacterial colonies (see, e.g., Hoogenboom, Nat. Biotechnol., 2005, 23:1105-16; Dufner, et al., Trends Biotechnol., 2006, 24:523-9; Feldhaus, et al., Nat. Biotechnol., 2003, 21:163-70; and Schlapschy et al., Protein Eng. Des. Sel., 2004, 17:847-60).
[0210] In the FR library approach, multiple residue variants are introduced at specific positions in the FR, and the library is then screened to select the FR that best supports the grafted CDR. The substituted residues may include some or all of the "vernier" residues identified as potential contributors to the CDR structure (see, e.g., Foote and Winter, J. Mol. Biol., 1992, 224:487-99), or may be from a more limited set of target residues identified by Baca, et al., J. Biol. Chem., 1997, 272:10678-84.
[0211] In FR shuffling, entire FRs are combined with non-human CDRs rather than creating a combinatorial library of selected residue variants (see, e.g., Dall'Acqua et al., Methods, 2005, 36:43-60). The library can be screened for binding in a two-step process, first humanizing the VL, followed by humanizing the VH. Alternatively, a one-step FR shuffling process can be used. Such a process has been shown to be more efficient than two-step screening, as the resulting antibodies exhibited improved biochemical and physicochemical properties, including enhanced expression, increased affinity, and thermal stability (see, e.g., Damschroder, et al., Mol. Immunol., 2007, 44:3049-60).
[0212] The "humaneering" method is based on the experimental identification of essential minimum specificity determinants (MSDs) and the sequential replacement of non-human fragments with a human FR library and evaluation of binding. The humaneering method starts with the CDR3 regions of the non-human VH and VL chains and gradually replaces other regions of the non-human antibody, including CDR1 and CDR2 of both VH and VL, with human FRs. This approach typically identifies multiple subclasses of antibodies that retain the epitope and have distinct CDRs in the human V segments. Humaneering allows the isolation of antibodies that are 91-96% homologous to human germline antibodies (see, e.g., Alfenito, Cambridge Healthtech Institute's Third Annual PEGS, The Protein Engineering Summit, 2007).
[0213] "Human engineering" methods involve modifying non-human antibodies or antibody fragments, such as mouse or chimeric antibodies or antibody fragments, by making specific changes to the amino acid sequence of the antibody to generate an altered antibody that retains the desired binding properties of the original non-human antibody while reducing immunogenicity in humans. In general, the techniques involve classifying amino acid residues of a non-human (e.g., mouse) antibody as "low risk", "moderate risk", or "high risk" residues. The classification is performed using a global risk / benefit calculation that assesses the predicted benefit (e.g., for immunogenicity in humans) of making a particular substitution against the risk that the substitution will affect the folding of the resulting antibody. The specific human amino acid residues to be substituted at a given position (e.g., low risk or moderate risk) of a non-human (e.g., mouse) antibody sequence can be selected by aligning the amino acid sequence from the variable region of the non-human antibody with the corresponding region of a specific or consensus human antibody sequence. Amino acid residues at low or moderate risk positions in the non-human sequence can be substituted with the corresponding residues in the human antibody sequence depending on the alignment.Technologies for producing human engineered proteins are described in detail in Studnicka et al., Protein Engineering, 1994, 7:805-14; U.S. Patent Nos. 5,766,886, 5,770,196, 5,821,123, and 5,869,619, and WO 93 / 11794.
[0214] Composite human antibodies can be generated, for example, using Composite Human Antibody™ technology (Antitope Ltd., Cambridge, United Kingdom). To generate composite human antibodies, fragments of multiple human antibody variable region sequences are engineered with variable region sequences in a way that avoids T-cell epitopes, thereby minimizing immunogenicity of the resulting antibody. Such antibodies can include human constant region sequences, e.g., a human light chain constant region and / or a human heavy chain constant region.
[0215] A deimmunized antibody is an antibody with T cell epitopes removed. Methods for making deimmunized antibodies have been described (see, for example, Jones, et al., Methods Mol Biol., 2009, 525:405-23; and De Groot, et al., Cell. Immunol., 2006, 244:148-153). A deimmunized antibody comprises a T cell epitope-depleted variable region and a human constant region. Briefly, the VH and VL of an antibody are cloned, and then T cell epitopes are identified by examining overlapping peptides derived from the VH and VL of the antibody in a T cell proliferation assay. T cell epitopes are identified by an in silico method to identify peptides that bind to human MHC class II. Mutations are introduced into the VH and VL to abolish binding to human MHC class II. The VH and VL are then utilized to generate a deimmunized antibody.
[0216] Antibody variants In some embodiments, modification(s) of the amino acid sequence of the antibody provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody, including but not limited to specificity, thermal stability, expression level, effector function, glycosylation (e.g., fucosylation), reduced immunogenicity, or solubility. Thus, in addition to the antibodies described herein, it is contemplated that antibody variants may also be prepared. For example, antibody variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA and / or by synthesizing the desired antibody or polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the antibody, such as changing the number or position of glycosylation sites, or altering membrane anchoring properties.
[0217] In some embodiments, the antibodies provided herein are chemically modified, for example, by covalently attaching any type of molecule to the antibody. Antibody derivatives can include antibodies that have been chemically altered, for example, by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, and the like. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, and the like. In addition, the antibody can include one or more non-classical amino acids.
[0218] Mutations can be substitutions, deletions, or insertions of one or more codons encoding the antibody or polypeptide that result in a change in the amino acid sequence compared to the native sequence antibody or polypeptide. Amino acid substitutions can be the result of replacing one amino acid with another amino acid with similar structural and / or chemical properties, such as, for example, conservative amino acid substitutions, such as replacement of leucine with serine. Standard techniques known to those of skill in the art can be used to introduce mutations into the nucleotide sequences encoding the molecules provided herein, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis resulting in amino acid substitutions. Insertions or deletions can optionally range from about 1 to 5 amino acids. In certain embodiments, the substitutions, deletions, or insertions include fewer than 25 amino acid substitutions, fewer than 20 amino acid substitutions, fewer than 15 amino acid substitutions, fewer than 10 amino acid substitutions, fewer than 5 amino acid substitutions, fewer than 4 amino acid substitutions, fewer than 3 amino acid substitutions, or fewer than 2 amino acid substitutions compared to the original molecule. In certain embodiments, the substitutions are conservative amino acid substitutions made at one or more predicted non-essential amino acid residues. Permissible variations can be determined by systematically making amino acid insertions, deletions, or substitutions in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
[0219] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion is an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., antibody-directed enzyme prodrug therapy) or a polypeptide which extends the serum half-life of the antibody.
[0220] A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues with similarly charged side chains have been defined. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of a coding sequence, such as by saturation mutagenesis, and the resulting mutants screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed and the activity of the protein determined.
[0221] Substantial modifications in the biological properties of the antibody can be achieved by selecting substitutions that differ significantly in their effect on maintaining (a) the structural backbone of the polypeptide in the region of substitution, e.g., a sheet or helix conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chains. Alternatively, conservative (e.g., within a group of amino acids with similar properties and / or side chains) substitutions can be made that maintain the properties or do not significantly change them. Amino acids can be grouped according to similarities in the properties of their side chains (see, e.g., Lehninger, Biochemistry 73--75 (2d ed. 1975)): (1) nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); and (4) basic: Lys (K), Arg (R), His (H)).
[0222] Alternatively, naturally occurring residues may be divided into groups based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe.
[0223] Non-conservative substitutions involve exchanging a member of one of these classes for a member of another class. Such substituted residues also may be introduced into the conservative substitution sites or into the remaining (non-conserved) sites.
[0224] Thus, in one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of an antibody described herein, such as an antibody described in Section 7, below.
[0225] In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 35% identical to the amino acid sequence of the antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 40% identical to the amino acid sequence of the antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 45% identical to the amino acid sequence of the antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 50% identical to the amino acid sequence of the antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 55% identical to the amino acid sequence of the antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 60% identical to the amino acid sequence of an antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 65% identical to the amino acid sequence of an antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 70% identical to the amino acid sequence of an antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of an antibody described herein. In one embodiment, the antibody that binds to the CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of an antibody described herein.In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of an antibody described herein.
[0226] Multivalent antibodies In yet another aspect, provided herein are methods for producing the various antibodies provided herein.
[0227] Multivalent antibodies may be internalized (and / or catabolized) more rapidly than bivalent antibodies by cells expressing the antigen to which the antibody binds. The antibodies of the present disclosure may be multivalent antibodies (other than IgM class) with three or more antigen binding sites (e.g., tetravalent antibodies), which can be readily produced by recombinant expression of nucleic acids encoding the polypeptide chains of the antibody. The multivalent antibody may comprise a dimerization domain and three or more antigen binding sites. In certain embodiments, the dimerization domain comprises (or consists of) an Fc region or a hinge region. In this context, the antibody will comprise an Fc region and three or more antigen binding sites that are amino-terminal to the Fc region. In certain embodiments, the multivalent antibody comprises (or consists of), for example, three to about eight antigen binding sites. In one such embodiment, the multivalent antibody comprises (or consists of) four antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (e.g., two polypeptide chains), and the polypeptide chain comprises two or more variable domains. For example, the polypeptide chain may comprise VD1-(X1)n-VD2-(X2)n-Fc, where VD1 is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, X1 and X2 represent amino acids or polypeptides, and n is 0 or 1. For example, the polypeptide chain may comprise VH-CH1-flexible linker-VH-CH1-Fc region chain; or VH-CH1-VH-CH1-Fc region chain. The multivalent antibody herein may further comprise at least two (e.g., four) light chain variable domain polypeptides. The multivalent antibody herein may comprise, for example, about two to about eight light chain variable domain polypeptides. The light chain variable domain polypeptides contemplated herein comprise a light chain variable domain and, optionally, further comprise a CL domain.
[0228] multispecific antibodies A multispecific antibody, such as a bispecific antibody, is a monoclonal antibody that has binding specificities for at least two different antigens. In certain embodiments, a multispecific antibody can be constructed based on the CDR sequences contained in the antibody sequences provided herein, for example, the VL and VH sequences provided herein. In certain embodiments, a multispecific antibody provided herein is a bispecific antibody. In certain embodiments, a bispecific antibody is a murine, chimeric, human, or humanized antibody. Methods for producing multispecific antibodies are known in the art, for example, by co-expression of two immunoglobulin heavy-light chain pairs, where the two heavy chains have different specificities (see, for example, Milstein and Cuello, Nature, 1983, 305:537-40). For further details on the generation of multispecific antibodies (e.g., bispecific antibodies), see, for example, Bispecific Antibodies (Kontermann, ed., 2011).
[0229] How to generate antibodies In yet another aspect, provided herein are methods for producing the various antibodies provided herein.
[0230] In some embodiments, recombinant expression of an antibody provided herein (e.g., a full-length antibody provided herein, a heavy and / or light chain of the antibody, or a mutant thereof) that binds to an antigen (e.g., CD22, GPRC5D, PSMA, or BCMA) requires construction of an expression vector containing a polynucleotide encoding the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody provided herein is obtained, variants of such polynucleotides can be generated by gene synthesis (e.g., Zhang, D., et al., supra), and / or site-directed mutagenesis (Clynes, RA, et al., Nature Medicine, 2000, 6(4):443-6), including K248E, T437R, or K248E / T437R mutations in the full-length antibody or its heavy chain.
[0231] Vectors for the production of antibody molecules can be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing proteins by expressing polynucleotides containing nucleotide sequences encoding antibodies are described herein. Methods well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. In some embodiments, these methods are, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. In some embodiments, these expression vectors are replicable vectors that contain nucleotide sequences encoding the antibody molecules provided herein, or the heavy or light chains of the antibody, operably linked to a promoter. In some embodiments, these vectors can contain nucleotide sequences encoding the constant regions of the antibody molecules (see, for example, WO 86 / 05807 and WO 89 / 01036, and U.S. Pat. No. 5,122,464), and the variable domains of the antibody can be cloned into such vectors for expression of the entire heavy chain, the entire light chain, or both the entire heavy and light chains.
[0232] In some embodiments, the expression vector is transferred into a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody provided herein. In some embodiments, the host cell contains nucleotides encoding an antibody provided herein, or a heavy or light chain thereof, operably linked to a heterologous promoter. In certain embodiments for expressing double-chain antibodies, vectors encoding both the heavy and light chains can be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.
[0233] A variety of host-expression vector systems can be utilized to express the fusion proteins provided herein (see, e.g., U.S. Pat. No. 5,807,715). Such host-expression systems represent vehicles in which coding sequences of interest may be produced and subsequently purified, but also cells that, when transformed or transfected with the appropriate nucleotide coding sequences, can express the antibody molecules provided herein in situ. In some embodiments, these host-expression systems are microorganisms, such as bacteria (e.g., E. coli and B. subtilis) transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors containing the antibody coding sequences. In some embodiments, these host expression systems are yeast (e.g., Saccharomyces) transformed with a recombinant yeast expression vector containing the antibody coding sequence. In some embodiments, these host expression systems are insect cell systems infected with a recombinant viral expression vector (e.g., baculovirus) containing the antibody coding sequence, plant cells infected with a recombinant viral expression vector (e.g., cauliflower mosaic virus, CaMV, tobacco mosaic virus, TMV) containing the antibody coding sequence or transformed with a recombinant plasmid expression vector (e.g., Ti plasmid) containing the antibody coding sequence. In some embodiments, these host expression systems are mammalian cell systems (e.g., COS, CHO, BHK, 293, NS0, and 3T3 cells) harboring recombinant expression constructs that include promoters derived from the genome of mammalian cells (e.g., metallothionein promoters) or from mammalian viruses (e.g., adenovirus late promoters; cowpox virus 7.5K promoters). In some embodiments, these host expression systems are cells such as E. coli or eukaryotic cells, particularly for expressing complete recombinant antibody molecules that can be used to express recombinant antibody molecules.In some embodiments, mammalian cells such as Chinese hamster ovary cells (CHO) provide an effective expression system for antibodies in combination with vectors such as the major intermediate-early gene promoter element from human cytomegalovirus (Foecking, et al., Gene, 1986, 45:101; and Cockett, et al., Bio / Technology, 1990, 8:2). In some embodiments, the antibodies provided herein are produced in CHO cells. In some embodiments, expression of nucleotide sequences encoding the antibodies provided herein that immunospecifically bind to a CD22, GPRC5D, PSMA, or BCMA antigen is regulated by a constitutive promoter, an inducible promoter, or a tissue-specific promoter.
[0234] In bacterial systems, many expression vectors can be advantageously selected depending on the intended use of the antibody molecule to be expressed. For example, when producing large amounts of such antibodies, a vector that directs the expression of a high level of a fusion protein product that is easily purified to produce a pharmaceutical composition of the antibody molecule may be desirable. Such vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther, et al., EMBO, 1983, 12:1791); pIN vector (Inouye & Inouye, Nucleic Acids Res., 1985, 13:3101-3109; Van Heeke & Schuster, J. Biol. Chem., 1989, 24:5503-9); and the like, in which the antibody coding sequence can be ligated into the vector in frame and separately with the lac Z coding region to produce a fusion protein. pGEX vectors can also be used to express foreign polypeptides as fusion proteins with glutathione 5-transferase (GST). In some embodiments, such fusion proteins are soluble and can be easily purified from lysed cells by adsorption and binding to matrix glutathione agarose beads followed by elution in the presence of free glutathione. In some embodiments, pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
[0235] In some embodiments, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in an insect system. In some embodiments, the virus grows in Spodoptera frugiperda cells. In some embodiments, antibody coding sequences may be cloned individually into non-essential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (e.g., the polyhedrin promoter).
[0236] In some embodiments, viral vectors, such as those based on tobacco mosaic virus (TMV), are used in plant cells and delivered systematically to multiple parts of the plant by Agrobacterium to express multiple antibodies of interest. (Giritch, A., et al., Proc. Natl. Acad. Sci. USA, 2006, 103(40):14701-6). In some embodiments, the use of plant cells as an expression system results in a significant increase in the production rate and yield of antibodies, as well as the ability to synthesize mammalian-type complex N-oligosaccharides. (Loos, A. and Steinkellner, H., Arch Biochem Biophys., 2012, 526-172(2):167-73).
[0237] In mammalian host cells, a number of viral-based expression systems may be utilized. In some embodiments, adenoviruses are used as expression vectors, and the antibody coding sequence of interest may be ligated to an adenovirus transcription / translation control complex, e.g., the late promoter and tripartite leader sequence. In some embodiments, this chimeric gene may then be inserted into the adenovirus genome by in vitro or in vivo recombination. In some embodiments, insertion into a non-essential region of the viral genome (e.g., region El or E3) results in a recombinant virus that is viable in an infected host and capable of expressing the antibody molecule (see, e.g., Logan & Shenk, Proc. Natl. Acad. Sci. USA, 1984, 8(1):355-9). In some embodiments, specific initiation signals may be required for efficient translation of the inserted antibody coding sequence. In some embodiments, these signals include the ATG initiation codon and adjacent sequences. In some embodiments, the initiation codon must be in frame with the desired coding sequence to ensure translation of the entire insert. In some embodiments, these exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic, In some embodiments, the efficiency of expression can be enhanced by the incorporation of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bittner, et al., Methods in Enzymol., 1987, 153:51-544).
[0238] In some embodiments, a host cell line may be selected that modulates the expression of the inserted sequences or modifies and processes the gene product in the specific manner desired. Such modifications (including, for example, glycosylation, fucosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. By choosing the appropriate cell line or host system, the expressed foreign protein can be correctly modified and processed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NS0 (a mouse myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O and HsS78Bst cells. The fully human monoclonal antibodies provided herein are produced in mammalian cells, such as CHO cells.
[0239] Standard techniques known to those skilled in the art can be used to generate the antibodies provided herein having heavy chains that do not have a fucose residue in their Asn-297 linked N-oligosaccharides. In some embodiments, cells that are deficient in GMD enzyme (e.g., CHO Lec13 cells) are used to generate antibodies that do not have a fucose residue in their Asn-297 linked N-oligosaccharides on the heavy chain. In some embodiments, cells that have reduced α-1,6 fucosyltransferase activity due to a mutated or inactivated FUT8 gene (e.g., rat hybridoma YB2 / 0 cell line) are used to generate antibodies that do not have a fucose residue in their Asn-297 linked N-oligosaccharides on the heavy chain. In some embodiments, cells that overexpress β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (GnT-III) are used to generate antibodies that do not have a fucose residue in their Asn-297 linked N-oligosaccharides on the heavy chain. In some embodiments, cells with an inactivated Golgi GDP-fucose transporter (GFT) gene Slc35c1 (e.g., CHO-gmt3 cells) are used to generate antibodies that do not have a fucose residue in the Asn-297 linked N-oligosaccharide on the heavy chain. In some embodiments, cells heterologously expressing a bacterial RMD are used to generate antibodies that do not have a fucose residue in the Asn-297 linked N-oligosaccharide on the heavy chain. In some embodiments, biochemical inhibitors of fucosylation (e.g., fucose analogs such as 2-fluorofucose and 5-alkynylfucose) are used in the expression system to produce antibodies that do not have a fucose residue in the Asn-297 linked N-oligosaccharide on the heavy chain (Pereira, NA, et al., supra; Shields, RL et al., supra; Kanda Y., supra). In some embodiments, plant cells in which α1,3-fucosyltransferase (FucT) and β1,2-xylosyltransferase (XylT) are disrupted are used to produce antibodies that do not have a fucose residue in the Asn-297 linked N-oligosaccharide on the heavy chain (Pereira, NA, et al., supra).In some embodiments, chemoenzymatic remodeling is used to generate antibodies that do not have fucose residues on the Asn-297 linked N-oligosaccharides on the heavy chain (Pereira, NA, et al., supra). For example, exoglycosidases such as fucosidases may be used to remove the fucose from the Asn-297 linked N-oligosaccharides on the heavy chain of the antibody (Pereira, NA, et al., supra).
[0240] Stable expression can be utilized for long-term, high-yield production of recombinant proteins. For example, cell lines can be engineered that stably express an antibody molecule. Rather than using expression vectors that contain a viral origin of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.) and a selectable marker. After introduction of the foreign DNA, engineered cells can be grown in enriched medium for 1-2 days and then switched to selective medium. In some embodiments, the selectable marker on the recombinant plasmid confers resistance to selection, allowing the cells to stably integrate the plasmid into their chromosomes and grow to form foci that can then be cloned and expanded into cell lines. This method can be advantageously used to engineer cell lines that express the antibody molecule. Such engineered cell lines can be particularly useful for screening and evaluating compositions that interact directly or indirectly with the antibody molecule.
[0241] A number of selection systems may be used, including but not limited to herpes simplex virus thymidine kinase (Wigler, et al., Cell, 1977, 11:223), hypoxanthine guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 1992, 48:202), and adenine phosphoribosyltransferase (Lowy, et al., Cell, 1980, 22:8-17)), genes which may be utilized in tk-, hgprt-, or aprt- cells, respectively. Antimetabolite resistance may also be used as a selection criterion for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., Natl. Acad. Sci. USA, 1980, 77:357; O'Hare, et al., Proc. Natl. Acad. Sci. USA, 1981, 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 1981, 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Wu and Wu, Biotherapy, 1991, 3:87-95; Tolstoshev, Ann. Rev. Pharmacol. Toxicol., 1993, 32:573-96; Mulligan, Science, 1993, 260:926-32; and Morgan and Anderson, Ann. Rev. Biochem., 1993, 62:191-217); and hygro, which confers resistance to hygromycin (Santerre, et al., Gene, 1984, 30:147).Methods generally known in the art in recombinant DNA technology can be routinely applied to select the desired recombinant clones, as described, for example, in Ausubel, et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and Chapters 12 and 13, Dracopoli, et al. (eds.), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin, et al., J. Mol. Biol., 1981, 150:1, which are incorporated herein by reference in their entireties.
[0242] The expression level of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, Use of Gene Amplification-Based Vectors for the Expression of Cloned Genes in Mammalian Cells in DNA Cloning, Vol. 3 (Academic Press, New York, 1987)). In some embodiments, if a marker in an antibody expression vector system is amplifiable, the amplified region will be associated with the antibody gene, and increasing the level of an inhibitor present in the host cell culture will increase the copy number of the marker gene and the production of antibody (Crouse et al., 1983, Mol. Cell. Biol. 3:257).
[0243] A host cell may be co-transfected with two expression vectors provided herein, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers that allow for equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used that is capable of encoding and expressing both heavy and light chain polypeptides. In such a situation, the light chain should be placed before the heavy chain to avoid an excess of free heavy chain, which is toxic (Proudfoot, Nature, 1986, 322:52; and Kohler, Proc. Natl. Acad. Sci. USA, 1980, 77:2197-9). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.
[0244] Once the antibody molecule provided herein has been produced by recombinant expression, it can be purified by any method known in the art for purifying immunoglobulin molecules, such as, for example, chromatography (e.g., ion exchange chromatography, affinity chromatography, particularly affinity chromatography for specific antigens followed by protein A chromatography, and size exclusion column chromatography), centrifugation, differential solubility, or any other standard technique for purifying proteins. Additionally, the antibodies provided herein can be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification. Particular methods for making the antibodies provided herein are described in Section 7 below.
[0245] Pharmaceutical Compositions In one aspect, the present disclosure further provides a pharmaceutical composition comprising at least one antibody of the present disclosure. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of an antibody or antigen-binding fragment thereof provided herein and a pharma- ceutical acceptable excipient.
[0246] In some embodiments, pharmaceutical compositions comprising antibodies are prepared by mixing the fusion protein having the desired purity with any physiologically acceptable excipient (see, e.g., Remington, Remington's Pharmaceutical Sciences (18th ed. 1980)) in aqueous solution or in lyophilized or other dried form for storage.
[0247] The antibodies of the disclosure may be formulated in any suitable form for delivery to target cells / tissues, for example, as microcapsules or macroemulsions (Remington, supra; Park, et al., Molecules, 2005, 10:146-61; Malik, et al., Curr. Drug. Deliv., 2007, 4:141-51), as sustained release formulations (Putney and Burke, Nature Biotechnol., 1998, 16:153-57), or in liposomes (Maclean, et al., Int. J. Oncol., 1997, 11:325-32; Kontermann, Curr. Opin. Mol. Ther., 2006, 8:39-45).
[0248] The antibodies provided herein can also be encapsulated in microcapsules, such as hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, prepared, for example, by coacervation techniques or by interfacial polymerization, respectively, in colloidal drug delivery systems (such as, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. Such techniques are disclosed, for example, in Remington, supra.
[0249] A variety of compositions and delivery systems are known and can be used with the antibodies described herein, including, but not limited to, in liposomes, in microparticles, encapsulation in microcapsules, recombinant cells capable of expressing the antibody, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem., 1987, 262:4429-32), construction of the nucleic acid as part of a retrovirus or other vector, etc. In one embodiment, pumps can be used to achieve controlled or sustained release (see, e.g., Langer, Science, 1990, 249:1527-33; Sefton, Crit. Ref. Biomed. Eng., 1987, 14:201-40; Buchwald, et al., Surgery, 1980, 88:507-16; and Saudek et al., N. Engl. J. Med., 1989, 321:569-74). In another embodiment, polymeric materials can be used to achieve controlled or sustained release of prophylactic or therapeutic agents (e.g., antibodies described herein) or compositions provided herein (see, e.g., Medical Applications of Controlled Release (Langer and Wise, eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball, eds., 1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem., 1983, 23:61-126; Levy, et al., Science, 1985, 228:190-92; During, et al., Ann. Neurol., 1989, 25:351-6; Howard, et al., al., J. Neurosurg., 1989, 71:105-12; U.S. Patent Nos. 5,679,377, 5,916,597, 5,912,015, 5,989,463, and 5,128,326; WO 99 / 15154 and WO 99 / 20253).Examples of polymers used in sustained release formulations include, but are not limited to, poly(2-hydroxyethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolide (PLG), polyanhydrides, poly(N-vinylpyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactide (PLA), poly(lactide-co-glycolide) (PLGA), and polyorthoesters. In one embodiment, the polymers used in the sustained release formulations are inert, free of leachable impurities, stable on storage, sterile, and biodegradable.
[0250] In yet another embodiment, a controlled or sustained release system can be placed in close proximity to a specific target tissue, such as the nasal cavity or lungs, such that only a fraction of the systemic dose is required (see, e.g., Goodson, Medical Applications of Controlled Release Vol. 2, 115-38 (1984)). Controlled release systems are discussed, for example, by Langer (supra). Any technique known to one of skill in the art can be used to prepare sustained release formulations comprising one or more antibodies described herein (see, e.g., U.S. Pat. No. 4,526,938; WO 91 / 05548 and WO 96 / 20698; Ning, et al., Radiotherapy & Oncology, 1996, 39:179-89; Song, et al., PDA J. of Pharma. Sci. & Tech., 1995, 50:372-97; Cleek, et al., Pro. Int'l. Symp. Control. Rel. Bioact. Mater., 1997, 24:853-4; and Lam, et al., Proc. Int'l. Symp. Control Rel. Bioact. Mater., 1997, 24:759-60).
[0251] Methods of Use, Administration and Dosage In one aspect, provided herein is a method of enhancing ADCC, CDC and / or ADCP activity of an antibody.
[0252] As another example, C42B and LNCaP cells stably transfected with GFP are seeded at 9,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and cells are allowed to adhere overnight. ADCC assays can be performed with freshly thawed PBMCs (Hemcare, PB009C-3) or NK cells isolated from frozen PBMCs by RoboSep™ Cell Separation Instruments. Isolated NK cells can be used immediately or stimulated overnight with low dose IL-2 (1 ng / ml, Miltenyi Biotec). The effector to target cell ratio per well can be 34:1 for PBMCs and 5:1 for isolated NK cells. In some embodiments, anti-PSMA antibodies are tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging can be performed under Incucyte® S3 instrument (Essen BioScience). Total intergraded GPF signal per well can be quantified with Incucyte® software. Data analysis can be performed by Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. Percentage of cell death can be calculated as (1-PSMAmAb / no mAb control)×100%.
[0253] As another example, C42B and LNCaP cells stably transfected with GFP are seeded at 9,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and cells are allowed to adhere overnight. ADCC assays can be performed with freshly thawed PBMCs (Hemcare, PB009C-3) or NK cells isolated from frozen PBMCs by RoboSep™ Cell Separation Instruments. Isolated NK cells can be used immediately or stimulated overnight with low dose IL-2 (1 ng / ml, Miltenyi Biotec). The effector to target cell ratio per well can be 34:1 for PBMCs and 5:1 for isolated NK cells. In some embodiments, anti-BCMA antibodies are tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging can be performed under an Incucyte® S3 instrument (Essen BioScience). Total GFP intergraded signal per well can be quantified with Incucyte® software. Data analysis can be performed by Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. Percentage of cell death can be calculated as (1-BCMAmAb / no mAb control)×100%.
[0254] In some embodiments, the antibodies provided herein cause at least 10% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 20% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 30% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 40% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 50% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 60% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 70% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 80% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 90% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 95% target cell death via ADCC.
[0255] In some embodiments, the CDC activity of anti-CD22, anti-GPRC5D, anti-PSMA, or anti-BCMA antibodies provided herein is determined by measuring the percentage of target cell death. For example, target cells endogenously expressing CD22, GPRC5D, PSMA, or BCMA can be cultured in DMEM medium containing 10% fetal bovine serum (FBS). In some embodiments, the antibody is added to the target cells and incubated at 37° C. for 30 minutes, after which baby rabbit serum is added to the target cells to a final concentration of 10% to provide a source of complement components for CDC. In some embodiments, such a mixture is incubated at 37° C. for 4 hours. 100 μL of CellTiter-Glo reagent (Promega) can be added to the mixture, followed by incubation at room temperature for 10 minutes. Target cell viability can be determined by measuring luminescence with a Tecan SPARK reader. Thus, target cell death can be determined as the difference between 100% and target cell viability.
[0256] In some embodiments, the antibodies provided herein cause at least 10% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 20% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 30% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 40% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 50% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 60% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 70% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 80% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 90% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 95% target cell death via CDC.
[0257] In some embodiments, the antibodies provided herein enhance ADCC activity at least about 2-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 5-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 10-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 20-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 30-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 40-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 50-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 60-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 70-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 80-fold. In some embodiments, the antibodies provided herein enhance ADCC activity at least about 90-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 100-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 200-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 500-fold.
[0258] In some embodiments, the antibodies provided herein enhance CDC activity at least about 2-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 5-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 10-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 20-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 30-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 40-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 50-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 60-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 70-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 80-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 90-fold. In some embodiments, the antibodies provided herein enhance CDC activity at least about 100-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 200-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 500-fold.
[0259] In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 2-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 5-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 10-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 20-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 30-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 40-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 50-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 60-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 70-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 80-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 90-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 100-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 200-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 500-fold.
[0260] In some embodiments, the antibodies provided herein have at least about a 2-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 5-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 10-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 20-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 30-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 40-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 50-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 60-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 70-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about 80-fold increased cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about 90-fold increased cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about 100-fold increased cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about 200-fold increased cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about 500-fold increased cell surface hexamerization ability.
[0261] In some embodiments, the antibodies provided herein have at least about a 2-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 5-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 10-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 20-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 30-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 40-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 50-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 60-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 70-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about an 80-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 90-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 100-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 200-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 500-fold increase in the ability to engage C1q.
[0262] In another aspect, provided herein is a method of treating a disease or disorder in a subject, comprising administering to the subject an effective amount of an antibody provided herein. In one embodiment, the disease or disorder is a CD22-mediated disease or disorder. In one embodiment, the disease or disorder is a GPRC5D-mediated disease or disorder. In one embodiment, the disease or disorder is a PSMA-mediated disease or disorder. In one embodiment, the disease or disorder is a BCMA-mediated disease or disorder. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune disease, inflammatory disease, cardiovascular disease, genetic disease, blood disease and / or pulmonary disease affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schonlein purpura, IgA nephropathy, atopic dermatitis (atopic eczema), psoriasis (plaque psoriasis), seborrheic eczema, asthma, proteinuric kidney disease. , liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor-induced nephrotoxicity, myotonic dystrophy, cardiac dysfunction and insufficiency, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling (see, e.g., Heider, KH, et al., J. Med. Soc. 2010, 143:131-132, 2010). al.,Blood,2011,118(15):4159-68;Carosella,ED,et al.,Adv.Immunol.,2015,127:33-144;Stathis,S.,et al.,Invest New Drugs,2018,36(5):869-76;Stilgenbauer,S.,et al.,Leukemia,2019,33:2531-5;Gomes,RG,et al.,Hum.Immunol.,2018,79(6):477-84;Moroso,V.,et al.,Transplantation,2015,99(12):2514-22;Lazarte,J.,et al.,Hum.Immunol.,2018,79(8):587-93;Rached,MR,et al.,Eur J Obstet Gynecol Reprod Biol.,2019,235:36-41;Koc,A.,et al.,Adv Clin Exp Med.,2018,27(9):1233-7;Ribeyre,C.,et al.,Front Immunol.,2018,9:278;Smith,EL,et al.,Sci Transl Med.,2019,11(485):eaau7746,Kodama,T.,et al.,Mol Cancer Ther.,2019,18(9):1555-64;Cohen,Y.,et al., Hematology, 2013, 18(6):348-51). .
[0263] Also provided herein are methods of treating a disease or disorder, where a subject is administered one or more therapeutic agents in combination with an antibody provided herein.
[0264] In another aspect, provided herein is the use of an antibody provided herein in the manufacture of a medicament for treating a disease or disorder in a subject.
[0265] In another aspect, provided herein is the use of a pharmaceutical composition provided herein in the manufacture of a medicament for treating a disease or disorder in a subject.
[0266] In specific embodiments, provided herein is a composition for use in the prevention and / or treatment of a disease or condition comprising an antibody provided herein. In one embodiment, provided herein is a composition for use in the prevention of a disease or condition, the composition comprising an antibody provided herein. In one embodiment, provided herein is a composition for use in the treatment of a disease or condition, the composition comprising an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated disease. In some embodiments, the disease or condition is a GPRC5D-mediated disease. In some embodiments, the disease or condition is a PSMA-mediated disease. In some embodiments, the disease or condition is a BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune disease, inflammatory disease, cardiovascular disease, genetic disease, blood disease and / or pulmonary disease affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schönlein purpura, IgA nephrophathy, atopic dermatitis (atopic eczema), psoriasis (plaque psoriasis), seborrheic eczema, asthma, proteinuric kidney disease, liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor induced nephrotoxicity, myotonic dystrophy, cardiac insufficiency and dysfunction, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0267] In certain embodiments, the subject is a subject in need of treatment thereof. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, the administration results in the prevention, management, treatment, or amelioration of a disease or condition.
[0268] In one embodiment, provided herein is a composition for use in the prevention and / or treatment of a symptom of a disease or condition, the composition comprising an antibody provided herein. In one embodiment, provided herein is a composition for use in the prevention of a symptom of a disease or condition, the composition comprising an antibody provided herein. In one embodiment, provided herein is a composition for use in the treatment of a symptom of a disease or condition, the composition comprising an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated, GPRC5D-mediated, PSMA-mediated disease and / or a BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune disease, inflammatory disease, cardiovascular disease, genetic disease, blood disease and / or pulmonary disease affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schönlein purpura, IgA nephrophathy, atopic dermatitis (atopic eczema), psoriasis (plaque psoriasis), seborrheic eczema, asthma, proteinuric kidney disease, liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor induced nephrotoxicity, myotonic dystrophy, cardiac insufficiency and dysfunction, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0269] In certain embodiments, the subject is a subject in need of treatment thereof. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, the administration results in prevention or treatment of a symptom of the disease or condition.
[0270] In another embodiment, provided herein is a method for preventing and / or treating a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for preventing a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for treating a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated, GPRC5D-mediated, PSMA-mediated disease and / or a BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune disease, inflammatory disease, cardiovascular disease, genetic disease, blood disease and / or pulmonary disease affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schönlein purpura, IgA nephrophathy, atopic dermatitis (atopic eczema), psoriasis (plaque psoriasis), seborrheic eczema, asthma, proteinuric kidney disease, liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor induced nephrotoxicity, myotonic dystrophy, cardiac insufficiency and dysfunction, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0271] In certain embodiments, the subject is a subject in need of treatment thereof. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, the administration results in prevention or treatment of a disease or condition.
[0272] In another embodiment, provided herein is a method for preventing and / or treating a symptom of a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for preventing a symptom of a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for treating a symptom of a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated, GPRC5D-mediated, PSMA-mediated disease and / or a BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune disease, inflammatory disease, cardiovascular disease, genetic disease, blood disease and / or pulmonary disease affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schonlein purpura, IgA nephropathy, atopic dermatitis (atopic eczema), psoriasis (plaque psoriasis), seborrheic eczema, asthma, rheumatoid arthritis ... and optionally the disease or disorder is selected from the group consisting of inflammatory bowel disease, proteinuric kidney disease, liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor induced nephrotoxicity, myotonic dystrophy, cardiac insufficiency and dysfunction, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0273] In certain embodiments, the subject is a subject in need of treatment thereof. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, the administration results in prevention or treatment of a symptom of the disease or condition.
[0274] Also provided herein are methods of preventing and / or treating a disease or condition by administering to a subject an effective amount of an antibody provided herein or a pharmaceutical composition comprising an antibody provided herein. In one aspect, the antibody is substantially purified (i.e., substantially free of substances that limit its effect or cause undesirable side effects). The subject to which the therapy is administered can be a mammal, such as a non-primate (e.g., cow, pig, horse, cat, dog, rat, etc.) or a primate (e.g., monkey, such as macaque (cynomolgus monkey), or human). In one embodiment, the subject is a human. In another embodiment, the subject is a human having a disease or condition.
[0275] In some embodiments, each or any of the above or below embodiments, the binding molecule is used to treat a solid tumor cancer. In other embodiments, the binding molecule is used to treat a hematological cancer. In other embodiments, the disease or disorder is an autoimmune disease or inflammatory disease. In other embodiments, the disease or disorder is an immune disease or disorder.
[0276] In some embodiments of each or any of the above or below embodiments, the disease or disorder is a disease of abnormal cell proliferation and / or dysregulated apoptosis. Examples of such diseases include cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, bone cancer, colon cancer, rectal cancer, anal cancer, stomach cancer, gastrointestinal tract (gastric, colorectal, and / or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue cancer, urethral cancer, penile cancer, testicular cancer, hepatocellular (liver and / or bile duct) cancer, primary or secondary central nervous system tumors, primary or secondary brain tumors. , Hodgkin's disease, chronic or acute leukemia, chronic myelogenous leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and / or ureter, renal cell carcinoma, cancer of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumor, brain stem glioma, pituitary adenoma, adrenal cortical carcinoma, gallbladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma, or a combination thereof.
[0277] In some embodiments of each or any of the above or below embodiments, the disease or disorder is selected from the group consisting of bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, and splenic cancer.
[0278] In some embodiments of each or any of the above or below embodiments, the disease or disorder is a blood cancer such as leukemia, lymphoma, or myeloma. In some embodiments of each or any of the above or below embodiments, the cancer is Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous B-cell lymphoma, activated B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular center lymphoma, transformed lymphoma, lymphocytic lymphoma of intermediate differentiation, intermediate lymphocytic lymphoma (ILL), diffuse poorly differentiated lymphocytic lymphoma (PDL), central cell lymphoma, diffuse small cleaved cell lymphoma (DSCCL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma. , mantle zone lymphoma, low-grade follicular lymphoma, multiple myeloma (MM), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), myelodysplastic syndromes (MDS), acute T-cell leukemia, acute myelocytic leukemia (AML), acute promyelocytic leukemia, acute myeloblastic leukemia, acute megakaryoblastic leukemia, precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt's leukemia (Burkitt's lymphoma), acute biphenotypic leukemia, chronic myelogenous lymphoma, chronic myelogenous leukemia (CML), and chronic monocytic leukemia. In certain embodiments, the disease or disorder is myelodysplastic syndromes (MDS). In another particular embodiment, the disease or disorder is acute myeloid leukemia (AML). In another particular embodiment, the disease or disorder is chronic lymphocytic leukemia. In yet another particular embodiment, the disease or disorder is multiple myeloma (MM).
[0279] In other embodiments, the disease or disorder is a solid tumor cancer. In some embodiments of each or any of the above or below embodiments, the solid tumor cancer is selected from the group consisting of carcinoma, adenocarcinoma, adrenocortical tumor, colon adenocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, ductal cell carcinoma, lung cancer, thyroid cancer, nasopharyngeal carcinoma, melanoma, non-melanoma skin cancer, liver cancer, and lung cancer.
[0280] In some embodiments of each or any of the above or below embodiments, the cancer is adrenal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is anal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is appendiceal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is bile duct cancer. In some embodiments of each or any of the above or below embodiments, the cancer is bladder cancer. In some embodiments of each or any of the above or below embodiments, the cancer is bone cancer. In some embodiments of each or any of the above or below embodiments, the cancer is brain cancer. In some embodiments of each or any of the above or below embodiments, the cancer is breast cancer. In some embodiments of each or any of the above or below embodiments, the cancer is cervical cancer. In some embodiments of each or any of the above or below embodiments, the cancer is colorectal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is esophageal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is gallbladder cancer. In some embodiments of each or any of the above or below embodiments, the cancer is gestational choriocarcinoma. In some embodiments of each or any of the above or below embodiments, the cancer is head and neck cancer. In some embodiments of each or any of the above or below embodiments, the cancer is Hodgkin's lymphoma. In some embodiments of each or any of the above or below embodiments, the cancer is intestinal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is renal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is leukemia. In some embodiments of each or any of the above or below embodiments, the cancer is liver cancer. In some embodiments of each or any of the above or below embodiments, the cancer is lung cancer. In some embodiments of each or any of the above or below embodiments, the cancer is melanoma.In some embodiments of each or any of the above or below embodiments, the cancer is mesothelioma. In some embodiments of each or any of the above or below embodiments, the cancer is multiple myeloma (MM). In some embodiments of each or any of the above or below embodiments, the cancer is a neuroendocrine tumor. In some embodiments of each or any of the above or below embodiments, the cancer is non-Hodgkin's lymphoma. In some embodiments of each or any of the above or below embodiments, the cancer is oral cancer. In some embodiments of each or any of the above or below embodiments, the cancer is ovarian cancer. In some embodiments of each or any of the above or below embodiments, the cancer is pancreatic cancer. In some embodiments of each or any of the above or below embodiments, the cancer is prostate cancer. In some embodiments of each or any of the above or below embodiments, the cancer is sinus cancer. In some embodiments of each or any of the above or below embodiments, the cancer is skin cancer. In some embodiments of each or any of the above or below embodiments, the cancer is soft tissue sarcoma spinal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is gastric cancer. In some embodiments of each or any of the above or below embodiments, the cancer is testicular cancer. In some embodiments of each or any of the above or below embodiments, the cancer is throat cancer. In some embodiments of each or any of the above or below embodiments, the cancer is thyroid cancer. In some embodiments of each or any of the above or below embodiments, the cancer is uterine cancer, endometrial cancer. In some embodiments of each or any of the above or below embodiments, the cancer is vaginal cancer. In some embodiments of each or any of the above or below embodiments, the cancer is vulvar cancer.
[0281] In some embodiments of each or any of the above or below embodiments, the adrenal cancer is an adrenocortical tumor (ACC), adrenocortical carcinoma, pheochromocytoma, or neuroblastoma. In some embodiments of each or any of the above or below embodiments, the anal cancer is squamous cell carcinoma, gross draining carcinoma, adenocarcinoma, basal cell carcinoma, or melanoma. In some embodiments of each or any of the above or below embodiments, the appendix cancer is a neuroendocrine tumor (NET), mucinous adenocarcinoma, goblet cell carcinoid, intestinal type adenocarcinoma, or signet ring cell adenocarcinoma. In some embodiments of each or any of the above or below embodiments, the cholangiocarcinoma is an extrahepatic cholangiocarcinoma, an adenocarcinoma, a hilar cholangiocarcinoma, a hilar region cholangiocarcinoma, a distal cholangiocarcinoma, or an intrahepatic cholangiocarcinoma. In some embodiments of each or any of the above or below embodiments, the bladder cancer is transitional cell carcinoma (TCC), papillary carcinoma, squamous carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, or sarcoma. In some embodiments of each or any of the above or below embodiments, th...
Claims
1. A binding molecule comprising an antigen-binding domain and an Fc region, (i) the antigen-binding domain is biparatopic or bispecific; (ii) the Fc region comprises K248E and T437R mutations (RE mutations), and the numbering of amino acid residues is according to the EU numbering system; the binding molecule has an increased ability to hexamerize on the cell surface and / or an increased ability to engage C1q; A binding molecule comprising an antigen-binding domain and an Fc region.
2. 2. The binding molecule of claim 1, wherein the antigen binding domain comprises a first domain comprising a first VH region and a first VL region, a first single domain antigen binding fragment, and / or a first engineered binding fragment, and a second domain comprising a second VH region and a second VL region, a second single domain antigen binding fragment, and / or a second engineered binding fragment, wherein the first domain and the second domain bind to two different epitopes of the same antigen or different antigen(s).
3. (a) each of the first domain and the second domain is a Fab fragment, an scFv, a single domain antigen-binding fragment, or an engineered binding fragment; (b) the first domain is a Fab fragment and the second domain is an scFv; (c) the first domain is a Fab fragment and the second domain is a single domain antigen-binding fragment; (d) the first domain is a Fab fragment and the second domain is an engineered binding fragment; (e) the first domain is an scFv and the second domain is a single domain antigen-binding fragment; (f) the first domain is an scFv and the second domain is an engineered binding fragment; or (g) the first domain is a single domain antigen-binding fragment and the second domain is an engineered binding fragment; The binding molecule of claim 2.
4. The binding molecule of any one of claims 1 to 3, wherein the oligosaccharide covalently attached to the Fc region via its N297 residue does not contain a core fucose residue.
5. The binding molecule of any one of claims 1 to 4, wherein the binding molecule is a biparatopic or bispecific antibody.
6. The binding molecule of any one of claims 1 to 5, wherein the binding molecule has enhanced antibody-dependent cellular cytotoxicity (ADCC), enhanced complement-dependent cytotoxicity (CDC), and / or enhanced antibody-dependent cellular phagocytosis (ADCP).
7. A binding molecule comprising a first means for enhancing CDC and a second means for enhancing CDC.
8. The binding molecule of claim 7, further comprising a third means for enhancing ADCC.
9. 9. The binding molecule of claim 7 or 8, further comprising a fourth means for enhancing ADCP.
10. The binding molecule of any one of claims 7 to 9, wherein the first means increases hexamerization of the binding molecule on the cell surface and / or increases C1q engagement by the binding molecule.
11. The binding molecule according to any one of claims 7 to 10, wherein the first means enhances CDC, ADCP, and / or ADCC.
12. The binding molecule of any one of claims 7 to 11, wherein the binding molecule is a biparatopic or bispecific antibody.
13. A population of binding molecules comprising the binding molecule of any one of claims 1 to 12.
14. a population of binding molecules, each binding molecule comprising an antigen binding domain and an Fc region; (i) the antigen-binding domain is biparatopic or bispecific; (ii) the Fc region comprises K248E and T437R mutations (RE mutations), and the numbering of amino acid residues is according to the EU numbering system; (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. A collection of binding molecules.
15. A population of binding molecules, (i) each binding molecule comprises an antigen-binding domain and an Fc region; (ii) the antigen-binding domains of at least 10% of the binding molecules in the population are biparatopic or bispecific; (iii) the Fc region of each binding molecule comprises a K248E and a T437R mutation (RE mutation), wherein the numbering of amino acid residues is according to the EU numbering system; (iv) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. A collection of binding molecules.
16. (a) the antigen-binding domains of at least 20% of the binding molecules in the population are biparatopic or bispecific; (b) the antigen-binding domains of at least 30% of the binding molecules in the population are biparatopic or bispecific; (c) the antigen-binding domains of at least 40% of the binding molecules in the population are biparatopic or bispecific. (d) the antigen-binding domains of at least 50% of the binding molecules in the population are biparatopic or bispecific. (e) the antigen-binding domains of at least 60% of the binding molecules in the population are biparatopic or bispecific. (f) the antigen-binding domains of at least 70% of the binding molecules in the population are biparatopic or bispecific. (g) the antigen-binding domains of at least 80% of the binding molecules in the population are biparatopic or bispecific; or (h) the antigen-binding domains of at least 90% of the binding molecules in the population are biparatopic or bispecific. A population of binding molecules according to claim 15.
17. (a) less than 70% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue; (b) less than 60% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (c) less than 50% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (d) less than 40% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (e) less than 30% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (f) fewer than 20% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue; or (g) less than 10% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. A population of binding molecules according to any one of claims 14 to 16.
18. 18. The population of binding molecules of any one of claims 14 to 17, wherein the antigen binding domains comprise a first domain comprising a first VH region and a first VL region, a first single domain antigen binding fragment and / or a first engineered binding fragment, and a second domain comprising a second VH region and a second VL region, a second single domain antigen binding fragment and / or a second engineered binding fragment, wherein the first domain and the second domain bind to two different epitopes of the same antigen or different antigen(s).
19. (a) each of the first domain and the second domain is a Fab fragment, an scFv, a single domain antigen-binding fragment, or an engineered binding fragment; (b) the first domain is a Fab fragment and the second domain is an scFv; (c) the first domain is a Fab fragment and the second domain is a single domain antigen-binding fragment; (d) the first domain is a Fab fragment and the second domain is an engineered binding fragment; (e) the first domain is an scFv and the second domain is a single domain antigen-binding fragment; (f) the first domain is an scFv and the second domain is an engineered binding fragment; or (g) the first domain is a single domain antigen-binding fragment and the second domain is an engineered binding fragment; A population of binding molecules according to any one of claims 14 to 17.
20. The population of binding molecules according to any one of claims 14 to 19, wherein the binding molecules are biparatopic or bispecific antibodies.
21. 21. The population of binding molecules of any one of claims 14 to 20, wherein the binding molecules are produced by expressing a polynucleotide encoding the binding molecule or a fragment thereof in a host cell that is deficient in the addition of fucose to the oligosaccharides attached to an antibody Fc region.
22. 22. The population of binding molecules of claim 21, wherein the host cell has reduced GDP-mannose 4,6-dehydratase (GMD) activity or reduced α-1,6 fucosyltransferase activity.
23. 23. The population of binding molecules of any one of claims 13 to 22, wherein the population of binding molecules has enhanced ADCC, enhanced CDC, and / or enhanced ADCP.
24. A nucleic acid encoding a binding molecule according to any one of claims 1 to 12.
25. A vector comprising the nucleic acid of claim 24.
26. 24. A method of making a binding molecule of any one of claims 1 to 12 or a population of binding molecules of any one of claims 13 to 23 comprising expressing a polynucleotide encoding said binding molecule or one or more of its fragments in a host cell which is defective in the addition of a fucose residue to the oligosaccharide attached to the antibody via the N297 residue.
27. (a) the host cell has reduced α-1,6 fucosyltransferase activity; (b) the host cell has reduced GDP-mannose 4,6-dehydratase activity. (c) the gene encoding the α-1,6 fucosyltransferase is mutated, expressed at lower than normal levels, or knocked out in the host cell; or (d) the gene encoding the GDP-mannose 4,6-dehydratase is mutated, expressed at a lower than normal level, or knocked out in the host cell.
27. The method of claim 26.
28. 1. A method of producing a population of binding molecules, each of said binding molecules comprising a biparatopic or bispecific antigen binding domain and an Fc region; (i) introducing K248E and T437R mutations (RE mutations) into the Fc region of the binding molecule; (ii) generating a population of binding molecules having reduced amounts of core fucose in the oligosaccharides attached to the binding molecule via the N297 residue of the Fc region; A method for producing a population of binding molecules, each of which comprises a monovalent antigen-binding domain and an Fc region, comprising:
29. A population of binding molecules produced according to the method of any one of claims 26 to 28.
30. 30. A pharmaceutical composition comprising a binding molecule according to any one of claims 1 to 12 or a population of binding molecules according to any one of claims 13 to 23 or 29, and a pharma- ceutically acceptable excipient.
31. 1. A method for enhancing CDC, ADCP, and / or ADCC in a system, comprising: (a) contacting said system with a binding molecule according to any one of claims 1 to 12, or (b) contacting said system with said population of binding molecules according to any one of claims 13 to 23 or 29; A method for enhancing CDC, ADCP, and / or ADCC in a system, comprising:
32. 1. A method for modulating immunity in a host, comprising: (a) administering a binding molecule according to any one of claims 1 to 12, or (b) administering a population of binding molecules according to any one of claims 13 to 23 or 29; The method of claim 1, further comprising:
33. 1. A method of treating a disease or disorder in a subject, comprising: (a) administering a binding molecule according to any one of claims 1 to 12, or (b) administering a population of binding molecules according to any one of claims 13 to 23 or 29; A method of treating a disease or disorder in a subject, comprising:
